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ABSTRACT 
Women with pregestational diabetes are at a high risk of having babies with 
congenital heart defects (CHDs). The mechanisms of CHD induction in the offspring of 
women with pregestational diabetes remain elusive. With an ever-increasing rate of 
diabetes in young adults, there is a pressing need to understand the underlying 
mechanisms and initiate effective preventative strategies. The aim of this thesis is to 
study the role of reactive oxygen species (ROS) signalling in heart morphogenesis, 
unravel molecular mechanisms of CHDs induced by pregestational diabetes and provide 
new insights on potential therapeutic strategies. To this end, a mouse model of 
pregestational diabetes induced by streptozotocin was employed. A spectrum of septal, 
conotruncal and coronary artery malformation were identified in the offspring of mice 
with pregestational diabetes. Reactive oxygen species (ROS) levels were elevated and 
glutathione levels were diminished in the fetal hearts of diabetic female mice. Oral 
treatment with an antioxidant, N-Acetylcysteine (NAC), significantly diminished the 
incidence of CHDs and prevented coronary artery malformation in the offspring of 
pregestational diabetic mice. Furthermore, pregestational diabetes reduced cell 
proliferation, altered transcript levels, and disrupted epithelial to mesenchymal transition 
(EMT) in the fetal heart of pregestational diabetic mice, which were all prevented by 
NAC treatment. To further study the role of basal ROS production in embryonic heart 
development, a NADPH oxidase Nox2 knockout mouse was utilized. We demonstrated 
that loss of Nox2 expression decreased ROS production, and impaired TGF-β/BMP 
signalling and endocardial EMT in embryonic hearts. This ultimately resulted in cardiac 
septum and valve defects. Thus, under normal physiological conditions ROS production 
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promotes heart development whereas excess ROS levels during pregestational diabetes 
induce CHDs. These studies show maintaining a balance of ROS levels is essential for 
normal embryonic heart development in mice. Furthermore, NAC may have a therapeutic 
potential in preventing the development of CHDs during pregestational diabetes.  
 
Key words: 
Reactive oxygen species, congenital heart defects, pregestational diabetes, oxidative 
stress, coronary artery development, endocardial cushion formation, epithelial to 
mesenchymal transition. 
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1. CHAPTER 1  
1.1 PREGESTATIONAL DIABETES 
Diabetes is a major health concern worldwide. To date, 382 million people have 
diabetes and with an increasing rate of 10 million people annually, the number of diabetic 
patients is estimated to reach 592 million by 2035 [1]. According to the Canadian 
Diabetes Association, one in every 10 Canadian adult has diabetes. About 3 to 9 women 
in every 1000 pregnancies in European or North American populations have diabetes 
before pregnancy, which is pregestational diabetes [2-6]. Women with pregestational 
diabetes are at risk of having infants with congenital abnormalities in the neural tube, 
musculoskeletal, renal and cardiovascular systems [7,8]. Among all types of congenital 
abnormalities, congenital heart defects (CHDs), with the prevalence of 3-5 fold higher 
than non-diabetic population, are the most common type of abnormalities [9-12]. 
Clinical studies have shown that maternal high blood glucose levels strongly 
correlate with the incidence and severity of congenital defects in the offspring [13-15], 
whereas, good glycemic control through insulin injections reduces the incidence of 
congenital defects in their offspring [16-18]. Therefore, health policies have been 
implemented to spread awareness and encourage diabetic women to maintain good 
glycemic control throughout gestation by insulin treatment. Despite these measures, the 
rate of congenital defects in pregestational diabetes is still significantly higher than the 
normal population [11,19,20]. The reasons, although not completely understood, are 
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suggested to be due to failure in maintaining optimal glycemic levels, especially during 
early gestational age when organogenesis is occurring [21].  
This thesis is dedicated to improve our understanding of the factors that interrupt 
fetal heart development due to pregestational diabetes. Specifically, I focused on the role 
of increased reactive oxygen species (ROS) levels in induction of CHDs and the 
efficiency of an antioxidant in preventing those defects that develop during pregestational 
diabetes. Additionally, I demonstrated that basal ROS signalling is required for 
embryonic heart development under normal physiological conditions. Overall, my studies 
show that maintaining a balance of ROS levels is essential for normal heart development 
in mice.   
1.2 HEART DEVELOPMENT 
The heart is one of the first organs to form and function in early embryonic life 
[22]. During development, cardiac progenitors undergo extensive proliferation, 
remodeling, migration and differentiation. The process of heart development is precisely 
regulated by a combination of transcription factors, signalling molecules and epigenetic 
factors [23]. The release of the genome sequence and advances in genetic tools during the 
past decades assisted in performing numerous studies on a variety of animal models to 
comprehend the sophisticated process of heart formation. Understanding the molecular 
mechanism of heart development is essential in order to enhance our perspective of 
congenital defects that arise during embryogenesis, and to identify possible therapeutic 
approaches to prevent those defects.  
  
3 
1.2.1 Origin of Heart Fields 
Cardiac progenitors arise from the mesoderm germ layer [24-26]. During 
gastrulation, cardiac progenitor cells, which are located in the anterior primitive streak 
migrate inward as part of the anterior lateral plate mesoderm (Figure 1.1 A-B) [27,28]. 
This migration results in formation of two lateral heart fields along the midline that 
express early cardiac markers. The lateral heart fields then expand across the midline to 
form a crescent-shaped cardiogenic plate (Figure 1.1 C). Subsequently, the two edges of 
the crescent-shaped structure will migrate towards the midline and join to form a tubular 
heart by E8 in mice (Figure 1.1 D). At this stage, slow peristaltic contractions are 
initiated [29,30]. The heart tube is composed of two concentric layers: the endocardium 
and myocardium, which are separated by a layer of extracellular matrix, termed the 
cardiac jelly. Structurally, the anterior end of the heart tube is linked to the arterial trunk 
and the posterior end is linked to the venous channels. In this system, blood drains from 
the venous channels into the atrium chamber then flows to the ventricular chamber and is 
directed out via the arterial trunk (Figure 1.1 D).   
Cardiac precursors rise in a temporal and spatial manner to contribute to 
development of a sophisticated cardiovascular system. Extensive analysis has revealed 
the origin of cardiac precursors, their molecular interactions and contribution to 
formation of cardiovascular structures. The earliest anatomical studies marked the cardiac 
crescent as the origin of cardiac precursors. However, further studies revealed that 
disruption of the cardiac crescent did not ablate heart tube formation [31]. This, in 
addition to specific expression domains identified by gene trap experiments [32], led to 
further studies to identify other potential heart fields and subsequently, a distinct 
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population of cardiac progenitors that are located on the dorsal and anterior side of the 
cardiac crescent was identified. Thus, the precursors located at the cardiac crescent were 
called the primary or first heart field (FHF) and the cells located on anterior-dorsal site of 
cardiac crescent were called the second heart field (SHF) (Figure 1.1 C). Lineage tracing 
experiments demonstrated participation of FHF cells to formation of the primary heart 
tube. Concurrent with formation of the heart tube, SHF cells will migrate into the venous 
and arterial channels of the heart tube and contribute to the heart tube’s elongation [31-
33]. In particular, FHF progenitors contribute to formation of the left ventricle and atria 
while the SHF lineage contributes to formation of the right ventricle [34], interventricular 
septum, the outflow tract (OFT) at the arterial pole of the heart, and portions of both atria 
[33] (Figure 1.1 E-F). Followed by elongation of the heart tube and cardiac looping, a 
group of cells arising from the cardiac neural crest will migrate from the dorsal neural 
tube structures through the pharyngeal arch toward the OFT of the looped heart (Figure 
1.1 E-F) [23,35]. Cardiac neural crest cells will then assist in remodeling of semilunar 
valves, formation of cardiac vessels and septation of the OFT (Figure 1.1 G).  
1.2.2 Heart looping  
As the heart tube elongates the common ventricular chamber bends ventrally and 
dorsally and then moves to the right, thus forming a looped heart tube (Figure 1.1 E). 
The process of heart looping occurs during embryonic day (E) 8.25 to E10.5 in mice and 
day 22 to 32 in human embryos [36]. Rightward heart looping that is essential for proper 
orientation of the atria and ventricles is directed by left right differences in embryo. 
During cardiac looping the atrial end will locate dorsal-cranially and shift to the left side  
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Figure 1.1. Development of the mammalian heart.    
Early cardiac precursors (orange) at the primitive streak (A), lateral plate mesoderm (B) 
and cardiac crescent (red and yellow) (C). The SHF (yellow) is located anterior and 
dorsal to the heart tube (D). Arrows indicate direction of SHF cells migration to the heart 
tube. Followed by SHF cell migration, the heart loops to the right and cardiac neural 
crest cells (blue) will migrate towards the OFT (E). Primary left and right atria and 
ventricular chambers appear (F). Further remodelling and growth of the heart will form a 
four-chambered heart (G).  A: Anterior, P: Posterior, R: Right, L: Left. Adapted with 
modifications from Srivastava, et al. Cell 2006, 126(6):1037-1048. 
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of the body, leading to formation of the right and left atrium [37] (Figure 1.1 H).  Heart 
looping positions the ventricles posteriorly and connected to the common OFT [38]. 
Although the molecular regulators of cardiac looping are not well known, differential 
gene expression in cells of inner and outer curvature of the looped heart suggests that 
cardiac looping is driven by intrinsic signalling [39]. In addition, concurrent 
incorporation of SHF cells into the heart tube and rightward looping indicates a possible 
role of SHF in cardiac looping. Followed by heart looping, development of the septal 
walls along the atria, ventricle and OFT is initiated to partition the heart into a four-
chambered structure with distinct inflow and outflow vessels. 
1.2.3 Septation of Ventricles and Atria  
Septation of the atria and ventricular chambers occurs during E9.5 to E14.5 in 
mice and during the 5th to 7th week of gestation in humans [36,40]. The ventricular 
septum of the adult heart has two parts: the muscular and membranous septum. At E10.5 
in mice, septation of the common ventricles initiates followed by ingrowth of muscular 
septum from the ventricular wall towards the base of the heart. The muscular septum 
does not fuse to the base of the heart at this stage, thus leaving an opening between the 
two ventricular chambers at the AV canal. This opening will close after formation of the 
membranous septum along the AV canal.  
An essential process in septation of AV canal is the development of the 
endocardial cushion. The endocardial cushion develops followed by heart looping, when 
the myocardium initiates deposition of extracellular matrix in regions of AV canal and 
OFT. Accumulation of specialized ECM, the cardiac jelly, between the myocardial and 
endocardial cell layer results in formation of bulging acellular structures. Subsequently, 
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endocardial cells of the cardiac cushion undergo epithelial to mesenchymal transition 
(EndMT) and migrate toward the cardiac jelly, forming the cellular structures termed the 
endocardial cushion [41]. The endocardial cushion that forms between the dorsal and 
ventral sides of the AV canal is called the AV cushion, which will participate in atrial and 
ventricular septation (membranous septum), as well as AV valve formation [41]. 
Therefore, proper development of the endocardial cushion is a critical process for 
formation of a functional cardiovascular system. 
 Septation of the atrium chamber occurs after development of two parallel septal 
structures called septum primum and septum secundum [36,41]. Formation of septum 
primum initiates at E9.5 in mice by outgrowth of a thin interatrial membranous septum 
on the dorsal side towards the AV cushion (Figure 1.2 B). On the edge of the septum 
primum a distinct cell layer forms a mesenchymal cap[36]. The septum primum and 
mesenchymal cap will grow towards the AV cushion but will not fully fuse with the AV 
cushion. Thus, it leaves an opening between the atrial chambers at the site close to the 
AV cushion (Figure 1.2 C). This opening is called the foramen primum and it allows 
blood shunting between the atria chambers (Figure 1.2 C) [36]. The foramen primum 
will fully close in the fetal heart after fusion of the septum primum to the endocardial 
cushion at E12.5 (Figure 1.2 D). However, before closure of the foramen primum, a new 
foramen appears by programmed cell death (apoptosis) in the anterior side of the septum 
primum  (Figure 1.2 C) [36]. This opening is called the foramen secundum and it enables 
a continuous passage of blood between the atria when the foramen primum is closed 
(Figure 1.2 D). At E13.5, the septum secundum grows on the right side of septum 
primum (Figure 1.2 E). Septum secundum is a thick muscular structure, which originates 
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from the anterior region of the right atrium [36]. Growth of the septum secundum covers 
the foramen secundum but does not fully cover the posterior inferior surface of the 
septum primum, leaving an opening that is called foramen ovale (Figure 1.2 F) [36]. The 
physiological significance of foramen ovale will be discussed in the fetal heart 
physiology sections. 
 
Figure 1.2. Formation of atrial septum. 
A) Four-chambered heart structure prior to septation. Note blood flows from both atria to 
the left and right ventricles. Blood from both ventricles flows to a common outflow tract 
(OFT).  B-F) Lateral view of atria and ventricle demonstrates stages of atrial septum 
development. Refer to the text for detailed explanation. A: atria, EC: endocardial 
cushion, FO: foramen ovale, FP: foramen primum, FS: foramen secundum, LA: left atria, 
LV: left ventricle, MC: mesenchymal cap, OFT: outflow tract, RA: right atria, RV: right 
ventricle, SP: septum primum, SS: septum secundum, V: ventricle. Adapted with 
modifications from Sylva, et al. Am J Med Genet A 2014, 164A(6):1347-1371. 
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1.2.4 Septation of the Outflow Tract  
Early in heart development, the right and left ventricles share a common OFT 
called truncus arteriosus. Septation of the truncus arteriosus begins at E9.5, dividing it 
into the aorta and pulmonary artery by E14.5 [42]. During OFT septation, a spiral septum 
forms in the midline of the truncus arteriosus and will grow down towards the 
interventricular septum and fuse with it [36,42]. This process will form an entwined 
structure of aorta and pulmonary artery which links the aorta to the left ventricle and 
pulmonary to the right ventricle. The OFT septum creates two same size arteries with 
dorsal-ventral orientation [42]. Loss of the dorsal-ventral patterning results in abnormal 
connection of aorta and pulmonary arteries to ventricular chambers. These malformations 
will be discussed in details in future sections.   
1.2.5 Physiology of Fetal Heart  
Due to the fetus’ dependence on the mother’s circulation, fetal blood circulation 
differs from postpartum circulation [43]. In the adult heart, deoxygenated blood flows 
from the inferior and superior vena cava to the right atrium and is pumped into the right 
ventricle. Venous blood in the right ventricle is then pumped to the pulmonary circulation 
via the pulmonary artery. Oxygenated blood from the lungs flows back via pulmonary 
veins to the left atria, pumped into the left ventricle and then ejected to systemic arteries 
via the aorta to distribute to all body organs [43]. In the fetus, oxygen is transferred via 
the placenta since the lungs are not functionally active. Thus, the fetal heart develops 
structural adaptations, called shunts to pass blood in different directions. An important 
blood shunt in the fetal heart is the ductus arteriosus that links the pulmonary artery to the 
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aorta. Fetal oxygenated blood received from placenta flows via the umbilical veins 
through the interior vena cava to the right atrium and then some is pumped to the right 
ventricle. When the right ventricle pumps blood towards the pulmonary artery, most of 
the blood is shunted through the ductus arteriosus and into the dorsal aorta due to the 
high-pressure resistance of the pulmonary artery. During fetal development, high oxygen 
tension and prostaglandin levels secreted from the placenta keep the ductus arteriosus 
opened [44]. The other important fetal shunt is the foramen ovale that shunts blood 
between the right and left atria. Increased pressure of right atria passes some of the 
oxygenated blood via the foramen ovale to the left atria. Following the first breath, the 
neonate’s lungs inflate and resistance in the pulmonary veins will significantly decrease, 
allowing more blood flow to the pulmonary circulation. In addition, due to reduced 
oxygen and increased pressure in the left atria, the septum secundum covers the foramen 
ovale and blocks atria blood shunt. Within hours to days after birth, with reduction of 
prostaglandin levels in the neonate, the ductus arteriosus is closed to avoid the mixture of 
oxygenated and deoxygenated blood [44]. Therefore, partitioning of the heart is 
functionally complete.  
1.2.6 Molecular Regulators of Early Heart Development 
1.2.6.1 Nkx2.5  
One of the early markers of cardiomyocyte specification is Nkx2.5 (NK2 
transcription factor, locus5) that is expressed in the cardiac crescent (starting at E7 in 
mice) and in their myogenic descendants [45,46]. Although the homologue of Nkx2.5 in 
Drosophila, Tinman, is essential for heart tube formation [47], Nkx2.5 expression in mice 
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is dispensable for heart tube formation [48], but it is specifically required for left 
ventricular chamber development [49]. Nkx2.5 is a DNA binding transcription factor that 
is expressed in both FHF and SHF during embryogenesis and demonstrates robust 
expression in adult cardiomyocytes as well [45,50,51]. Importantly, Nkx2.5 regulates 
expression of cardiac genes that determine terminal differentiation of cardiomyocytes 
[52]. Additionally, Nkx2.5 is robustly expressed in specialized cardiac conducting cells 
during embryogenesis, suggesting its possible role in development of the conduction 
system [53]. Nkx2.5 null mice demonstrate impaired cardiac morphogenesis including 
reduced myocardial growth and trabeculation [52]. Therefore, loss of Nkx2.5 results in 
arrest of heart development in early stages of embryonic development after heart looping 
[48,52].  
1.2.6.2 GATA 4, 5, 6 
The GATA family is a group of zinc finger transcription factors, which interact 
with the guanine-adenine-thymine-adenine (GATA) binding site of DNA to regulate 
expression of downstream genes. Six isoforms of the GATA transcription factor have 
been identified in vertebrates, three of which are expressed in cardiac progenitors: 
GATA4, GATA5 and GATA6 [54]. GATA4 is expressed in embryonic and adult 
cardiomyocytes [55,56]. Although, GATA4 expression is not critical for cardiac lineage 
specification [57],  loss of Gata4 in endoderm is lethal due to impairment of cardiac 
morphogenesis [58,59]. Specifically, in Gata4 null mice, the lateral cardiac crescents fail 
to fuse, thus the heart tube will not form, leading to formation of cardiac bifida [58,59]. 
In addition, GATA4 directs transcriptional activation of factors that regulate 
cardiomyocyte proliferation and differentiation [60,61]. Furthermore, epicardial 
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expression of GATA4 and GATA6 are essential for development of endocardial cushion 
and cardiac vasculature [62,63]. GATA5 expression in the heart is identified as early as 
E9.5 in endocardial cells and later on in the endocardial cushion up to E12.5 in mice [64]. 
GATA5 plays a critical role in endocardial differentiation, aortic valve development and 
through interaction with GATA4 and GATA6, it contributes to formation of the OFT [64-
66]. In addition to their role in regulation of cardiac development, GATA4 and GATA5 
regulate cardiomyocyte proliferation cooperatively [67]. There have been limited 
numbers of studies on the role of GATA6 in mammalian heart development. Early 
investigation demonstrated that GATA6 expression is essential for development of extra-
embryonic tissues at early embryonic stages, and full body knockout embryos die before 
implantation [68]. Studies in amphibians demonstrated that GATA6 is required for 
cardiac maturation, and its loss in cardiac progenitors delays cardiomyocyte terminal 
differentiation [69]. Notably, GATA4 and GATA6 double mutants demonstrate loss of 
cardiac differentiation resulting in acardia phenotype in mice [70]. With recent reports of 
GATA6 mutations in cases with CHDs, a more thorough analysis of GATA6 function in 
heart development is essential [71,72].  
1.2.6.3 TBX5 
TBX5 (T-box 5) transcription factor expression is observed in the cardiac crescent 
as early as E8 in mice, and then it is observed in the posterior part of the linear heart tube, 
corresponding to the region that will form the future sinus venosus and atria. TBX5 
expression in the myocardium of the linear heart tube will become more robust and 
restricted to the left ventricle as the heart tube loops to the right. The asymmetric pattern 
of TBX5 expression persists up to E11.5, leaving no expression in the right ventricle and 
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OFT. At E13.5, expression of TBX5 will be more robust in the left superior vena cava, 
atria walls, septum primum and secundum [73,74]. Tbx5 null mutation disrupts 
expression pattern of several genes including Gata4, resulting in hypoplasia of the 
primitive atria, inflow tract and left ventricle, leading to arrest of cardiac development by 
E9.5 [75]. A 50% reduction of Tbx5 mRNA levels in Tbx5+/- mice caused defects in 
formation of atrial septum secundum and primum and occasionally defects in the 
ventricular septum.  
1.2.6.4 MEF2 
Monocyte enhancer factor 2  (MEF2) is a transcription factor that binds to 
adenine-thymine (AT) rich DNA domains to regulate expression of muscle specific genes 
[76]. In the mouse MEF2 family, there are four genes: Mef1A, Mef2B, Mef2C and Mef2D. 
Although all of the genes are expressed during early heart development, Mef2C received 
considerable attention as the first Mef2 factor to be expressed in cardiac precursors and its 
requirement for heart looping [77,78]. SHF precursor cells residing medial to the cardiac 
crescent express MEF2C and this expression will continue in the OFT and right ventricle 
[79]. Null mutations in Mef2c results in impaired heart looping, absence of right ventricle 
formation and reduced expression of cardiac alpha-actin [78]. Expression of Mef2C is 
regulated through specific interactions of transcription factors GATA4 and ISL1 with its 
promoter [79].  
1.2.7 Transcription Factor Interactions  
Regulation of heart development by transcription factor activity is a sophisticated 
phenomenon. Often individuals with mutations in different transcription factors 
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demonstrate the same cardiac abnormality. As an example, mutations in Gata4, Nkx2.5 or 
Tbx5 may manifest as septal defects in the atria or ventricles or other CHDs that are often 
associated with conduction defects [23,80,81]. There has been accumulating evidence 
that transcription factors work in combinations to activate expression of downstream 
genes. As an example, functional interaction of NKX2.5 with TBX5 or GATA4, and 
functional interaction of GATA4 with TBX5 has been demonstrated to be essential for 
regulation of downstream genes controlling cardiomyocytes differentiation or septal 
development [82-84]. Moreover, cardiac transcription factors may activate transcriptional 
expression of their cofactors. As an example, GATA4 activates transcriptional expression 
of Nkx2.5 through interaction with the GATA binding sites on the Nkx2.5 promoter 
region [85] and Nkx2.5 activates expression of GATA6 through interaction with its 
promoter [86]. Thus, when analyzing the genetics of CHD, a sophisticated model of 
interacting transcription factors should be considered.   
1.2.8 Regulators of Endocardial Cushion Development 
Endocardial cushion development is critical for normal heart development and its 
malformation is associated with severe septal and valvular defects [87]. Formation of 
cellular structures in the endocardial cushion is initiated by activation of endocardial cells 
to undergo epithelial to mesenchymal transition (EndMT).  This process has three 
essential stages: 1) activation of endothelial cell transformation in response to paracrine 
and autocrine signals from the myocardium and endocardium, respectively, 2) 
modulation of cell-cell adhesion and acquisition of a mesenchymal phenotype, and 3) 
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migration and residing in the cardiac cushion. The following is a description of growth 
factors and signalling molecules that are essential to form endocardial cushion structures.  
EndMT is initiated upon receiving signals from the myocardium [88]. The two 
important classes of signalling molecules in the initiation of EndMT are bone 
morphogenic proteins (BMPs) and transforming growth factor β (TGF-β) that are 
members of the TGF-β superfamily. There are three isoforms of TGF-β: TGF-β1, 2, and 
3. Around the time of endocardial cushion development, TGF-β1 shows ubiquitous 
endocardial expression that will gradually be restricted to endocardial cells at the AV and 
OFT [89]. TGF-β2 expression is restricted to the OFT and AV myocardium. TGF-β3 
expression is not detectable until after formation of the cardiac cushion, and it is 
expressed in the myocardial as well as in endothelial and mesenchymal cells [90-92]. Due 
to the broad activity of the TGF-β family during early embryogenesis, null mutations in 
Tgf-β1 [93-95], Tgf-β2 [96] and Tgf-β3 [97,98] cause a wide range of developmental 
defects and early lethality in mice. Therefore, most studies on TGF-β regulation of EMT 
have been performed on endocardial cushion explants. These studies demonstrated that 
addition of either TGF-β2 or 3 or a combination of both stimulates EndMT induction in 
chick AV explant culture [92,99,100]. However, the significance of TGF-β isoforms 
varies in different species. In contrast to observations in chicks, TGF-β3 knockout mice 
do not exhibit overt endocardial cushion defects [97], and the role of TGF-β2 in the 
regulation of EndMT seems to be more prominent [101]. Differences in the temporal and 
spatial patterning of TGF-β2 and 3 expression suggests that TGF-β2 and TGF-β3 are 
sequentially and separately involved in the process of EMT in mice. While TGF-β2 
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mediates the initial endothelial cell-cell separation, TGF-β3 is required for 
the cell morphological changes that enable migration of cells into the underlying  
extracellular matrix [102]. 
The BMP family has numerous isoforms with distinct or overlapping functions. 
The important BMP ligands that participate in endocardial cushion formation are BMP2 
and BMP4 that are expressed in the myocardium of the AV cushion in the same temporal 
and spatial pattern as TGF-β expression [103,104], indicating functional interaction 
between TGF-β and BMPs. Knockouts of Bmp2 or Bmp4 are both embryonic lethal 
before E9.5 making in vivo analysis difficult to perform [105,106]. However, 
development of antisense technology has made it feasible to examine the significance of 
BMPs in the regulation of EndMT [107]. These experiments demonstrated that although 
BMP2 is required for the initiation of EndMT, it is not sufficient to induce EMT in 
endocardial cells. These studies also demonstrated that BMP2 acts synergistically with 
TGF-β3 in the induction and regulation of EMT [108,109].  
A common mediator of BMP and TGF-β signalling in the regulation of EndMT is 
the SMAD protein family [110,111]. Through distinct signalling pathways, both BMP 
and TGF-β phosphorylate and activate different family members of SMADs, which leads 
to nuclear localization of SMAD4 for regulation of downstream target genes such as 
Snail1, an important regulator of cell migration [112,113]. Another pathway that 
regulates Snail1 expression is the Notch1 signalling pathway that works in parallel with 
TGF-β in regulation of EndMT. Notch1 is expressed in endocardial cells and promotes 
TGF-β2-induced EMT through transcriptional activation of Snail1 expression [114,115]. 
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Mutations in NOTCH1 or its ligand (DELTA or JAGGED) are associated with aortic 
valve or OFT defects, respectively [116,117].  
Apart from differentiation, proliferation of endocardial cells is an essential part of 
endocardial cushion formation. Vascular endothelial growth factor A (VEGF-A) is an 
important growth factor that is expressed in endocardial and myocardial cells during early 
embryogenesis. During heart development, VEGF-A expression is gradually restricted to 
endocardial cells adjacent to the AV cushion and OFT region [118]. Myocardial 
overexpression of VEGF-A at E9.5 inhibits endocardial cushion formation in mice and 
induces CHDs [119]. Additionally, overexpression of VEGF-A in endocardial cells in 
mice resulted in severe abnormalities in ventricular septation and OFT remodelling, 
causing embryonic lethality by E12 to 14.5 [120]. NFAT (nuclear factor in activated T 
cells) is a transcription factor that is expressed in endocardial cells covering AV cushion, 
and it is crucial for endocardial cushion development [121,122]. Loss of NFATc1 in mice 
results in defects of endocardial cushion development, as a result of impaired cell 
proliferation. Importantly, VEGF is upstream regulator of this NFAT activation and 
nuclear localization [88,123]. Overall, these studies suggest that VEGF-A is an important 
regulator of endocardial cushion development and any alterations in VEGF-A dosage 
impairs cardiac development [88].   
1.2.9 Morphological Aspect of Coronary Artery Development    
 The coronary vasculature originates from the ascending aorta at the sinus of the 
aortic valves to distribute oxygenated blood to the heart [124]. Coronary arteries branch 
from the base of the aorta and travel along well-defined paths to reach the cardiac apex. 
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Arteries form a vascular network to ensure an efficient supply of oxygenated blood to the 
myocardial cells. Deoxygenated blood is collected into capillary veins, which drain into 
the right atrium, inferior to the opening of superior vena cava. Structurally, coronary 
arteries are composed of three cell layers: endothelium, smooth muscle cells and 
fibroblasts. In the following, I will describe the process of coronary network formation 
during embryogenesis.  
 The coronary network in the myocardium forms during two processes: 
vasculogenesis and angiogenesis [125]. Vasculogenesis refers to de novo formation of the 
primitive vessels network and angiogenesis refers to growth and remodeling of the 
primitive network into a complex network. During heart development, vasculogenesis 
initiates after the formation of an epicardial cell layer at E10.5, followed by development 
of the vascular network through the process of angiogenesis. Here, I will review the 
morphological aspects of vasculogenesis in the embryonic heart and then describe 
essential molecular factors in the regulation of coronary artery formation in the heart.  
Early precursors that participate in the formation of the vascular network in the 
heart emerge from outside of the heart field around E9.5 in mice [126], form a structure 
called the proepicardium organ (PEO). The PEO are a group of cells that emerge from a 
region close to the sinus venosus and the liver primordium. During E9.5 to E10.5 in mice, 
cells of the PEO migrate toward the heart and proliferate to expand over the myocardium 
and form the epicardial cell layer [127-129]. While epicardial cells proliferate to cover 
the myocardium, some of the epicardial cells undergo epithelial to mesenchymal 
transition (EMT) and dissociate from the epicardial cell layer to invade the myocardium 
[130]. Cells of epicardial origin that undergo EMT are called epicardial derived cells 
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(EPDCs). EPDCs primarily reside in the subepicardial space and after migration into the 
myocardium, they differentiate into a variety of cell types including smooth muscle cells, 
perivascular and interstitial fibroblasts [131-133]. The endothelial capillary network 
works as a scaffold for EPDCs, where they differentiate into smooth muscle cells and 
fibroblasts to establish the coronary artery network at E14.5. Interaction of smooth 
muscle cells and endothelial cells is critical since vessels will regress easily if they are 
not covered with smooth muscle cells [134].  
The developmental origin of coronary endothelial cells has been the subject of 
many experimental studies and still remains a controversial issue [135-137]. Primarily, 
endothelial progenitors have been reported in the subepicardial space, growing into the 
myocardium and eventually connecting to the aortic root [138-140]. Studies on quail-
chick chimera embryos demonstrated that coronary endothelial cells emerge from the 
PEO, where they arise as EPDCs and form primary endothelial tubes in the myocardium 
[136,141-143]. However, this developmental model was later challenged in epicardial 
lineage tracing studies of mice where very few Wt1+ and no Tbx18+ EPDCs in the 
myocardium obtained an endothelial cell fate [137,144]. Recent studies have provided a 
better understanding of endothelial cell origin by demonstrating that endothelial cells 
originate from the endothelial sprouts of the sinus venosus, which is located in the 
subepicardial space. Endothelial cells later on migrate into the subepicardial space and 
then the myocardium to form the endothelial cell population of coronary arteries 
[145,146]. This conflict appeared to be resolved after a group of researchers 
demonstrated that a subpopulation of cells from the PEO contribute to the formation of 
the sinus venosus and also cardiac endothelial cells [147]. Additionally, fate mapping and 
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clonal analysis demonstrated a subset of endothelial cells originated from endocardial 
cells [148]. Overall, coronary endothelial cells originate from a mixed precursor 
population. Both EPDCs and subepicardial endothelial cells contribute to the development 
of coronary arteries with minor contribution from the endocardium. 
1.2.10 Molecular Regulators of Coronary Artery Development   
Transcription factors, signalling molecules and growth factors that regulate 
formation of the epicardium and EPDCs are numerous [149]. Signals that regulate 
coronary artery development arise from two sources: epicardial and myocardial cells. 
Epicardial and myocardial cells signal to each other to coordinate formation of the 
vascular network and growth of the myocardium [150]. It is believed that hypoxia is the 
initial signal that drives vasculogenesis. Hypoxia inducible factor 1 (HIF1) is a 
transcription factor that is expressed during hypoxia and oxygen levels will alter its 
stabilization or degradation [151]. HIF1 will activate transcriptional expression of several 
pathways including genes that are involved in angiogenesis, cell proliferation, apoptosis, 
glucose metabolism, and cell survival [152,153]. HIF1 transcription factor is composed 
of two isomers called α and β, which dimerize for transcriptional activity [154]. 
Functional studies in embryos revealed high activity of HIF1α in the regulation of 
vasculogenesis. Reduced HIF1α expression impairs normal coronary artery development 
[155,156]. One of the downstream targets of HIF1α that has a pivotal role in coronary 
vasculature formation is Wilms tumor-1 (Wt1) [157]. During cardiac development, Wt1 
is a key regulator in the formation of the PEO and epicardial cells [158]. Conditional 
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knock out of Wt1 in epicardial cells results in loss of coronary artery development and 
fetal lethality between E16.5 to E18.5 [159].  
A prominent downstream target of Wt1 in the regulation of epicardial EMT are 
the transcriptional factors Snail1 and Slug that belong to the family of zinc finger 
transcription factors [159-162]. Slug expression is detected in the PEO, epicardial cells as 
well as epithelial and mesenchymal cells in the avian heart [163]. Snail1 expression is not 
detected in the PEO but it is present in epicardial and subepicardial cells at E10.5-12.5 as 
well as in EPDCs at E14.5-16.5 in mice [164]. Snail1 and Slug promotes EMT through 
repressing the expression of E-cadherin, a transmembrane protein that forms cellular 
junctions and inhibit cell migration. However, in comparison to Snail, Slug demonstrates 
less ability to inhibit E-cadherin expression [162,165].  
Retinoic acid (RA), the active derivative of vitamin A, has a prominent role in the 
development and growth of the myocardium and coronary vasculature [166]. In 
particular, RA signalling mediates vasculature development by maintaining myocardial 
and epicardial cell adhesion that is essential for proper signalling between the 
myocardium and epicardium. As well, RA signalling promotes epicardial EMT, EPDCs 
differentiation and cardiomyocyte proliferation through activation of bFGF secretion 
from the myocardium [167,168]. RA depletion during early embryogenesis impairs 
growth and development of the early heart tube and also diminishes Gata4 transcriptional 
expression [169,170]. In addition, depletion of RA signalling during vasculogenesis 
impairs epicardial cell layer formation, myocardial growth and formation of the vascular 
network [168,171]. Notably, Wt1 and retinaldehyde dehydrogenase (RALDH2), the 
enzyme that catalyzes a critical step in RA production, have an epicardial expression 
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pattern [158,172]. Recent studies demonstrated that Wt1 regulates epicardial expression 
of RALDH2 [173,174] in the regulation of coronary vasculogenesis in mice [175 ]. 
Hence, through various mechanisms, RA regulates myocardial growth and vascular 
development of cardiac progenitors in the heart. 
1.3 CONGENITAL HEART DEFECTS  
As discussed in the previous sections, heart development is ruled by precise 
regulation of gene expression and signalling molecules. Modifications to gene expression 
during heart development will lead to abnormalities in heart structure and impair heart 
function. The morphological defects that occur during heart development in embryos are 
called congenital heart defects (CHDs). The incidence of CHDs in the general population 
is 1-5% [176,177]. With advances in cardiac repair surgeries, many children born with 
CHDs will survive to adulthood, thus, genetic factors that induce cardiac defects will be 
more likely to be passed onto the next generation [178]. Based on recent reports, the 
prevalence of CHDs in infants born to mothers with CHDs is 2-20% [179].  This raises a 
public health concern and demonstrates a critical need to understand the underlying 
molecular mechanism of CHD and development of preventative and therapeutic 
strategies.  
1.3.1 Genetics and Environmental Basis of CHDs 
Abnormalities in cardiovascular development are caused by inherited or non-
inherited factors [180,181]. Inherited factors are presented as chromosomal disorders, 
Mendelian syndrome or non-syndromal single gene mutations. Chromosomal disorders 
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account for 8 to 10% of CHDs, Mendelian syndrome accounts for 3 to 5% of CHDs and 
non-syndromal single mutation accounts for a very small population of CHDs [181]. 
Thus, at present, only about 15% of CHDs can be attributed to a genetic factor while the 
cause of the other 85% of CHDs still remains unknown. Non-inherited factors refer to 
environmental conditions that increase the prevalence of CHDs in infants. These factors 
include maternal alcohol consumption, nicotinic smoke, and maternal illness such as 
pregestational diabetes [12].  Collectively, it is speculated that the majority of CHDs have 
a multifactorial origin, referring to a combination of genetic and environmental factors. 
1.3.2 Types of Congenital Heart Defects 
CHDs studied in this thesis can be divided into four groups: septal, conotruncal, 
valvular and coronary artery malformations. Septal defects include malformation of the 
atrial or ventricular septum. Conotruncal defects include tetralogy of Fallot (TOF), 
pulmonary atresia, double outlet right ventricle (DORV), and dextro-transposition of 
great arteries (d-TGA or TGA). Cardiac valve defects include malformation of aortic or 
atrioventricular valves, and coronary artery malformations include formation of 
hypoplastic coronary arteries. The following section is a description of the origin of these 
defects and their genetic basis.   
1.3.3 Atrial Septal Defects 
Atrial septal defect (ASD) occurs when there is a failure in formation of the 
septum between the right and left atria, thus blood shunts between atrial chambers. ASD 
is a common type of CHDs with a worldwide prevalence of 1.6 per 1000 live births 
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[182]. ASD reduces heart function but it is not a cyanotic type of heart defect, meaning 
that it does not cause blue coloring of the skin or lips. This is due to the fact that the 
higher pressure in the left atrium will direct oxygenated blood into the deoxygenated 
right atrium. ASDs may occur in the septum primum or septum secundum. Defects in 
formation of the septum primum occur as a result of failure in fusion of the septum 
primum to the endocardial cushion. Thus, ASD primum defects may rise due to 
decreased cell proliferation of the septum primum or abnormal development of 
endocardial cushion [183].  Secundum ASD is persistence of the foramen ovale, which 
may occur as a result of inadequate growth of septum secundum or excess apoptosis in 
septum primum. As discussed in previous sections, foramen secundum forms by 
apoptosis (Figure 1.1). However, excessive apoptosis in the septum primum could result 
in an oversized foramen secundum that does not cover up the septum secundum 
membrane. Holt Oram syndrome, associated with TBX5 mutation and DiGeorge 
syndrome, associated with TBX1 mutation, are both chromosomal abnormalities that 
result in ASD secundum defects [184]. In addition, non-syndromal familial single 
mutations in NKX2.5 [185], TBX5 and GATA4 [84] are also associated with secundum 
defects. Recent reports indicated a molecular interaction of GATA4, NKX2.5 and TBX5, 
which is required and critical for formation of the atrial septum [186]. 
1.3.4 Ventricular Septal Defects 
As mentioned before, the ventricular septum is composed of membranous and 
muscular structures. The membranous septum is a small part of the ventricular septum 
and is located beneath the AV valves at the base of the heart. The muscular septum 
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extends from the apical side of the ventricles to the membranous septum. Septal defects 
can occur either in the muscular or membranous part of the ventricular septum [187]. The 
worldwide prevalence of ventricular septal defect (VSD) is 2.6 per 1000 live births [182]. 
Interruption in formation of the membranous septum or fusion of the membranous to 
muscular ventricular septum results in an opening in the septum that allows blood flow 
communication between oxygenated and deoxygenated blood of the two ventricles. 
Mutations in NKX2.5 and GATA4 genes have been reported in cases with VSD [188-
193]. Additionally, Holt-Oram syndrome or TBX5 mutation is associated with VSD [84]. 
Notably, human genetic studies reported a GATA4 mutation that impairs its functional 
interaction with TBX5 and is associated with familial incidence of VSD [84,194]. This 
data implies that functional interaction of GATA4, NKX2.5 and TBX5 may be essential 
for ventricular septum development.  
1.3.5 Atrioventricular Septal Defects 
Atrioventricular septal defect (AVSD) or atrioventricular canal defect (AVCD) is 
occurrence of an ASD at the site of ostium primum that is higher than the AV valves 
accompanied by a membranous VSD [195]. Structurally, AVSD is caused by 
malformation of the endocardial cushion and is often associated with abnormal AV valve 
(mitral and tricuspid) formation. AVSD has a 48% postnatal mortality rate [196] and with 
the prevalence of 0.24-0.31 per 1000 live births, it is considered a rare type of CHD 
[197,198]. The incidence of AVSD in neonates with trisomy 21 (Down’s Syndrome) is 
17% [199,200]. The genes involved in non-syndromic AVSD include NKX2.5, GATA4, 
and TBX5 [201-205]. Although the mechanism underlying this defect is not fully 
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understood, pre-gestational diabetes significantly increases the risk of both syndromic 
[206] and non-syndromic complete AVSD [207]. 
1.3.6 Tetralogy of Fallot 
The most common cyanotic defect is tetralogy of Fallot (TOF), which originates 
due to malformation of the aorticopulmonary septum. This defect includes four elements: 
pulmonary stenosis, right ventricular hypertrophy, overriding aorta and VSD. Pulmonary 
stenosis occurs as a result of unequal partitioning of the OFT. Thus, the aorta is wider and 
the pulmonary artery is narrowed. The second element of TOF is overriding aorta, which 
is the opening of the aorta over both ventricles. Overriding aorta occurs due to 
misalignment of the OFT septation which slightly shifts the OFT to the right and it 
straddles over both ventricles. The third element of TOF is a VSD, which is due to 
abnormal formation of the interventricular septum. The forth element is hypertrophy of 
the right ventricle, which is a physiological response to the narrowed pulmonary artery. 
Since the pulmonary artery is narrowed it has a higher resistance and the right ventricle 
must pump with more force to overcome the resistance, resulting in right ventricle 
hypertrophy. The consequence of TOF is shunting of the deoxygenated blood from the 
right ventricle to left ventricle through the VSD and misaligned aorta.  
TOF is reported in 3.3 per 10,000 live births and corresponds to 6.8% of all types 
of CHDs [182,208]. TOF may occur as a result of anomalies in chromosomes 8 and 22 
[209,210]. In chromosome 22 anomaly (DiGeorge syndrome), the TBX1 gene lies within 
the deleted region. Additionally, TBX1 polymorphism has been reported in individuals 
with OFT defects [211]. Single gene mutations in JAG-1, a Notch1 ligand, VEGF-a, 
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NKX2.5, GATA4 and its cofactor FOG2, have been identified in individuals with TOF 
[181,212-214]. However, these mutations are identified in a limited population of TOF 
patients. As an example, only 1-4% of TOF patients have a mutation in the NKX2.5 gene 
[215,216] and only 1.3% of TOF patients have mutations in FOG2 [215,217 ]. 
Additionally, despite a report on VEGF-a mutation in patients with TOF, a recent meta-
analysis of a large population of TOF patients did not find a significant contribution of 
VEGF-a mutation to the incidence of TOF [218]. Therefore, our knowledge on genetic 
regulators of TOF is still limited. The environmental risk factors of TOF include maternal 
alcohol consumptions, RA (vitamin A) deficiency and maternal illnesses such as 
diabetes, rubella and phenylketonuria [181].  
1.3.7 Dextro-Transposition of the Great Arteries 
  In the normal heart, the aorta originates from the left ventricle and the pulmonary 
artery originates from the right ventricle. Septation of the aorta and pulmonary artery 
occurs after formation of a spiral shaped aorticopulmonary septum. In the case of dextro-
transposition of great arteries (d-TGA or TGA), the aorticopulmonary septum does not 
form in a spiral shape and instead it forms a straight septum [182,219]. This division 
causes the aorta to open into the right ventricle and the pulmonary trunk to open into the 
left ventricle. Consequently, in the case of TGA, the pulmonary artery transfers 
oxygenated blood to the lungs and aorta caries deoxygenated blood to the body. 
Prenatally, this defect will not cause death due to the placenta blood transfer. Babies with 
TGA are born alive due to the opening of the ductus arteriosus, which is a vessel that 
links the aorta and pulmonary and allows mixture of oxygenated and deoxygenated 
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blood. However, corrective surgery is required otherwise death will occur. The 
worldwide prevalence of TGA is 3.5 per 10,000 live births [182,219]. Mutations in 
NKX2.5 and NODAL are associated with non-syndromal causes of TGA. Environmental 
conditions such as maternal diabetes is a risk factor for TGA [181].  
1.3.8 Double Outlet Right Ventricle 
Double outlet right ventricle (DORV) occurs as a result of disruption in 
remodeling of the OFT. In this type of defect, both the aorta and pulmonary are 
connected to the right ventricle. Hearts with DORV have an obligatory VSD for 
circulation of blood between the heart chambers. The incidence of DORV is estimated to 
be 1.6 per 1000 live births [213]. A small percentage of DORV is associated with 
chromosomal abnormalities such as trisomy 18 [181,220] or chromosomal deletion of 
22q11 [221-223]. Single gene mutations in NKX2.5 or GATA4 have a rare contribution to 
the incidence of DORV [220,224]. Mutation in the GATA4 cofactor, FOG2 was 
identified in 15% of patients with DORV [215]. Additionally, DORV demonstrated 
strong association with pregestational diabetes [225]. 
1.3.9 Hypoplastic coronary artery disease 
Hypoplastic coronary artery disease refers to abnormal development of coronary 
arteries, with marked reduction in the length or diameter of one or more major branches 
[226]. This condition may severely affect the heart’s function and results in sudden 
cardiac arrest in young or middle age adults [227-231]. Hypoplastic coronary artery is a 
silent disease and usually unexpectedly identified during angiography [232] or the 
autopsy following sudden cardiac death [233]. The incidence of coronary artery 
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anomalies in patients that are suspected for coronary artery obstruction is about 1% [234-
237]. Our knowledge on the genetic roots or environmental conditions that result in 
hypoplastic coronary artery disease is limited. A recent study showed that deficiency in 
nitric oxide release from endothelial nitric oxide synthase during heart development 
diminishes Wt1 and Gata4 transcript levels and results in formation of hypoplastic 
coronary arteries and consequently myocardial infarction in neonatal mice [238].  
1.4 MECHANISM OF CHDS IN PREGNANCIES AFFECTED BY 
DIABETES 
As discussed in previous sections, maternal diabetes before pregnancy elevates 
the risk of CHDs in the offspring. A combination of in vivo and in vitro experiments has 
been performed to enhance our understanding of the factors that induce congenital 
anomalies in pregnancies affected by diabetes. Primarily, studies in the 80’s 
demonstrated that the teratogenic effect of diabetes is related to elevation of blood 
glucose levels and not decreased insulin levels [239-243]. In vitro, addition of high 
glucose interrupted embryonic development and induced major embryonic malformations 
[244-246].  Supplementation of insulin-treated serum from diabetic mice to embryonic 
cultures reduced congenital malformations but did not prevent the risk of abnormalities 
[247,248], suggesting that serum of diabetic mice contains other teratogenic factors that 
were not eliminated by insulin treatments.   
The predominant form of glucose transportation in the placenta and embryonic 
heart tissue is glucose transporter 1 (GLUT1) [249,250] that is independent of insulin. 
Females with hyperglycemia will have excess glucose that is freely transported across the 
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placenta and metabolized in the embryonic tissue [251]. Increased glucose levels will 
increase glycolysis and this will lead to increased levels of NADH and FADH2, which 
are the electron donors for the electron transport chain of mitochondria. Increased 
mitochondria respiratory chain activity leads to increased oxygen consumption and ATP 
production. As a result of this process, superoxide generation that is a by-product of ATP 
production will be increased [252,253]. Interaction of superoxide with other molecules 
generates a combination of reactive oxygen species (ROS) that are highly reactive and 
can damage DNA or proteins. Additionally, diabetes is often associated with attenuation 
of antioxidant bioavailability. Overall, this condition that is defined as excess ROS 
generation and reduction of antioxidants levels is called oxidative stress and it is 
detrimental to embryonic growth, organogenesis and remodelling [254].  
In physiological conditions, excess ROS is depleted by an antioxidant defense 
system including catalase, superoxide dismutase and glutathione peroxidase. Glutathione 
peroxidase is an important antioxidant enzyme in depletion of ROS. In this enzymatic 
reaction, glutathione peroxidase breaks down H2O2 to H2O and O2 with the consumption 
of reduced glutathione (GSH) and converts it to oxidized glutathione (GSSG) [255]. In 
diabetic conditions, due to increased activity of glutathione peroxidase [256], reduced 
GSH are mostly oxidized. In addition, de novo GSH synthesis is diminished [256] that 
leads to reduced antioxidant capacity. Thus, H2O2 will be converted to hydroxyl radicals 
(OH•), which will cause extensive damage to molecular and cellular structures including 
DNA and proteins [254]. Overall, several studies have suggested a strong correlation of 
hyperglycemia with oxidative stress and congenital defects in embryos. However, the 
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specific molecular mechanism that leads to these defects and the potential therapeutic 
strategies remained elusive.  
Experiments in the late 90’s indicated that oxidative stress plays a major role in 
induction of birth defects. Early evidence on the role of oxidative stress in induction of 
birth defects appeared following reports that indicated supplementation of superoxide 
scavengers to embryonic culture media inhibited malformation induced by 
hyperglycemia [257]. Specifically, addition of ROS scavengers such as superoxide 
dismutase (SOD), catalase and glutathione peroxidase inhibited hyperglycemia-induced 
malformation. In addition, another study confirmed that overexpression of SOD led to 
reduced fetal malformations in the offspring of diabetic mice [258]. Furthermore, 
extensive studies revealed that addition of antioxidants such as vitamin E, C, butylated 
hydroxytoluene and GSH-ester to diabetic animals or high glucose cultures reduced the 
rate of malformations [256,259-263]. Therefore, these findings strongly implied that 
diabetic induced malformations were caused by oxidative stress and decreasing oxidative 
stress in embryos could be an important therapeutic approach.   
1.4.1 ROS Regulation of Growth and Development  
ROS refers to the derivatives of oxygen free radicals including O2– (superoxide 
anion), HO– (hydroxyl radical) and H2O2 (hydrogen peroxide) that are produced from 
different cellular sources under physiological or pathophysiological conditions [264]. The 
main sources of ROS production are: i) mitochondria respiratory mechanism, ii) NADPH 
oxidases, and iii) enzymatic activities such as xanthine oxidase and cytochrome p450. In 
embryos, a prominent source of intracellular ROS production is NADPH oxidase. 
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NADPH oxidase is a holoenzyme complex, with 7 isoforms of its catalytic subunit 
including NOX 1-5 and DOUX 1-2 [265]. NADPH oxidase enzyme complex is mostly 
localized on the plasma membrane. The produced superoxide may pass through 
aquaporin channels in the form of H2O2 and enter the cell to be involved in different 
biological reactions.  
ROS can mediate a variety of fundamental cellular process such as proliferation, 
differentiation, migration and apoptosis [266]. It is suggested that ROS functions as a 
classical signalling molecule, where the levels of ROS release determines the cell’s 
response. As an example, excess ROS levels induce cellular apoptosis and it is 
detrimental to embryonic growth [267-269], whereas, low or basal ROS levels mediates 
expression of genes required for differentiation [270] or proliferation [271,272]. 
1.4.2 Glutathione and Its Precursor N-Acetylcysteine 
Glutathione (GSH) is an important intracellular antioxidant with high intracellular 
concentration. Structurally, glutathione is a tripeptide that is composed of glutamate, 
cysteine and glycine [255]. GSH is the product of two enzymatic reactions that are 
mediated by two enzymes: glutamate-cysteine ligase (GCL) and GSH synthase. In the 
first reaction, cysteine is conjugated with glutamate by enzymatic activity of GCL and in 
the second reaction, glycine is added to glutamate-cysteine by enzymatic activity of GSH 
synthase (Figure 1.3). GCL activity is regulated by feedback inhibition of its final 
product, GSH [273]. Thus this metabolic reaction is considered as a rate-limiting step for 
GSH synthesis. Cysteine is required for GSH production. A major source of cysteine in 
humans is through diet or catabolism of proteins or methionine in the liver.  
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Figure 1.3. Glutathione synthesis 
Through an enzymatic reaction, N-Acetylcysteine (NAC) is converted to amino acid 
cysteine (Cys). Addition of amino acids glutamate (Glu) and glycine (Gly) to cysteine 
will produce glutathione peptide (GSH). Adapted with modifications from Rushworth 
and Megson, Pharmacol Ther 2013, 141(2), 150-9. 
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A precursor of cysteine is N-Acetylcysteine (NAC). Structurally, NAC is composed of an 
acetyl group attached to the nitrogen atom of the amino acid cysteine (Figure 1.3). Due 
to its small molecular size, NAC can cross the placenta and cell membrane. 
Intracellularly, NAC exerts its antioxidant effects by reacting with OH• and O2• 
[274,275]. In addition, most of the NAC is deacetylated to cysteine and utilized to 
replenish GSH levels [276,277].  NAC has a long history in clinical use to overcome 
glutathione deficiency in several disease conditions including: pulmonary disease, 
acetaminophen (paracetamol) toxicity, neurodegenerative disease and nephropathy [278-
282]. Overall, these studies reported that the protective effects of NAC are through 
attenuation of oxidative stress and apoptosis. Moreover, experimental analysis 
demonstrated that the teratogenic effects of diabetic serum or high glucose in rat 
embryonic development are prevented by NAC supplementation  [283,284]. In addition, 
NAC improved neural crest cell migration in a high glucose environment, in vitro and in 
ovo [285,286]. Thus, these studies suggest that NAC may exert beneficial effects in 
protecting embryos against oxidative stress induced in diabetic conditions. 
1.5 OVERALL HYPOTHESIS AND AIMS 
Pregestational maternal diabetes is associated with 3-5 fold increased risk of 
CHDs in neonates [9-12]. With the ever-increasing population of young adults with 
diabetes, our understanding of the molecular causes of birth defects and the therapeutic 
strategies to prevent these defects is critical. Accumulating evidence demonstrated excess 
ROS production and a reduced antioxidant defense system lead to oxidative stress in 
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embryos affected by pregestational diabetes [256-263]. The main goal of this thesis 
project is to understand the role of ROS during cardiac morphogenesis in diabetic and 
non-diabetic pregnancies. The overall hypothesis of this thesis is that maintaining 
proper ROS balance is required for expression of critical factors that regulate 
cardiac morphogenesis.  
The first aim of this thesis was to characterize CHDs in the offspring of mice with 
pregestational diabetes and to further investigate the state of oxidative stress and 
molecular mechanisms that are impaired in fetal heart during diabetic embryopathy. We 
further investigated therapeutic strategies to prevent CHDs in the offspring of mice with 
pregestational diabetes. In Chapter 2, I hypothesized that pregestational diabetes elevates 
oxidative stress in embryonic heart, alters cardiac gene expression levels and induces 
CHDs in neonates. Furthermore, I hypothesized that treatment of diabetic mice during 
gestation with an antioxidant, NAC, will reduce oxidative stress in the embryonic heart, 
and restore gene levels to prevent the development of CHDs in the offspring. A 
streptozotocin (STZ) induced mouse model was employed to characterize CHDs in the 
offspring. We characterized a broad range of defects including septal and conotruncal 
defects in the offspring of diabetic females. Both glutathione and ROS levels were 
determined in fetal hearts. In addition, cell proliferation and apoptosis, as well as 
expression levels of growth factors and transcription factors were assessed. Furthermore, 
the effect of NAC treatment in diabetic dams during gestation on fetal heart development 
was studied.  
CHDs may include abnormal formation of coronary artery structures, leading to 
null coronary artery or hypoplastic coronary artery disease [238]. Formation of coronary 
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arteries is pivotal for myocardial development and abnormalities in coronary artery 
structure elevates the risk of sudden cardiac death in youth [227]. Whether pregestational 
diabetes impairs coronary artery development is not known. Therefore, in Chapter 3, I 
examined the formation of coronary vasculature in the neonate born to mice with 
pregestational diabetes. I hypothesized that pregestational diabetes interrupts formation of 
coronary arteries by elevating ROS levels, altering expression levels of genes essential 
for vasculogenesis and interrupting migration of progenitor cells that participate in 
formation of coronary arteries. To test this hypothesis, formation of the capillary network 
and coronary arteries was assessed in the fetal and neonatal hearts of the offspring using 
histology and immunostaining. To study epicardial contribution to coronary artery 
formation, Wt1-mediated lineage tracing was performed. The expression of genes 
essential for vasculogenesis and epicardial cell migration and proliferation were 
determined. Additionally, effects of NAC treatment in the diabetic dams on their 
offspring’s coronary vasculature development, ROS production, gene expression and 
epicardial cell migration and proliferation were investigated.  
Excess ROS levels are detrimental to embryonic growth and development [287]. 
However, the role of basal ROS levels in regulating heart development and growth 
remained elusive. In Chapter 4, I investigated the role of basal ROS production in 
embryonic heart development. I hypothesized that physiological levels of ROS are 
essential for normal heart development in mice.  To address this hypothesis, I employed 
mice with a deletion in the NADPH oxidase Nox2 locus, which abolishes ROS production 
from NOX2 source. Heart morphology was examined for congenital heart defects in 
neonates. In vivo cell proliferation, apoptosis and cell density of endocardial cushions 
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were assessed. Additionally, the number of cells undergoing EndMT was studied ex vivo. 
Furthermore, the role of the ROS/TGF-β/BMP signalling pathway in the regulation of 
EndMT was investigated. Thus, this thesis sought to examine the impact of pathological 
and physiological levels of ROS production in heart morphogenesis and their molecular 
mechanisms. The ultimate goal of my studies was to provide novel insights in developing 
therapeutic strategies in the prevention of CHDs in the offspring of pregestational 
diabetes. 
 
  
  
38 
1.6 REFERENCES 
1. International Diabetes Federation: IDF Diabetes Atlas, 5th edn. Brussels, 
Belgium: IDF. 2011. 
2. Sheffield JS, Butler-Koster EL, Casey BM, McIntire DD, Leveno KJ: Maternal 
diabetes mellitus and infant malformations. Obstet Gynecol 2002, 100(5 Pt 
1):925-930. 
3. Penney GC, Mair G, Pearson DW: Outcomes of pregnancies in women with type 
1 diabetes in Scotland: a national population-based study. BJOG 2003, 
110(3):315-318. 
4. Savona-Ventura C, Ellul A, Chircop M: The outcome of diabetic pregnancies in 
Malta. Int J Gynaecol Obstet 2003, 82(2):217-218. 
5. Feig DS, Razzaq A, Sykora K, Hux JE, Anderson GM: Trends in deliveries, 
prenatal care, and obstetrical complications in women with pregestational 
diabetes: a population-based study in Ontario, Canada, 1996-2001. Diabetes Care 
2006, 29(2):232-235. 
6. Fong A, Serra A, Herrero T, Pan D, Ogunyemi D: Pre-gestational versus 
gestational diabetes: A population based study on clinical and demographic 
differences. J Diabetes Complications 2013. 
7. Correa A, Gilboa SM, Besser LM, Botto LD, Moore CA, Hobbs CA, Cleves MA, 
Riehle-Colarusso TJ, Waller DK, Reece EA: Diabetes mellitus and birth defects. 
Am J Obstet Gynecol 2008, 199(3):237.e231-239. 
8. Garne E, Loane M, Dolk H, Barisic I, Addor M-C, Arriola L, Bakker M, Calzolari 
E, Matias Dias C, Doray B et al: Spectrum of congenital anomalies in pregnancies 
with pregestational diabetes. Birth Defect Res A 2012, 94(3):134-140. 
9. Bird TM, Hobbs CA, Cleves MA, Tilford JM, Robbins JM: National rates of birth 
defects among hospitalized newborns. Birth Defects Res A Clin Mol Teratol 2006, 
76(11):762-769. 
10. Lisowski LA, Verheijen PM, Copel JA, Kleinman CS, Wassink S, Visser GHA, 
Meijboom E-J: Congenital heart disease in pregnancies complicated by maternal 
diabetes mellitus. An international clinical collaboration, literature review, and 
meta-analysis. Herz 2010, 35(1):19-26. 
11. Wren C, Birrell G, Hawthorne G: Cardiovascular malformations in infants of 
diabetic mothers. Heart 2003, 89(10):1217-1220. 
12. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, 
Warnes CA, Webb CL: Noninherited risk factors and congenital cardiovascular 
defects: current knowledge: a scientific statement from the American Heart 
Association Council on Cardiovascular Disease in the Young: endorsed by the 
American Academy of Pediatrics. Circulation 2007, 115(23):2995-3014. 
13. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner RE: Pre-conception care 
of diabetes, congenital malformations, and spontaneous abortions. Diabetes Care 
1996, 19(5):514-541. 
14. Eriksson UJ, Cederberg J, Wentzel P: Congenital malformations in offspring of 
diabetic mothers--animal and human studies. Rev Endocr Metab Disord 2003, 
4(1):79-93. 
  
39 
15. Galindo A, Burguillo AG, Azriel S, Fuente Pde L: Outcome of fetuses in women 
with pregestational diabetes mellitus. J Perinat Med 2006, 34(4):323-331. 
16. Jensen DM, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard JG, Moeller 
M, Beck-Nielsen H: Outcomes in type 1 diabetic pregnancies: a nationwide, 
population-based study. Diabetes Care 2004, 27(12):2819-2823. 
17. Langer O, Anyaegbunam A, Brustman L, Guidetti D, Levy J, Mazze R: 
Pregestational diabetes: insulin requirements throughout pregnancy. Am J Obstet 
Gynecol 1988, 159(3):616-621. 
18. Kitzmiller JL, Wallerstein R, Correa A, Kwan S: Preconception care for women 
with diabetes and prevention of major congenital malformations. Birth Defects 
Res A Clin Mol Teratol 2010, 88(10):791-803. 
19. Evers IM, de Valk HW, Visser GH: Risk of complications of pregnancy in 
women with type 1 diabetes: nationwide prospective study in the Netherlands. 
BMJ 2004, 328(7445):915. 
20. Jonasson JM, Brismar K, Sparen P, Lambe M, Nyren O, Ostenson CG, Ye W: 
Fertility in women with type 1 diabetes: a population-based cohort study in 
Sweden. Diabetes Care 2007, 30(9):2271-2276. 
21. Handisurya A, Bancher-Todesca D, Schober E, Klein K, Tobler K, Schneider B, 
Pollak A, Husslein P, Luger A, Kautzky-Willer A: Risk factor profile and 
pregnancy outcome in women with type 1 and type 2 diabetes mellitus. J Womens 
Health (Larchmt) 2011, 20(2):263-271. 
22. DeRuiter MC, Poelmann RE, VanderPlas-de Vries I, Mentink MM, Gittenberger-
de Groot AC: The development of the myocardium and endocardium in mouse 
embryos. Fusion of two heart tubes? Anat Embryol (Berl) 1992, 185(5):461-473. 
23. Srivastava D: Making or Breaking the Heart: From Lineage Determination to 
Morphogenesis. Cell 2006, 126(6):1037-1048. 
24. Lawson KA, Meneses JJ, Pedersen RA: Clonal analysis of epiblast fate during 
germ layer formation in the mouse embryo. Development 1991, 113(3):891-911. 
25. Parameswaran M, Tam PP: Regionalisation of cell fate and morphogenetic 
movement of the mesoderm during mouse gastrulation. Dev Genet 1995, 
17(1):16-28. 
26. Lawson KA, Pedersen RA: Clonal analysis of cell fate during gastrulation and 
early neurulation in the mouse. Ciba Found Symp 1992, 165:3-21; discussion 21-
26. 
27. Tam PP, Parameswaran M, Kinder SJ, Weinberger RP: The allocation of epiblast 
cells to the embryonic heart and other mesodermal lineages: the role of ingression 
and tissue movement during gastrulation. Development 1997, 124(9):1631-1642. 
28. Garcia-Martinez V, Schoenwolf GC: Primitive-streak origin of the cardiovascular 
system in avian embryos. Dev Biol 1993, 159(2):706-719. 
29. Hoff EC KT, DuBois D, Patten BM. : The development of the electrocardiogram 
of the embryonic heart Am Heart J 1939, 17: 470–488. 
30. Christoffels VM, Smits GJ, Kispert A, Moorman AF: Development of the 
pacemaker tissues of the heart. Circ Res 2010, 106(2):240-254. 
31. Mjaatvedt CH, Nakaoka T, Moreno-Rodriguez R, Norris RA, Kern MJ, Eisenberg 
CA, Turner D, Markwald RR: The outflow tract of the heart is recruited from a 
novel heart-forming field. Dev Biol 2001, 238(1):97-109. 
  
40 
32. Kelly RG, Brown NA, Buckingham ME: The arterial pole of the mouse heart 
forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev Cell 2001, 
1(3):435-440. 
33. Waldo KL, Kumiski DH, Wallis KT, Stadt HA, Hutson MR, Platt DH, Kirby ML: 
Conotruncal myocardium arises from a secondary heart field. Development 2001, 
128(16):3179-3188. 
34. Zaffran S, Kelly RG, Meilhac SM, Buckingham ME, Brown NA: Right 
ventricular myocardium derives from the anterior heart field. Circ Res 2004, 
95(3):261-268. 
35. Black BL: Transcriptional pathways in second heart field development. Seminars 
in Cell &amp; Developmental Biology 2007, 18(1):67-76. 
36. Sylva M, van den Hoff MJ, Moorman AF: Development of the human heart. Am J 
Med Genet A 2014, 164A(6):1347-1371. 
37. Brand T: Heart development: molecular insights into cardiac specification and 
early morphogenesis. Dev Biol 2003, 258(1):1-19. 
38. Miquerol L, Kelly RG: Organogenesis of the vertebrate heart. Wiley Interdiscip 
Rev Dev Biol 2013, 2(1):17-29. 
39. Srivastava D, Olson EN: A genetic blueprint for cardiac development. Nature 
2000, 407(6801):221-226. 
40. Lin CJ, Lin CY, Chen CH, Zhou B, Chang CP: Partitioning the heart: 
mechanisms of cardiac septation and valve development. Development 2012, 
139(18):3277-3299. 
41. Anderson RH, Spicer DE, Brown NA, Mohun TJ: The Development of Septation 
in the Four-Chambered Heart. Anat Rec (Hoboken) 2014. 
42. Sizarov A, Lamers WH, Mohun TJ, Brown NA, Anderson RH, Moorman AF: 
Three-dimensional and molecular analysis of the arterial pole of the developing 
human heart. J Anat 2012, 220(4):336-349. 
43. Opie LH: Heart physiology :from cell to circulation, 4 edn. Philadelphia: 
Lippincott Willians & Wilkins; 2004. 
44. Lucas A, Mitchell MD: Prostaglandins in patients ductus arteriosus. Lancet 1978, 
2(8096):937-938. 
45. Lints TJ, Parsons LM, Hartley L, Lyons I, Harvey RP: Nkx-2.5: a novel murine 
homeobox gene expressed in early heart progenitor cells and their myogenic 
descendants. Development 1993, 119(2):419-431. 
46. Schultheiss TM, Xydas S, Lassar AB: Induction of avian cardiac myogenesis by 
anterior endoderm. Development 1995, 121(12):4203-4214. 
47. Bodmer R: The gene tinman is required for specification of the heart and visceral 
muscles in Drosophila. Development 1993, 118(3):719-729. 
48. Lyons I, Parsons LM, Hartley L, Li R, Andrews JE, Robb L, Harvey RP: 
Myogenic and morphogenetic defects in the heart tubes of murine embryos 
lacking the homeo box gene Nkx2-5. Genes Dev 1995, 9(13):1654-1666. 
49. Yamagishi H, Yamagishi C, Nakagawa O, Harvey RP, Olson EN, Srivastava D: 
The combinatorial activities of Nkx2.5 and dHAND are essential for cardiac 
ventricle formation. Dev Biol 2001, 239(2):190-203. 
50. Harvey RP: NK-2 homeobox genes and heart development. Dev Biol 1996, 
178(2):203-216. 
  
41 
51. Kasahara H, Ueyama T, Wakimoto H, Liu MK, Maguire CT, Converso KL, Kang 
PM, Manning WJ, Lawitts J, Paul DL et al: Nkx2.5 homeoprotein regulates 
expression of gap junction protein connexin 43 and sarcomere organization in 
postnatal cardiomyocytes. J Mol Cell Cardiol 2003, 35(3):243-256. 
52. Tanaka M, Chen Z, Bartunkova S, Yamasaki N, Izumo S: The cardiac homeobox 
gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart 
development. Development 1999, 126(6):1269-1280. 
53. Thomas PS, Kasahara H, Edmonson AM, Izumo S, Yacoub MH, Barton PJ, 
Gourdie RG: Elevated expression of Nkx-2.5 in developing myocardial 
conduction cells. Anat Rec 2001, 263(3):307-313. 
54. Molkentin JD: The zinc finger-containing transcription factors GATA-4, -5, and -
6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol 
Chem 2000, 275(50):38949-38952. 
55. Heikinheimo M, Scandrett JM, Wilson DB: Localization of transcription factor 
GATA-4 to regions of the mouse embryo involved in cardiac development. Dev 
Biol 1994, 164(2):361-373. 
56. Arceci RJ, King AA, Simon MC, Orkin SH, Wilson DB: Mouse GATA-4: a 
retinoic acid-inducible GATA-binding transcription factor expressed in 
endodermally derived tissues and heart. Mol Cell Biol 1993, 13(4):2235-2246. 
57. Narita N, Bielinska M, Wilson DB: Cardiomyocyte differentiation by GATA-4-
deficient embryonic stem cells. Development 1997, 124(19):3755-3764. 
58. Molkentin JD, Lin Q, Duncan SA, Olson EN: Requirement of the transcription 
factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev 
1997, 11(8):1061-1072. 
59. Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, Soudais 
C, Leiden JM: GATA4 transcription factor is required for ventral morphogenesis 
and heart tube formation. Genes Dev 1997, 11(8):1048-1060. 
60. Rojas A, Kong SW, Agarwal P, Gilliss B, Pu WT, Black BL: GATA4 is a direct 
transcriptional activator of cyclin D2 and Cdk4 and is required for cardiomyocyte 
proliferation in anterior heart field-derived myocardium. Mol Cell Biol 2008, 
28(17):5420-5431. 
61. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, 
Srivastava D: Direct reprogramming of fibroblasts into functional cardiomyocytes 
by defined factors. Cell 2010, 142(3):375-386. 
62. Rivera-Feliciano J, Lee KH, Kong SW, Rajagopal S, Ma Q, Springer Z, Izumo S, 
Tabin CJ, Pu WT: Development of heart valves requires Gata4 expression in 
endothelial-derived cells. Development 2006, 133(18):3607-3618. 
63. Kolander KD, Holtz ML, Cossette SM, Duncan SA, Misra RP: Epicardial GATA 
factors regulate early coronary vascular plexus formation. Dev Biol 2014, 
386(1):204-215. 
64. Nemer G, Nemer M: Cooperative interaction between GATA5 and NF-ATc 
regulates endothelial-endocardial differentiation of cardiogenic cells. 
Development 2002, 129(17):4045-4055. 
65. Laforest B, Andelfinger G, Nemer M: Loss of Gata5 in mice leads to bicuspid 
aortic valve. Journal of Clinical Investigation 2011, 121(7):2876-2887. 
  
42 
66. Laforest B, Nemer M: GATA5 interacts with GATA4 and GATA6 in outflow 
tract development. Developmental Biology 2011:1-11. 
67. Singh MK, Li Y, Li S, Cobb RM, Zhou D, Lu MM, Epstein JA, Morrisey EE, 
Gruber PJ: Gata4 and Gata5 cooperatively regulate cardiac myocyte proliferation 
in mice. J Biol Chem 2010, 285(3):1765-1772. 
68. Koutsourakis M, Langeveld A, Patient R, Beddington R, Grosveld F: The 
transcription factor GATA6 is essential for early extraembryonic development. 
Development 1999, 126(9):723-732. 
69. Peterkin T, Gibson A, Patient R: GATA-6 maintains BMP-4 and Nkx2 expression 
during cardiomyocyte precursor maturation. EMBO J 2003, 22(16):4260-4273. 
70. Zhao R, Watt AJ, Battle MA, Li J, Bondow BJ, Duncan SA: Loss of both GATA4 
and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. 
Dev Biol 2008, 317(2):614-619. 
71. Bui PH, Dorrani N, Wong D, Perens G, Dipple KM, Quintero-Rivera F: First 
report of a de novo 18q11.2 microdeletion including GATA6 associated with 
complex congenital heart disease and renal abnormalities. Am J Med Genet A 
2013, 161A(7):1773-1778. 
72. Lin X, Huo Z, Liu X, Zhang Y, Li L, Zhao H, Yan B, Liu Y, Yang Y, Chen YH: 
A novel GATA6 mutation in patients with tetralogy of Fallot or atrial septal 
defect. J Hum Genet 2010, 55(10):662-667. 
73. Chapman DL, Garvey N, Hancock S, Alexiou M, Agulnik SI, Gibson-Brown JJ, 
Cebra-Thomas J, Bollag RJ, Silver LM, Papaioannou VE: Expression of the T-
box family genes, Tbx1-Tbx5, during early mouse development. Dev Dyn 1996, 
206(4):379-390. 
74. Bruneau BG, Logan M, Davis N, Levi T, Tabin CJ, Seidman J, Seidman CE: 
Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram 
syndrome. Developmental Biology 1999, 211(1):100-108. 
75. Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner 
DA, Gessler M, Nemer M, Seidman CE et al: A murine model of Holt-Oram 
syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis 
and disease. Cell 2001, 106(6):709-721. 
76. Gossett LA, Kelvin DJ, Sternberg EA, Olson EN: A new myocyte-specific 
enhancer-binding factor that recognizes a conserved element associated with 
multiple muscle-specific genes. Mol Cell Biol 1989, 9(11):5022-5033. 
77. Edmondson DG, Lyons GE, Martin JF, Olson EN: Mef2 gene expression marks 
the cardiac and skeletal muscle lineages during mouse embryogenesis. 
Development 1994, 120(5):1251-1263. 
78. Lin Q, Schwarz J, Bucana C, Olson EN: Control of mouse cardiac morphogenesis 
and myogenesis by transcription factor MEF2C. Science 1997, 276(5317):1404-
1407. 
79. Dodou E, Verzi MP, Anderson JP, Xu SM, Black BL: Mef2c is a direct 
transcriptional target of ISL1 and GATA factors in the anterior heart field during 
mouse embryonic development. Development 2004, 131(16):3931-3942. 
80. Nemer G, Nemer M: Regulation of heart development and function through 
combinatorial interactions of transcription factors. Ann Med 2001, 33(9):604-610. 
  
43 
81. Bruneau BG: Transcriptional Regulation of Vertebrate Cardiac Morphogenesis. 
Circulation Research 2002, 90(5):509-519. 
82. Hiroi Y, Kudoh S, Monzen K, Ikeda Y, Yazaki Y, Nagai R, Komuro I: Tbx5 
associates with Nkx2-5 and synergistically promotes cardiomyocyte 
differentiation. Nat Genet 2001, 28(3):276-280. 
83. Durocher D, Charron F, Warren R, Schwartz RJ, Nemer M: The cardiac 
transcription factors Nkx2-5 and GATA-4 are mutual cofactors. EMBO J 1997, 
16(18):5687-5696. 
84. Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, Rothrock 
CR, Eapen RS, Hirayama-Yamada K, Joo K et al: GATA4 mutations cause 
human congenital heart defects and reveal an interaction with TBX5. Nature 
2003, 424(6947):443-447. 
85. Brewer AC, Alexandrovich A, Mjaatvedt CH, Shah AM, Patient RK, Pizzey JA: 
GATA factors lie upstream of Nkx 2.5 in the transcriptional regulatory cascade 
that effects cardiogenesis. Stem Cells Dev 2005, 14(4):425-439. 
86. Molkentin JD, Antos C, Mercer B, Taigen T, Miano JM, Olson EN: Direct 
activation of a GATA6 cardiac enhancer by Nkx2.5: evidence for a reinforcing 
regulatory network of Nkx2.5 and GATA transcription factors in the developing 
heart. Dev Biol 2000, 217(2):301-309. 
87. Briggs LE, Kakarla J, Wessels A: The pathogenesis of atrial and atrioventricular 
septal defects with special emphasis on the role of the dorsal mesenchymal 
protrusion. Differentiation 2012, 84(1):117-130. 
88. Armstrong EJ, Bischoff J: Heart valve development: endothelial cell signaling 
and differentiation. Circ Res 2004, 95(5):459-470. 
89. Akhurst RJ, Lehnert SA, Faissner A, Duffie E: TGF beta in murine 
morphogenetic processes: the early embryo and cardiogenesis. Development 
1990, 108(4):645-656. 
90. Dickson MC, Slager HG, Duffie E, Mummery CL, Akhurst RJ: RNA and protein 
localisations of TGF beta 2 in the early mouse embryo suggest an involvement in 
cardiac development. Development 1993, 117(2):625-639. 
91. Millan FA, Denhez F, Kondaiah P, Akhurst RJ: Embryonic gene expression 
patterns of TGF beta 1, beta 2 and beta 3 suggest different developmental 
functions in vivo. Development 1991, 111(1):131-143. 
92. Nakajima Y, Yamagishi T, Nakamura H, Markwald RR, Krug EL: An autocrine 
function for transforming growth factor (TGF)-beta3 in the transformation of 
atrioventricular canal endocardium into mesenchyme during chick heart 
development. Dev Biol 1998, 194(1):99-113. 
93. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ: 
Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 
1 knock out mice. Development 1995, 121(6):1845-1854. 
94. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, 
Doetschman T: Early-onset multifocal inflammation in the transforming growth 
factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci U S A 1995, 
92(26):12215-12219. 
  
44 
95. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB: 
Maternal rescue of transforming growth factor-beta 1 null mice. Science 1994, 
264(5167):1936-1938. 
96. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin 
GP, Cardell EL, Doetschman T: TGFbeta2 knockout mice have multiple 
developmental defects that are non-overlapping with other TGFbeta knockout 
phenotypes. Development 1997, 124(13):2659-2670. 
97. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, 
Groffen J: Abnormal lung development and cleft palate in mice lacking TGF-beta 
3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995, 
11(4):415-421. 
98. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, 
Ferguson MW, Doetschman T: Transforming growth factor-beta 3 is required for 
secondary palate fusion. Nat Genet 1995, 11(4):409-414. 
99. Brown CB, Boyer AS, Runyan RB, Barnett JV: Antibodies to the Type II 
TGFbeta receptor block cell activation and migration during atrioventricular 
cushion transformation in the heart. Dev Biol 1996, 174(2):248-257. 
100. Potts JD, Dagle JM, Walder JA, Weeks DL, Runyan RB: Epithelial-mesenchymal 
transformation of embryonic cardiac endothelial cells is inhibited by a modified 
antisense oligodeoxynucleotide to transforming growth factor beta 3. Proc Natl 
Acad Sci U S A 1991, 88(4):1516-1520. 
101. Camenisch TD, Molin DG, Person A, Runyan RB, Gittenberger-de Groot AC, 
McDonald JA, Klewer SE: Temporal and distinct TGFbeta ligand requirements 
during mouse and avian endocardial cushion morphogenesis. Dev Biol 2002, 
248(1):170-181. 
102. Boyer AS, Ayerinskas, II, Vincent EB, McKinney LA, Weeks DL, Runyan RB: 
TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial-
mesenchymal cell transformation in the embryonic heart. Dev Biol 1999, 
208(2):530-545. 
103. Lyons KM, Pelton RW, Hogan BL: Organogenesis and pattern formation in the 
mouse: RNA distribution patterns suggest a role for bone morphogenetic protein-
2A (BMP-2A). Development 1990, 109(4):833-844. 
104. Jones CM, Lyons KM, Hogan BL: Involvement of Bone Morphogenetic Protein-4 
(BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse. 
Development 1991, 111(2):531-542. 
105. Zhang H, Bradley A: Mice deficient for BMP2 are nonviable and have defects in 
amnion/chorion and cardiac development. Development 1996, 122(10):2977-
2986. 
106. Winnier G, Blessing M, Labosky PA, Hogan BL: Bone morphogenetic protein-4 
is required for mesoderm formation and patterning in the mouse. Genes Dev 1995, 
9(17):2105-2116. 
107. Nakajima Y, Yamagishi T, Hokari S, Nakamura H: Mechanisms involved in 
valvuloseptal endocardial cushion formation in early cardiogenesis: roles of 
transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). 
Anat Rec 2000, 258(2):119-127. 
  
45 
108. Yamagishi T, Nakajima Y, Miyazono K, Nakamura H: Bone morphogenetic 
protein-2 acts synergistically with transforming growth factor-beta3 during 
endothelial-mesenchymal transformation in the developing chick heart. J Cell 
Physiol 1999, 180(1):35-45. 
109. Townsend TA, Robinson JY, Deig CR, Hill CR, Misfeldt A, Blobe GC, Barnett 
JV: BMP-2 and TGFbeta2 shared pathways regulate endocardial cell 
transformation. Cells Tissues Organs 2011, 194(1):1-12. 
110. Kretzschmar M, Massague J: SMADs: mediators and regulators of TGF-beta 
signaling. Curr Opin Genet Dev 1998, 8(1):103-111. 
111. Moskowitz IP, Wang J, Peterson MA, Pu WT, Mackinnon AC, Oxburgh L, Chu 
GC, Sarkar M, Berul C, Smoot L et al: Transcription factor genes Smad4 and 
Gata4 cooperatively regulate cardiac valve development. [corrected]. Proc Natl 
Acad Sci U S A 2011, 108(10):4006-4011. 
112. Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K: Snail 
is required for TGFbeta-induced endothelial-mesenchymal transition of 
embryonic stem cell-derived endothelial cells. J Cell Sci 2008, 121(Pt 20):3317-
3324. 
113. Wang J, Sridurongrit S, Dudas M, Thomas P, Nagy A, Schneider MD, Epstein 
JA, Kaartinen V: Atrioventricular cushion transformation is mediated by ALK2 in 
the developing mouse heart. Dev Biol 2005, 286(1):299-310. 
114. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, 
Aranda S, Palomo S, McCormick F, Izpisua-Belmonte JC et al: Notch promotes 
epithelial-mesenchymal transition during cardiac development and oncogenic 
transformation. Genes Dev 2004, 18(1):99-115. 
115. Luna-Zurita L, Prados B, Grego-Bessa J, Luxan G, del Monte G, Benguria A, 
Adams RH, Perez-Pomares JM, de la Pompa JL: Integration of a Notch-
dependent mesenchymal gene program and Bmp2-driven cell invasiveness 
regulates murine cardiac valve formation. J Clin Invest 2010, 120(10):3493-3507. 
116. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld 
PD, Srivastava D: Mutations in NOTCH1 cause aortic valve disease. Nature 
2005, 437(7056):270-274. 
117. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, Qi M, Trask BJ, Kuo 
WL, Cochran J et al: Alagille syndrome is caused by mutations in human 
Jagged1, which encodes a ligand for Notch1. Nat Genet 1997, 16(3):243-251. 
118. Miquerol L, Gertsenstein M, Harpal K, Rossant J, Nagy A: Multiple 
developmental roles of VEGF suggested by a LacZ-tagged allele. Dev Biol 1999, 
212(2):307-322. 
119. Dor Y, Camenisch TD, Itin A, Fishman GI, McDonald JA, Carmeliet P, Keshet E: 
A novel role for VEGF in endocardial cushion formation and its potential 
contribution to congenital heart defects. Development 2001, 128(9):1531-1538. 
120. Miquerol L, Langille BL, Nagy A: Embryonic development is disrupted by 
modest increases in vascular endothelial growth factor gene expression. 
Development 2000, 127(18):3941-3946. 
121. de la Pompa JL, Timmerman LA, Takimoto H, Yoshida H, Elia AJ, Samper E, 
Potter J, Wakeham A, Marengere L, Langille BL et al: Role of the NF-ATc 
  
46 
transcription factor in morphogenesis of cardiac valves and septum. Nature 1998, 
392(6672):182-186. 
122. Ranger AM, Grusby MJ, Hodge MR, Gravallese EM, de la Brousse FC, Hoey T, 
Mickanin C, Baldwin HS, Glimcher LH: The transcription factor NF-ATc is 
essential for cardiac valve formation. Nature 1998, 392(6672):186-190. 
123. Johnson EN, Lee YM, Sander TL, Rabkin E, Schoen FJ, Kaushal S, Bischoff J: 
NFATc1 mediates vascular endothelial growth factor-induced proliferation of 
human pulmonary valve endothelial cells. J Biol Chem 2003, 278(3):1686-1692. 
124. Faletra FF, Pandian NG, Ho SY: Anatomy of the heart by multislice computed 
tomography. Chichester, UK ;; Hoboken, NJ: Wiley-Blackwell; 2008. 
125. Tomanek RJ: Formation of the coronary vasculature during development. 
Angiogenesis 2005, 8(3):273-284. 
126. Ho E, Shimada Y: Formation of the epicardium studied with the scanning electron 
microscope. Developmental Biology 1978, 66(2):579-585. 
127. Manasek FJ: Embryonic development of the heart. II. Formation of the 
epicardium. J Embryol Exp Morphol 1969, 22(3):333-348. 
128. Viragh S, Challice CE: The origin of the epicardium and the embryonic 
myocardial circulation in the mouse. Anat Rec 1981, 201(1):157-168. 
129. Manner J, Perez-Pomares JM, Macias D, Munoz-Chapuli R: The origin, 
formation and developmental significance of the epicardium: a review. Cells 
Tissues Organs 2001, 169(2):89-103. 
130. Pérez-Pomares JM, Macías D, García-Garrido L, Muñoz-Chápuli R: Contribution 
of the primitive epicardium to the subepicardial mesenchyme in hamster and 
chick embryos. Dev Dyn 1997, 210(2):96-105. 
131. Viragh S, Gittenberger-de Groot AC, Poelmann RE, Kálmán F: Early 
development of quail heart epicardium and associated vascular and glandular 
structures. Anat Embryol 1993, 188(4):381-393. 
132. Vrancken Peeters MP, Gittenberger-de Groot AC, Mentink MM, Poelmann RE: 
Smooth muscle cells and fibroblasts of the coronary arteries derive from 
epithelial-mesenchymal transformation of the epicardium. Anat Embryol 1999, 
199(4):367-378. 
133. Dettman RW, Denetclaw W, Jr., Ordahl CP, Bristow J: Common epicardial origin 
of coronary vascular smooth muscle, perivascular fibroblasts, and intermyocardial 
fibroblasts in the avian heart. Dev Biol 1998, 193(2):169-181. 
134. Benjamin LE, Hemo I, Keshet E: A plasticity window for blood vessel 
remodelling is defined by pericyte coverage of the preformed endothelial network 
and is regulated by PDGF-B and VEGF. Development 1998, 125(9):1591-1598. 
135. Gittenberger-de Groot AC, Vrancken Peeters MP, Mentink MM, Gourdie RG, 
Poelmann RE: Epicardium-derived cells contribute a novel population to the 
myocardial wall and the atrioventricular cushions. Circ Res 1998, 82(10):1043-
1052. 
136. Manner J: Does the subepicardial mesenchyme contribute myocardioblasts to the 
myocardium of the chick embryo heart? A quail-chick chimera study tracing the 
fate of the epicardial primordium. Anat Rec 1999, 255(2):212-226. 
  
47 
137. Zhou B, Ma Q, Rajagopal S, Wu SM, Domian I, Rivera-Feliciano J, Jiang D, von 
Gise A, Ikeda S, Chien KR et al: Epicardial progenitors contribute to the 
cardiomyocyte lineage in the developing heart. Nature 2008, 454(7200):109-113. 
138. Heintzberger CF: Development of myocardial vascularisation in the rat. Acta 
Morphol Neerl Scand 1983, 21(4):267-284. 
139. Bogers AJ, Gittenberger-de Groot AC, Poelmann RE, Peault BM, Huysmans HA: 
Development of the origin of the coronary arteries, a matter of ingrowth or 
outgrowth? Anat Embryol (Berl) 1989, 180(5):437-441. 
140. Waldo KL, Willner W, Kirby ML: Origin of the proximal coronary artery stems 
and a review of ventricular vascularization in the chick embryo. Am J Anat 1990, 
188(2):109-120. 
141. Mikawa T, Fischman DA: Retroviral analysis of cardiac morphogenesis: 
discontinuous formation of coronary vessels. Proc Natl Acad Sci U S A 1992, 
89(20):9504-9508. 
142. Perez-Pomares JM, Carmona R, Gonzalez-Iriarte M, Atencia G, Wessels A, 
Munoz-Chapuli R: Origin of coronary endothelial cells from epicardial 
mesothelium in avian embryos. Int J Dev Biol 2002, 46(8):1005-1013. 
143. Mikawa T, Gourdie RG: Pericardial mesoderm generates a population of coronary 
smooth muscle cells migrating into the heart along with ingrowth of the epicardial 
organ. Dev Biol 1996, 174(2):221-232. 
144. Cai CL, Martin JC, Sun Y, Cui L, Wang L, Ouyang K, Yang L, Bu L, Liang X, 
Zhang X et al: A myocardial lineage derives from Tbx18 epicardial cells. Nature 
2008, 454(7200):104-108. 
145. Red-Horse K, Ueno H, Weissman IL, Krasnow MA: Coronary arteries form by 
developmental reprogramming of venous cells. Nature 2010, 464(7288):549-553. 
146. Tian X, Hu T, Zhang H, He L, Huang X, Liu Q, Yu W, He L, Yang Z, Zhang Z et 
al: Subepicardial endothelial cells invade the embryonic ventricle wall to form 
coronary arteries. Cell Res 2013, 23(9):1075-1090. 
147. Katz TC, Singh MK, Degenhardt K, Rivera-Feliciano J, Johnson RL, Epstein JA, 
Tabin CJ: Distinct Compartments of the Proepicardial Organ Give Rise to 
Coronary Vascular Endothelial Cells. Developmental Cell 2012, 22(3):639-650. 
148. Wu B, Zhang Z, Lui W, Chen X, Wang Y, Chamberlain AA, Moreno-Rodriguez 
RA, Markwald RR, O'Rourke BP, Sharp DJ et al: Endocardial cells form the 
coronary arteries by angiogenesis through myocardial-endocardial VEGF 
signaling. Cell 2012, 151(5):1083-1096. 
149. Olivey HE, Svensson EC: Epicardial-myocardial signaling directing coronary 
vasculogenesis. Circ Res 2010, 106(5):818-832. 
150. Wada AM, Willet SG, Bader D: Coronary vessel development: a unique form of 
vasculogenesis. Arterioscler Thromb Vasc Biol 2003, 23(12):2138-2145. 
151. Chan DA, Sutphin PD, Yen SE, Giaccia AJ: Coordinate regulation of the oxygen-
dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell 
Biol 2005, 25(15):6415-6426. 
152. Dery MA, Michaud MD, Richard DE: Hypoxia-inducible factor 1: regulation by 
hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005, 37(3):535-
540. 
  
48 
153. Semenza GL: HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 
2001, 13(2):167-171. 
154. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL: Dimerization, DNA binding, 
and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996, 
271(30):17771-17778. 
155. Wikenheiser J, Wolfram JA, Gargesha M, Yang K, Karunamuni G, Wilson DL, 
Semenza GL, Agani F, Fisher SA, Ward N et al: Altered hypoxia-inducible 
factor-1 alpha expression levels correlate with coronary vessel anomalies. Dev 
Dyn 2009, 238(10):2688-2700. 
156. Licht AH, Muller-Holtkamp F, Flamme I, Breier G: Inhibition of hypoxia-
inducible factor activity in endothelial cells disrupts embryonic cardiovascular 
development. Blood 2006, 107(2):584-590. 
157. Wagner KD, Wagner N, Wellmann S, Schley G, Bondke A, Theres H, Scholz H: 
Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves 
hypoxia-inducible factor-1 (HIF-1). FASEB J 2003, 17(10):1364-1366. 
158. Moore AW, McInnes L, Kreidberg J, Hastie ND, Schedl A: YAC 
complementation shows a requirement for Wt1 in the development of epicardium, 
adrenal gland and throughout nephrogenesis. Development 1999, 126(9):1845-
1857. 
159. Martínez-Estrada OM, Lettice LA, Essafi A, Guadix JA, Slight J, Velecela V, 
Hall E, Reichmann J, Devenney PS, Hohenstein P et al: Wt1 is required for 
cardiovascular progenitor cell formation through transcriptional control of Snail 
and E-cadherin. Nat Genet 2010, 42(1):89-93. 
160. Takeichi M, Nimura K, Mori M, Nakagami H, Kaneda Y: The transcription 
factors Tbx18 and Wt1 control the epicardial epithelial-mesenchymal transition 
through bi-directional regulation of Slug in murine primary epicardial cells. PLoS 
One 2013, 8(2):e57829. 
161. Nieto MA, Sargent MG, Wilkinson DG, Cooke J: Control of cell behavior during 
vertebrate development by Slug, a zinc finger gene. Science 1994, 264(5160):835-
839. 
162. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, 
Portillo F, Nieto MA: The transcription factor snail controls epithelial-
mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000, 
2(2):76-83. 
163. Carmona R, Gonzalez-Iriarte M, Macias D, Perez-Pomares JM, Garcia-Garrido L, 
Munoz-Chapuli R: Immunolocalization of the transcription factor Slug in the 
developing avian heart. Anat Embryol (Berl) 2000, 201(2):103-109. 
164. Casanova JC, Travisano S, de la Pompa JL: Epithelial-to-mesenchymal transition 
in epicardium is independent of Snail1. Genesis 2013, 51(1):32-40. 
165. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A: The 
transcription factor Slug represses E-cadherin expression and induces epithelial to 
mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 
2003, 116(Pt 3):499-511. 
166. Pan J, Baker KM: Retinoic acid and the heart. Vitam Horm 2007, 75:257-283. 
167. Azambuja AP, Portillo-Sanchez V, Rodrigues MV, Omae SV, Schechtman D, 
Strauss BE, Costanzi-Strauss E, Krieger JE, Perez-Pomares JM, Xavier-Neto J: 
  
49 
Retinoic acid and VEGF delay smooth muscle relative to endothelial 
differentiation to coordinate inner and outer coronary vessel wall morphogenesis. 
Circ Res 2010, 107(2):204-216. 
168. Lin SC, Dolle P, Ryckebusch L, Noseda M, Zaffran S, Schneider MD, 
Niederreither K: Endogenous retinoic acid regulates cardiac progenitor 
differentiation. Proc Natl Acad Sci U S A 2010, 107(20):9234-9239. 
169. Niederreither K, Subbarayan V, Dolle P, Chambon P: Embryonic retinoic acid 
synthesis is essential for early mouse post-implantation development. Nat Genet 
1999, 21(4):444-448. 
170. Kostetskii I, Jiang Y, Kostetskaia E, Yuan S, Evans T, Zile M: Retinoid signaling 
required for normal heart development regulates GATA-4 in a pathway distinct 
from cardiomyocyte differentiation. Dev Biol 1999, 206(2):206-218. 
171. Merki E, Zamora M, Raya A, Kawakami Y, Wang J, Zhang X, Burch J, Kubalak 
SW, Kaliman P, Izpisua Belmonte JC et al: Epicardial retinoid X receptor alpha is 
required for myocardial growth and coronary artery formation. Proc Natl Acad 
Sci U S A 2005, 102(51):18455-18460. 
172. Moss JB, Xavier-Neto J, Shapiro MD, Nayeem SM, McCaffery P, Drager UC, 
Rosenthal N: Dynamic patterns of retinoic acid synthesis and response in the 
developing mammalian heart. Dev Biol 1998, 199(1):55-71. 
173. Guadix JA, Ruiz-Villalba A, Lettice L, Velecela V, Munoz-Chapuli R, Hastie 
ND, Perez-Pomares JM, Martinez-Estrada OM: Wt1 controls retinoic acid 
signalling in embryonic epicardium through transcriptional activation of Raldh2. 
Development 2011, 138(6):1093-1097. 
174. Zhao D, McCaffery P, Ivins KJ, Neve RL, Hogan P, Chin WW, Drager UC: 
Molecular identification of a major retinoic-acid-synthesizing enzyme, a 
retinaldehyde-specific dehydrogenase. Eur J Biochem 1996, 240(1):15-22. 
175. von Gise A, Zhou B, Honor LB, Ma Q, Petryk A, Pu WT: WT1 regulates 
epicardial epithelial to mesenchymal transition through beta-catenin and retinoic 
acid signaling pathways. Dev Biol 2011, 356(2):421-431. 
176. Hoffman JI, Kaplan S: The incidence of congenital heart disease. J Am Coll 
Cardiol 2002, 39(12):1890-1900. 
177. Pierpont ME, Basson CT, Benson DWJ, Gelb BD, Giglia TM, Goldmuntz E, 
McGee G, Sable CA, Srivastava D, Webb CL: Genetic basis for congenital heart 
defects: current knowledge: a scientific statement from the American Heart 
Association Congenital Cardiac Defects Committee, Council on Cardiovascular 
Disease in the Young: endorsed by the American Academy of Pediatrics. 
Circulation 2007, 115(23):3015-3038. 
178. Fesslova V, Brankovic J, Lalatta F, Villa L, Meli V, Piazza L, Ricci C: 
Recurrence of congenital heart disease in cases with familial risk screened 
prenatally by echocardiography. J Pregnancy 2011, 2011:368067. 
179. van der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder 
BJ: The changing epidemiology of congenital heart disease. Nat Rev Cardiol 
2011, 8(1):50-60. 
180. J.W. Roos-Hesselink WSK-F, F.J. Meijboom, and P.G. Pieper: Inheritance of 
congenital heart disease. Netherland Heart Journal 2005, 13(3):88-91. 
  
50 
181. Blue GM, Kirk EP, Sholler GF, Harvey RP, Winlaw DS: Congenital heart 
disease: current knowledge about causes and inheritance. Med J Aust 2012, 
197(3):155-159. 
182. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, 
Takkenberg JJ, Roos-Hesselink JW: Birth prevalence of congenital heart disease 
worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011, 
58(21):2241-2247. 
183. Webb G, Gatzoulis MA: Atrial septal defects in the adult: recent progress and 
overview. Circulation 2006, 114(15):1645-1653. 
184. Posch MG, Perrot A, Berger F, Ozcelik C: Molecular genetics of congenital atrial 
septal defects. Clin Res Cardiol 2010, 99(3):137-147. 
185. Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, Moak JP, Maron 
BJ, Seidman CE, Seidman JG: Congenital heart disease caused by mutations in 
the transcription factor NKX2-5. Science 1998, 281(5373):108-111. 
186. Nadeau M, Georges RO, Laforest B, Yamak A, Lefebvre C, Beauregard J, Paradis 
P, Bruneau BG, Andelfinger G, Nemer M: An endocardial pathway involving 
Tbx5, Gata4, and Nos3 required for atrial septum formation. Proc Natl Acad Sci 
USA 2010, 107(45):19356-19361. 
187. Minette MS, Sahn DJ: Ventricular septal defects. Circulation 2006, 
114(20):2190-2197. 
188. Stallmeyer B, Fenge H, Nowak-Gottl U, Schulze-Bahr E: Mutational spectrum in 
the cardiac transcription factor gene NKX2.5 (CSX) associated with congenital 
heart disease. Clin Genet 2010, 78(6):533-540. 
189. Pang S, Shan J, Qiao Y, Ma L, Qin X, Wanyan H, Xing Q, Wu G, Yan B: Genetic 
and functional analysis of the NKX2-5 gene promoter in patients with ventricular 
septal defects. Pediatr Cardiol 2012, 33(8):1355-1361. 
190. Wang J, Xin YF, Liu XY, Liu ZM, Wang XZ, Yang YQ: A novel NKX2-5 
mutation in familial ventricular septal defect. Int J Mol Med 2011, 27(3):369-375. 
191. Yang YQ, Li L, Wang J, Liu XY, Chen XZ, Zhang W, Wang XZ, Jiang JQ, Liu 
X, Fang WY: A novel GATA4 loss-of-function mutation associated with 
congenital ventricular septal defect. Pediatr Cardiol 2012, 33(4):539-546. 
192. Wang J, Fang M, Liu XY, Xin YF, Liu ZM, Chen XZ, Wang XZ, Fang WY, Liu 
X, Yang YQ: A novel GATA4 mutation responsible for congenital ventricular 
septal defects. Int J Mol Med 2011, 28(4):557-564. 
193. Chen MW, Pang YS, Guo Y, Pan JH, Liu BL, Shen J, Liu TW: GATA4 
mutations in Chinese patients with congenital cardiac septal defects. Pediatr 
Cardiol 2010, 31(1):85-89. 
194. Maitra M, Schluterman MK, Nichols HA, Richardson JA, Lo CW, Srivastava D, 
Garg V: Interaction of Gata4 and Gata6 with Tbx5 is critical for normal cardiac 
development. Dev Biol 2009, 326(2):368-377. 
195. Meisner H, Guenther T: Atrioventricular septal defect. Pediatr Cardiol 1998, 
19(4):276-281. 
196. Bader RS, Punn R, Silverman NH: Evaluation of Risk Factors for Prediction of 
Outcome in Fetal Spectrum of Atrioventricular Septal Defects. Congenit Heart 
Dis 2013. 
  
51 
197. Grabitz RG, Joffres MR, Collins-Nakai RL: Congenital heart disease: incidence in 
the first year of life. The Alberta Heritage Pediatric Cardiology Program. Am J 
Epidemiol 1988, 128(2):381-388. 
198. Grech V: Epidemiology, and diagnostic and surgical trends in atrioventricular 
septal defect in Malta. Eur J Epidemiol 1999, 15(4):403-405. 
199. Freeman SB, Taft LF, Dooley KJ, Allran K, Sherman SL, Hassold TJ, Khoury 
MJ, Saker DM: Population-based study of congenital heart defects in Down 
syndrome. Am J Med Genet 1998, 80(3):213-217. 
200. Tubman TR, Shields MD, Craig BG, Mulholland HC, Nevin NC: Congenital 
heart disease in Down's syndrome: two year prospective early screening study. 
BMJ 1991, 302(6790):1425-1427. 
201. Reamon-Buettner SM, Borlak J: Somatic NKX2-5 mutations as a novel 
mechanism of disease in complex congenital heart disease. J Med Genet 2004, 
41(9):684-690. 
202. Reamon-Buettner SM, Borlak J: GATA4 zinc finger mutations as a molecular 
rationale for septation defects of the human heart. J Med Genet 2005, 42(5):e32. 
203. Reamon-Buettner SM, Cho SH, Borlak J: Mutations in the 3'-untranslated region 
of GATA4 as molecular hotspots for congenital heart disease (CHD). BMC Med 
Genet 2007, 8:38. 
204. Reamon-Buettner SM, Borlak J: TBX5 mutations in non-Holt-Oram syndrome 
(HOS) malformed hearts. Hum Mutat 2004, 24(1):104. 
205. Reamon-Buettner SM, Hecker H, Spanel-Borowski K, Craatz S, Kuenzel E, 
Borlak J: Novel NKX2-5 mutations in diseased heart tissues of patients with 
cardiac malformations. Am J Pathol 2004, 164(6):2117-2125. 
206. Loffredo CA, Hirata J, Wilson PD, Ferencz C, Lurie IW: Atrioventricular septal 
defects: possible etiologic differences between complete and partial defects. 
Teratology 2001, 63(2):87-93. 
207. Loffredo CA, Wilson PD, Ferencz C: Maternal diabetes: an independent risk 
factor for major cardiovascular malformations with increased mortality of 
affected infants. Teratology 2001, 64(2):98-106. 
208. Ferencz C, Rubin JD, McCarter RJ, Brenner JI, Neill CA, Perry LW, Hepner SI, 
Downing JW: Congenital heart disease: prevalence at livebirth. The Baltimore-
Washington Infant Study. Am J Epidemiol 1985, 121(1):31-36. 
209. Gelb BD, Towbin JA, McCabe ER, Sujansky E: San Luis Valley recombinant 
chromosome 8 and tetralogy of Fallot: a review of chromosome 8 anomalies and 
congenital heart disease. Am J Med Genet 1991, 40(4):471-476. 
210. Momma K, Kondo C, Matsuoka R: Tetralogy of Fallot with pulmonary atresia 
associated with chromosome 22q11 deletion. J Am Coll Cardiol 1996, 27(1):198-
202. 
211. Xu YJ, Wang J, Xu R, Zhao PJ, Wang XK, Sun HJ, Bao LM, Shen J, Fu QH, Li F 
et al: Detecting 22q11.2 deletion in Chinese children with conotruncal heart 
defects and single nucleotide polymorphisms in the haploid TBX1 locus. BMC 
Med Genet 2011, 12:169. 
212. Lambrechts D, Devriendt K, Driscoll DA, Goldmuntz E, Gewillig M, Vlietinck R, 
Collen D, Carmeliet P: Low expression VEGF haplotype increases the risk for 
  
52 
tetralogy of Fallot: a family based association study. J Med Genet 2005, 
42(6):519-522. 
213. Wessels MW, Willems PJ: Genetic factors in non-syndromic congenital heart 
malformations. Clin Genet 2010, 78(2):103-123. 
214. Eldadah ZA, Hamosh A, Biery NJ, Montgomery RA, Duke M, Elkins R, Dietz 
HC: Familial Tetralogy of Fallot caused by mutation in the jagged1 gene. Hum 
Mol Genet 2001, 10(2):163-169. 
215. De Luca A, Sarkozy A, Ferese R, Consoli F, Lepri F, Dentici ML, Vergara P, De 
Zorzi A, Versacci P, Digilio MC et al: New mutations in ZFPM2/FOG2 gene in 
tetralogy of Fallot and double outlet right ventricle. Clin Genet 2011, 80(2):184-
190. 
216. Goldmuntz E, Geiger E, Benson DW: NKX2.5 mutations in patients with 
tetralogy of fallot. Circulation 2001, 104(21):2565-2568. 
217. Pizzuti A, Sarkozy A, Newton AL, Conti E, Flex E, Digilio MC, Amati F, Gianni 
D, Tandoi C, Marino B et al: Mutations of ZFPM2/FOG2 gene in sporadic cases 
of tetralogy of Fallot. Hum Mutat 2003, 22(5):372-377. 
218. Griffin HR, Hall DH, Topf A, Eden J, Stuart AG, Parsons J, Peart I, Deanfield JE, 
O'Sullivan J, Babu-Narayan SV et al: Genetic variation in VEGF does not 
contribute significantly to the risk of congenital cardiovascular malformation. 
PLoS One 2009, 4(3):e4978. 
219. Unolt M, Putotto C, Silvestri LM, Marino D, Scarabotti A, Valerio M, Caiaro A, 
Versacci P, Marino B: Transposition of great arteries: new insights into the 
pathogenesis. Front Pediatr 2013, 1:11. 
220. Van Praagh S, Truman T, Firpo A, Bano-Rodrigo A, Fried R, McManus B, Engle 
MA, Van Praagh R: Cardiac malformations in trisomy-18: a study of 41 
postmortem cases. J Am Coll Cardiol 1989, 13(7):1586-1597. 
221. Takahashi K, Kido S, Hoshino K, Ogawa K, Ohashi H, Fukushima Y: Frequency 
of a 22q11 deletion in patients with conotruncal cardiac malformations: a 
prospective study. Eur J Pediatr 1995, 154(11):878-881. 
222. Frohn-Mulder IM, Wesby Swaay E, Bouwhuis C, Van Hemel JO, Gerritsma E, 
Niermeyer MF, Hess J: Chromosome 22q11 deletions in patients with selected 
outflow tract malformations. Genet Couns 1999, 10(1):35-41. 
223. Goldmuntz E, Clark BJ, Mitchell LE, Jawad AF, Cuneo BF, Reed L, McDonald-
McGinn D, Chien P, Feuer J, Zackai EH et al: Frequency of 22q11 deletions in 
patients with conotruncal defects. J Am Coll Cardiol 1998, 32(2):492-498. 
224. Tomita-Mitchell A, Maslen CL, Morris CD, Garg V, Goldmuntz E: GATA4 
sequence variants in patients with congenital heart disease. J Med Genet 2007, 
44(12):779-783. 
225. Ferencz C, Rubin JD, McCarter RJ, Clark EB: Maternal diabetes and 
cardiovascular malformations: predominance of double outlet right ventricle and 
truncus arteriosus. Teratology 1990, 41(3):319-326. 
226. Zugibe FT, Zugibe FT, Jr., Costello JT, Breithaupt MK: Hypoplastic coronary 
artery disease within the spectrum of sudden unexpected death in young and 
middle age adults. Am J Forensic Med Pathol 1993, 14(4):276-283. 
  
53 
227. De Giorgio F, Abbate A, Stigliano E, Capelli A, Arena V: Hypoplastic coronary 
artery disease causing sudden death. Report of two cases and review of the 
literature. Cardiovasc Pathol 2010, 19(4):e107-111. 
228. Amabile N, Fraisse A, Quilici J: Hypoplastic coronary artery disease: report of 
one case. Heart 2005, 91(2):e12. 
229. Buchika S, Morrow PL, Adams SP: Hypoplastic coronary artery disease within 
the spectrum of sudden unexpected death in young and middle age adults. Am J 
Forensic Med Pathol 1996, 17(1):86. 
230. Sim DS, Jeong MH, Choi S, Yoon NS, Yoon HJ, Moon JY, Hong YJ, Kim KH, 
Park HW, Kim JH et al: Myocardial Infarction in a Young Man due to a 
Hypoplastic Coronary Artery. Korean Circ J 2009, 39(4):163-167. 
231. Casta A: Hypoplasia of the left coronary artery complicated by reversible 
myocardial ischemia in a newborn. Am Heart J 1987, 114(5):1238-1241. 
232. Fraisse A, Quilici J, Canavy I, Savin B, Aubert F, Bory M: Images in 
cardiovascular medicine. Myocardial infarction in children with hypoplastic 
coronary arteries. Circulation 2000, 101(10):1219-1222. 
233. Taylor AJ, Rogan KM, Virmani R: Sudden cardiac death associated with isolated 
congenital coronary artery anomalies. J Am Coll Cardiol 1992, 20(3):640-647. 
234. Angelini P, Velasco JA, Flamm S: Coronary anomalies: incidence, 
pathophysiology, and clinical relevance. Circulation 2002, 105(20):2449-2454. 
235. Baltaxe HA, Wixson D: The incidence of congenital anomalies of the coronary 
arteries in the adult population. Radiology 1977, 122(1):47-52. 
236. Click RL, Holmes DR, Jr., Vlietstra RE, Kosinski AS, Kronmal RA: Anomalous 
coronary arteries: location, degree of atherosclerosis and effect on survival--a 
report from the Coronary Artery Surgery Study. J Am Coll Cardiol 1989, 
13(3):531-537. 
237. Yamanaka O, Hobbs RE: Coronary artery anomalies in 126,595 patients 
undergoing coronary arteriography. Cathet Cardiovasc Diagn 1990, 21(1):28-40. 
238. Liu Y, Lu X, Xiang FL, Poelmann RE, Gittenberger-de Groot AC, Robbins J, 
Feng Q: Nitric oxide synthase-3 deficiency results in hypoplastic coronary arteries 
and postnatal myocardial infarction. Eur Heart J 2014, 35(14):920-931. 
239. Widness JA, Goldman AS, Susa JB, Oh W, Schwartz R: Impermeability of the rat 
placenta to insulin during organogenesis. Teratology 1983, 28(3):327-332. 
240. Miller E, Hare JW, Cloherty JP, Dunn PJ, Gleason RE, Soeldner JS, Kitzmiller 
JL: Elevated maternal hemoglobin A1c in early pregnancy and major congenital 
anomalies in infants of diabetic mothers. N Engl J Med 1981, 304(22):1331-1334. 
241. Ylinen K, Aula P, Stenman UH, Kesaniemi-Kuokkanen T, Teramo K: Risk of 
minor and major fetal malformations in diabetics with high haemoglobin A1c 
values in early pregnancy. Br Med J (Clin Res Ed) 1984, 289(6441):345-346. 
242. Fuhrmann K, Reiher H, Semmler K, Glockner E: The effect of intensified 
conventional insulin therapy before and during pregnancy on the malformation 
rate in offspring of diabetic mothers. Exp Clin Endocrinol 1984, 83(2):173-177. 
243. Greene MF, Hare JW, Cloherty JP, Benacerraf BR, Soeldner JS: First-trimester 
hemoglobin A1 and risk for major malformation and spontaneous abortion in 
diabetic pregnancy. Teratology 1989, 39(3):225-231. 
  
54 
244. Deuchar EM: Embryonic malformations in rats, resulting from maternal diabetes: 
preliminary observations. J Embryol Exp Morphol 1977, 41:93-99. 
245. Sadler TW: Effects of maternal diabetes on early embryogenesis: II. 
Hyperglycemia-induced exencephaly. Teratology 1980, 21(3):349-356. 
246. Garnham EA, Beck F, Clarke CA, Stanisstreet M: Effects of glucose on rat 
embryos in culture. Diabetologia 1983, 25(3):291-295. 
247. Wentzel P, Eriksson UJ: Insulin treatment fails to abolish the teratogenic potential 
of serum from diabetic rats. Eur J Endocrinol 1996, 134(4):459-466. 
248. Buchanan TA, Denno KM, Sipos GF, Sadler TW: Diabetic teratogenesis. In vitro 
evidence for a multifactorial etiology with little contribution from glucose per se. 
Diabetes 1994, 43(5):656-660. 
249. Wang C, Hu S-M: Developmental regulation in the expression of rat heart glucose 
transporters. Biochem Biophys Res Commun 1991, 177(3):1095-1100. 
250. Kahn BB: Facilitative glucose transporters: regulatory mechanisms and 
dysregulation in diabetes. J Clin Invest 1992, 89(5):1367-1374. 
251. Sussman I, Matschinsky FM: Diabetes affects sorbitol and myo-inositol levels of 
neuroectodermal tissue during embryogenesis in rat. Diabetes 1988, 37(7):974-
981. 
252. Jain SK, McVie R, Duett J, Herbst JJ: Erythrocyte membrane lipid peroxidation 
and glycosylated hemoglobin in diabetes. Diabetes 1989, 38(12):1539-1543. 
253. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. 
Nature 2001, 414(6865):813-820. 
254. Takahashi M: Oxidative stress and redox regulation on in vitro development of 
mammalian embryos. J Reprod Dev 2012, 58(1):1-9. 
255. Lu SC: Regulation of glutathione synthesis. Mol Aspects Med 2009, 30(1-2):42-
59. 
256. Sakamaki H, Akazawa S, Ishibashi M, Izumino K, Takino H, Yamasaki H, 
Yamaguchi Y, Goto S, Urata Y, Kondo T et al: Significance of glutathione-
dependent antioxidant system in diabetes-induced embryonic malformations. 
Diabetes 1999, 48(5):1138-1144. 
257. Eriksson UJ, Borg LA: Protection by free oxygen radical scavenging enzymes 
against glucose-induced embryonic malformations in vitro. Diabetologia 1991, 
34(5):325-331. 
258. Hagay ZJ, Weiss Y, Zusman I, Peled-Kamar M, Reece EA, Eriksson UJ, Groner 
Y: Prevention of diabetes-associated embryopathy by overexpression of the free 
radical scavenger copper zinc superoxide dismutase in transgenic mouse embryos. 
Am J Obstet Gynecol 1995, 173(4):1036-1041. 
259. Trocino RA, Akazawa S, Ishibashi M, Matsumoto K, Matsuo H, Yamamoto H, 
Goto S, Urata Y, Kondo T, Nagataki S: Significance of glutathione depletion and 
oxidative stress in early embryogenesis in glucose-induced rat embryo culture. 
Diabetes 1995, 44(8):992-998. 
260. Siman CM, Eriksson UJ: Vitamin C supplementation of the maternal diet reduces 
the rate of malformation in the offspring of diabetic rats. Diabetologia 1997, 
40(12):1416-1424. 
261. Simán CM, Eriksson UJ: Vitamin E decreases the occurrence of malformations in 
the offspring of diabetic rats. Diabetes 1997, 46(6):1054-1061. 
  
55 
262. Sivan E, Lee YC, Wu YK, Reece EA: Free radical scavenging enzymes in fetal 
dysmorphogenesis among offspring of diabetic rats. Teratology 1997, 56(6):343-
349. 
263. Viana M, Herrera E, Bonet B: Teratogenic effects of diabetes mellitus in the rat. 
Prevention by vitamin E. Diabetologia 1996, 39(9):1041-1046. 
264. Halliwell B: Reactive oxygen species in living systems: source, biochemistry, and 
role in human disease. Am J Med 1991, 91(3C):14S-22S. 
265. Brown DI, Griendling KK: Nox proteins in signal transduction. Free Radic Biol 
Med 2009, 47(9):1239-1253. 
266. Covarrubias L, Hernandez-Garcia D, Schnabel D, Salas-Vidal E, Castro-Obregon 
S: Function of reactive oxygen species during animal development: passive or 
active? Dev Biol 2008, 320(1):1-11. 
267. Forsberg H, Eriksson UJ, Welsh N: Apoptosis in embryos of diabetic rats. 
Pharmacol Toxicol 1998, 83(3):104-111. 
268. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, 
Hatzopoulos AK, Just U, Sinowatz F et al: Essential role for mitochondrial 
thioredoxin reductase in hematopoiesis, heart development, and heart function. 
Mol Cell Biol 2004, 24(21):9414-9423. 
269. Gardiner CS, Reed DJ: Status of glutathione during oxidant-induced oxidative 
stress in the preimplantation mouse embryo. Biol Reprod 1994, 51(6):1307-1314. 
270. Li J, Stouffs M, Serrander L, Banfi B, Bettiol E, Charnay Y, Steger K, Krause 
KH, Jaconi ME: The NADPH oxidase NOX4 drives cardiac differentiation: Role 
in regulating cardiac transcription factors and MAP kinase activation. Mol Biol 
Cell 2006, 17(9):3978-3988. 
271. Gnocchi D, Leoni S, Incerpi S, Bruscalupi G: 3,5,3'-triiodothyronine (T3) 
stimulates cell proliferation through the activation of the PI3K/Akt pathway and 
reactive oxygen species (ROS) production in chick embryo hepatocytes. Steroids 
2012, 77(6):589-595. 
272. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J: Endothelin-1 enhances 
oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein 
endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J 
Pharmacol 2005, 145(3):323-333. 
273. Seelig GF, Simondsen RP, Meister A: Reversible dissociation of gamma-
glutamylcysteine synthetase into two subunits. J Biol Chem 1984, 259(15):9345-
9347. 
274. Aruoma OI, Halliwell B, Hoey BM, Butler J: The antioxidant action of N-
Acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, 
and hypochlorous acid. Free Radical Biology and Medicine 1989, 6(6):593-597. 
275. Benrahmoune M, Thérond P, Abedinzadeh Z: The reaction of superoxide radical 
with< i> N</i>-acetylcysteine. Free Radical Biology and Medicine 2000, 
29(8):775-782. 
276. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA: N-Acetylcysteine--a 
safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007, 
7(4):355-359. 
277. Sen CK: Nutritional biochemistry of cellular glutathione. The journal of 
Nutritional Biochemistry 1997, 8(12):660-672. 
  
56 
278. Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the impact of N-
Acetylcysteine on contrast nephropathy. Kidney International 2004, 65(4):1366-
1374. 
279. Green JL, Heard KJ, Reynolds KM, Albert D: Oral and Intravenous 
Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review 
and Meta-analysis. West J Emerg Med 2013, 14(3):218-226. 
280. Bonella F, Wessendorf TE, Costabel U: [Clinical experience with pirfenidone for 
the treatment of idiopathic pulmonary fibrosis]. Dtsch Med Wochenschr 2013, 
138(11):518-523. 
281. Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R, Weisgarten J, Morrow JD, 
Stein MC, Golik A: The effect of N-Acetylcysteine on renal function, nitric oxide, 
and oxidative stress after angiography. Kidney Int 2003, 64(6):2182-2187. 
282. Arakawa M, Ito Y: N-Acetylcysteine and neurodegenerative diseases: basic and 
clinical pharmacology. Cerebellum 2007, 6(4):308-314. 
283. Wentzel P, Eriksson UJ: Antioxidants diminish developmental damage induced 
by high glucose and cyclooxygenase inhibitors in rat embryos in vitro. Diabetes 
1998, 47(4):677-684. 
284. Wentzel P, Thunberg L, Eriksson UJ: Teratogenic effect of diabetic serum is 
prevented by supplementation of superoxide dismutase and N-Acetylcysteine in 
rat embryo culture. Diabetologia 1997, 40(1):7-14. 
285. Suzuki N, Svensson K, Eriksson UJ: High glucose concentration inhibits 
migration of rat cranial neural crest cells in vitro. Diabetologia 1996, 39(4):401-
411. 
286. Roest PAM, van Iperen L, Vis S, Wisse LJ, Poelmann RE, Steegers-Theunissen 
RPM, Molin DGM, Eriksson UJ, Gittenberger-De Groot AC: Exposure of neural 
crest cells to elevated glucose leads to congenital heart defects, an effect that can 
be prevented by N-Acetylcysteine. Birth Defect Res A Clin Mol Teratol 2007, 
79(3):231-235. 
287. Dennery PA: Oxidative stress in development: nature or nurture? Free Radic Biol 
Med 2010, 49(7):1147-1151. 
  
57 
2 CHAPTER 2 
 
N-Acetylcysteine prevents congenital heart defects induced by 
pregestational diabetes 
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2.1 CHAPTER SUMMARY 
Pregestational diabetes is a major risk factor of congenital heart defects (CHDs). 
Glutathione is depleted and reactive oxygen species (ROS) production is elevated in 
diabetes. In the present study, we examined whether treatment with N-Acetylcysteine 
(NAC), which increases glutathione synthesis and inhibits ROS production, prevents 
CHDs induced by pregestational diabetes. Female mice were treated with streptozotocin 
(STZ) to induce pregestational diabetes prior to breeding with normal males to produce 
offspring. Some diabetic mice were treated with N-Acetylcysteine (NAC) in drinking 
water from E0.5 to the end of gestation or harvesting of the embryos. CHDs were 
identified by histology. ROS levels, cell proliferation and gene expression in the fetal 
heart were analyzed. Our data show that pregestational diabetes resulted in CHDs in 58% 
of the offspring, including ventricular septal defect (VSD), atrial septal defect (ASD), 
atrioventricular septal defects (AVSD), transposition of great arteries (TGA), double 
outlet right ventricle (DORV) and tetralogy of Fallot (TOF). Treatment with NAC in 
drinking water in pregestational diabetic mice completely eliminated the incidence of 
AVSD, TGA, TOF and significantly diminished the incidence of ASD and VSD. 
Furthermore, pregestational diabetes increased ROS, impaired cell proliferation, and 
altered Gata4, Gata5 and Vegf-a expression in the fetal heart of diabetic offspring, which 
were all prevented by NAC treatment. Treatment with NAC increases GSH levels, 
decreases ROS levels in the fetal heart and prevents the development of CHDs in the 
offspring of pregestational diabetes. Our study suggests that NAC may have therapeutic 
potential in the prevention of CHDs induced by pregestational diabetes. 
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2.2 INTRODUCTION 
Congenital heart defects (CHDs) are the most common birth defects affecting up to 
5% of live births in the general population [1]. Pregestational diabetes mellitus, either 
type 1 or type 2, increases the risk of CHDs in infants by 3–5 fold compared to non-
diabetic pregnancies [2-6]. With an increase in the number of young adults having 
diabetes mellitus [7, 8], the incidence of pregestational diabetes and CHDs caused by 
maternal diabetes may further increase, with significant social and economic 
consequences. 
Although factors responsible for the high incidence of CHDs in pregestational 
diabetes are still not fully understood, evidence suggests that oxidative stress may play a 
role [9, 10]. For example, the antioxidant capacity of the developing embryo is limited 
[11, 12], and reactive oxygen species (ROS) production is exacerbated as the expression 
and activities of major ROS scavenging enzymes including superoxide dismutase and 
glutathione peroxidase are decreased during maternal diabetes[13-15]. In addition, 
maternal hyperglycemia diminishes the level of an important intracellular antioxidant, 
glutathione (GSH) [16, 17], which places the developing embryo in an extremely 
vulnerable state to oxidative stress. 
N-Acetylcysteine (NAC) is a thiol-containing antioxidant agent and can cross the 
placenta [18]. The main biological effect of NAC as a precursor of cysteine is to 
replenishing cellular GSH levels and to preserve the thiol redox status. Additionally, 
NAC also reacts with hydroxyl radical (˙OH), nitrogen dioxide (˙NO2) and thiol radicals 
to reduce oxidative stress [19]. Furthermore, NAC treatment in vitro and in ovo 
diminishes high glucose-induced developmental defects in mouse and chicken embryos 
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[10, 20]. In the present study, we hypothesized that NAC treatment in diabetic mice 
during gestation diminishes ROS production and prevents the development of CHDs in 
their offspring. To test this hypothesis, a pregestational diabetes mouse model was 
established to closely simulate CHDs in patients with pregestational diabetes. We 
demonstrated that NAC treatment in pregestational diabetic mice decreased ROS levels 
and improved cell proliferation during embryonic heart development, and prevented 
CHDs in the offspring of diabetic mice. 
2.3 METHODS 
2.3.1 Animals 
C57BL/6 wild type mice were purchased from Jackson Laboratory (Bar Harbor, 
Maine). A breeding program was implemented to generate fetal and postnatal mice. 
Animals in this study were handled in accordance with the Guide for the Care and Use of 
Laboratory Animals, published by the U.S. National Institutes of Health (NIH publ. no. 
85–23, revised 1996). Use of animals was approved by the Animal Use Subcommittee at 
the University of Western Ontario, Canada. 
2.3.2 Induction of Diabetes Mellitus and N-Acetylcysteine Treatment 
Eight week old C57BL/6 female mice were treated with streptozotocin (STZ, 80 
mg/kg body weight, IP, Sigma, Canada) for 3 consecutive days. STZ was dissolved in 
sodium citrate (pH 4.0) and mice treated with sodium citrate were served as controls. 
Non-fasting blood glucose levels were determined one week after STZ injection using a 
glucose meter (OneTouch Ultra2, LifeScan, Canada, Burnaby, BC, Canada). Mice with 
blood glucose levels higher than 11 mmol/l were bred to normal adult males. Mating was 
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verified by observation of a vaginal plug, which was counted as day E0.5 of pregnancy. 
A subset of control and diabetic mice received 4 mg/ml N-Acetylcysteine (NAC, 1 g/kg 
body weight/day) in drinking water [21] from E0.5 to the end of gestation or harvesting 
of the embryos. Non-fasting blood glucose levels were monitored in all groups during 
gestation. Water and food intake of pregnant mice was measured and normalized to body 
weight. 
2.3.3 Histological Analysis 
Heart morphology was analyzed in postnatal day 0 (P0) mice and cell 
proliferation was analyzed by phospho-histone H3 (pHH3) staining in E12.5 hearts. 
Briefly, the mouse thorax was fixed in 4% paraformaldehyde overnight, dehydrated in 
ethanol, embedded in paraffin and serially sectioned into 5-µm sections. Heart sections 
were stained with hematoxylin/eosin (H/E) and images were captured using a light 
microscope (Observer D1, Zeiss, Germany). Images were taken on every 25 µm of the 
heart and the three-dimensional visualization of heart structures was reconstructed using 
AMIRA® program (FEI, Hillsboro, OR, USA). To analyze cell proliferation and 
apoptosis, heart sections were immunostained using anti-pHH3 (phospho S10) antibody 
(1:500, Abcam, Toronto, ON, Canada) and anti-cleaved caspase-3 antibody (1:300, Cell 
Signaling), respectively, followed by incubation with biotinylated goat anti-rabbit IgG 
(1:500, Vector Laboratories, Burlingame, CA, USA). Signals were visualized by 3-3’di-
aminobenzidine tetrahydrochloride (Sigma-Aldrich Chemie, St. Louis, MO, USA). 
Counterstaining was performed with modified Mayer’s hematoxylin (Thermo Scientific, 
Waltham, MA, USA). The number of pHH3+ cells from at least 3 individual heart 
sections per sample was quantified and normalized to areas of the myocardium. 
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2.3.4 Analysis of Superoxide Levels 
Embryonic heart tissues were harvested at E12.5 in all four groups. Frozen 
samples were cut into 10-µm sections using a cryostat (CM1950, Leica, Germany). 
Superoxide levels were assessed by incubation of heart sections with 2 µM 
dihydroethidium (DHE) (Invitrogen Life Technologies, Burlington, ON, Canada) for 30 
minutes in a humidified and light protected chamber in room air at 37 °C [22]. DHE 
fluorescence signals were detected using a fluorescence microscope (Observer D1, Zeiss, 
Germany). For analysis of superoxide levels, 5–8 images of each heart sample were 
captured using fixed exposure time for all groups. The intensity of fluorescence signals 
per myocardial area was quantified using AxioVision software. A limitation of this assay 
is that the oxygen level was not adjusted to that of the embryonic hearts in vivo [23]. 
2.3.5 Real-time RT-PCR Analysis 
Total RNA was extracted from individual E11.5 fetal hearts using RNeasy Mini 
kit (Qiagen, Burlington, ON, Canada) as per manufacturer’s instructions. One hundred 
nanograms of total RNA were used to synthesize cDNA using M-MLV reverse 
transcriptase. Real-time PCR was conducted using EvaGreen qPCR MasterMix (Applied 
Biological Materials, Vancouver, BC, Canada). Specific primers were designed for 
Nkx2.5, Gata4, Gata5, Tbx5, Tgf-β1, Vegf-a, Mef2c, cyclin D1 and Bmp4 (Table 2.1). 
Samples were amplified for 35 cycles using Eppendorf Realplex (Eppendorf, Hamburg, 
Germany). Values were normalized with 28S ribosomal RNA. The mRNA levels in 
relation to 28S rRNA were determined using a comparative CT method [24]. 
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Gene Accession No. Product Size Primer Sequence (5′→3′) 
Nkx2.5 
  
NM_008700.2 162 F: GACAGCGGCAGGACCAGACT 
R: CGTTGTAGCCATAGGCATTG 
Vegfa NM_001025257.3  194 F: GATTGAGACCCTGGTGGACAT 
R: TCTCCTATGTGCTGGCTTTGG 
Gata4 NM_008092.3 134 F: GCCTGCGATGTCTGAGTGAC 
R: CACTATGGGCACAGCAGCTC 
Gata5 NM_008093.2 167 F: ACCCCACAACCTACCCAGCA 
R: GCCCTCACCAGGGAACTCCT 
Bmp4 NM_007554.2 250 F: GTTATGAAGCCCCCAGCAGA 
R: CCCAATCTCCACTCCCTTGA 
Tbx5 NM_011537.3 103 F: AGGAGCACAGTGAGGCACAA 
R: GGGCCAGAGACACCATTCTC 
Tgf-β1 NM_011577.1 139 F: GCCCGAAGCGGACTACTATG 
R: CACTGCTTCCCGAATGTCTG 
28S NR_003279.1 178 F: GGGCCACTTTTGGTAAGCAG 
R: TTGATTCGGCAGGTGAGTTG 
Cyclin D1 NM_007631.2 135 F: CTGACACCAATCTCCTCAACG 
R: CTCACAGACCTCCAGCATCCA 
Mef2c NM_001170537.1 405 F: CACCGAGTACAACGAGCCGCA 
R: CTGGTGCCTGCACCGGATGTC 
 
Table 2.1. Primer sequences for real-time PCR analysis 
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2.3.6 Glutathione Levels in Fetal Hearts 
Briefly, E14.5 fetal hearts were washed in PBS and snap frozen in liquid nitrogen. 
Heart samples were homogenized in 6% sulfosalicylic acid and 1 mM EDTA then 
centrifuged at 8,000 g for 5 minutes at 4°C. Total and reduced glutathione were assessed 
using a modified ultra-performance liquid chromatography (UPLC) method [25, 26]. N-
isoamyl alcohol was added to 50 µL of supernatant fraction of all samples. To determine 
total glutathione, thiols were reduced with NaBH4 followed by the addition of HCl to 
adjust the pH to approximately 8.0, and then derivatized by the addition of 25 mM 
monobromobimane. To determine reduced glutathione, the pH of the sample was raised 
to approximately 8.0 with NaOH and the samples were immediately derivatized as 
described above. Following derivatization, the pH of all samples was decreased to 
approximately 4.0 with glacial acetic acid and 5 µL was injected onto a Kinetex C18 
column (50 X 2.1 mm, 1.7 µm particle, Phenomenex, Torrance, CA) which was 
maintained at 40°C in a Waters AQUITY UPLCTM H-Class System. The mobile phase 
consisted 5% acetonitrile and 95% 5 mM KH2PO4 with 0.1% triethylamine, pH 4.0. The 
derivatized glutathione was detected by a Waters ACQUITY UPLC® fluorescence 
detector with the excitation set to 390 nm and the emission set to 480 nm. 
2.3.7 Statistical Analysis 
Data are presented as means ± SEM. Statistical analysis was performed using two-
way analysis of variance (ANOVA) followed by Bonferroni post test. The incidence of 
congenital malformations was analyzed by Chi-square test. P < 0.05 was considered 
statistically significant. 
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2.4 RESULTS 
2.4.1 Effects of NAC on Maternal Blood Glucose Levels, Litter Size and 
Mortality at Birth 
One week after STZ injection, female mice with blood glucose levels higher than 
11 mM were set up to breed with normal males. Diabetic mice had significantly higher 
blood glucose levels at the time of vaginal plugging (E0.5) compared to controls (P < 
0.001, Figure 2.1 A). Additionally, time to vaginal plugging that lead to successful 
pregnancy was 10 times longer in the diabetic compared to control mice (26.7±6.1 vs. 
2.7±0.9 days, P < 0.01), indicating decreased fertility rate in diabetic females. From E0.5 
to E18.5 of gestation, blood glucose levels of diabetic mice were progressively increased 
but not significantly altered by NAC treatment (Figure 2.1 A). Average litter size of 
neonates from diabetic mice at P0 was significantly less than controls (Figure 2.1 B). 
Additionally, neonates from diabetic mice had 46% mortality rate at birth (P < 0.001, 
Figure 2.1 C). Administration of NAC in diabetic dams improved litter size of the 
offspring (P < 0.05) and diminished their mortality at birth to 11.5% (P < 0.001). The 
body weight of neonates born to diabetic mice was significantly lower compared to 
controls at P0 (P < 0.001, Figure 2.1 D). NAC treatment did not affect body weight of 
neonates in control mice, but significantly improved the body weight of the diabetic 
offspring (P < 0.001, Figure 2.1 D). Food and water intake was significantly higher in the 
diabetic females, which was decreased by NAC treatment (Figure 2.2 A-B).   
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Figure 2.1.  Blood glucose levels of pregnant mice, litter size, mortality and body 
weight of neonates at P0. 
A) Non-fasting blood glucose levels before mating (basal), and E0.5 to E18.5 after 
pregnancy in STZ-treated and control female mice with and without NAC treatment (n = 
7-10 mice per group). B) The offspring litter size. C) Mortality of neonates at birth. The 
numbers in brackets indicate the number of death to total. D) Body weight of the 
offspring at birth (n = 27-29 per group). *P < 0.001 vs. untreated control, †P < 0.001 vs. 
untreated diabetes. Data are means ± SEM. 
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A-B) Water and food intake was significantly higher in diabetic females. NAC treatment 
decreased food and water intake of diabetic females. Data are means ± SEM. N=12-15 
females per group. *P<0.001 vs. untreated control, †P<0.001 vs. untreated diabetic and 
control NAC.  
 
 
 
  
 
Figure 2.2. Water and food consumption in female mice. 
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2.4.2 Effects of NAC on Incidence of CHDs in Diabetic Offspring 
Pregestational diabetes resulted in 58% CHDs in the offspring at postnatal day 0 
(Table 2.2). The majority of the defects were malformations of the septum with 31% 
atrial septal defect (ASD, Figure 2.3 B) and 40%, ventricular septal defect (VSD, Figure 
2.3 C). In addition, 7% of diabetic offspring showed atrioventricular septal defect 
(AVSD, Figure 2.3 D). Defects in the outflow tract included 13% double outlet right 
ventricle (DORV, Figure 2.3 G) and 7% transposition of great arteries (TGA, Figure 2.3 
I). Furthermore, 5% of diabetic offspring showed tetralogy of fallot (TOF) with 
pulmonary stenosis (Figure 2.3 E), overriding aorta and VSD associated with right 
ventricle hypertrophy (Figure 2.3 F). Treatment with NAC in diabetic mice during 
gestation significantly reduced the incidence of CHDs to 16% (Table 2.2). Specifically, 
NAC treatment decreased incident of ASD and VSD to 14% and 12%, respectively. Also, 
outflow tract formation and remodeling were improved as the rate of DORV was reduced 
to 7% while AVSD, TGA and TOF were fully rescued by NAC treatment in the diabetic 
mice (Table 2.2). Craniofacial defects were also observed in diabetic embryos (5%, 
Figure 2.4 J). However, none of the controls or NAC treated groups showed any 
craniofacial defects. 
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Total 
N/litters 
Control Diabetes Control NAC Diabetes NAC 
30/4 62/15 30/4 43/7 
 n % n % n % n % 
Normal 30 100 26 41.9** 27 90 36 83.7†† 
Abnormal 0 0 36 58.1** 3 10 7 16.3†† 
ASD 0 0 19 30.6** 2 6.7 6 13.9† 
VSD 0 0 25 40.3** 1 3.3 5 11.6†† 
AVSD 0 0 4 6.5 0 0 0 0 
TGA 0 0 4 6.5 0 0 0 0 
DORV 0 0 8 12.9* 0 0 3 6.9 
TOF 0 0 3 4.8 0 0 0 0 
Data were analyzed by Chi-square test. * P < 0.05, ** P < 0.001 vs. untreated control, †P 
< 0.05, ††P < 0.001 vs. untreated diabetes. ASD, atrial septal defect; VSD, ventricular 
septal defect; AVSD, atrioventricular septal defect; TGA, transposition of great arteries; 
DORV, double outlet right ventricle; TOF, Tetralogy of Fallot. 
Table 2.2. The rate of congenital heart defects in the offspring of diabetic and 
control females with and without N-Acetylcysteine (NAC) treatment. 
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(A) A normal heart of control offspring. The offspring of mice with pregestational 
diabetes show (B) atrial septal defect (ASD), (C) ventricular septal defect (VSD), (D) 
atrioventricular septal defect (AVSD), (E and F) tetralogy of Fallot (TOF). (E) 
*pulmonary stenosis (PS), (F) VSD, overriding aorta (OA) marked by an arrow, and RV 
hypertrophy (RVH), (G) double outlet right ventricle (DORV), and (I) transposition of 
great arteries (TGA). Panels (H) and (I) are 3D-reconstructed images of a normal heart 
and a TGA, respectively. In panel (H) the aorta (red) is connected to the right ventricle 
(RV) while the pulmonary artery (PA in blue) is connected to LV. This defect is 
associated with a VSD. (J) Craniofacial defect in diabetic offspring. RA: right atria, LA: 
left atria, LV: left ventricle. Arrows indicate ASD or VSD. Scale bar is 200 µm. 
 
 
 
  
  
Figure 2.3. Congenital defects in the diabetic offspring at P0 
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2.4.3 Effects of NAC on Glutathione and ROS levels in the Fetal Heart 
of Diabetic Mice 
Fetal glutathione levels were measured in E14.5 hearts. Diabetic offspring has 
significant reductions in total glutathione, GSH and GSSG levels compared to non-
diabetic controls (P < 0.01, Figure 2.3 A-C). The GSH/total glutathione ratio was lower 
while GSSG/total glutathione ratio was higher in fetal hearts from diabetic mice (P < 
0.05, Figure 2.3 D and E). NAC treatment completely restored total glutathione and GSH 
levels in the offspring of diabetic mice (P < 0.001, Figure 2.3 A and B), leading to higher 
GSH/total glutathione ratio and lower GSSG/total glutathione ratio (P < 0.01, Figure 2.4 
D-E). NAC treatment in non-diabetic females during gestation had no effect on total 
glutathione levels but decreased GSSG levels, and consequently GSH/total glutathione 
ratio was increased (P < 0.05, Figure 2.4 D). To examine the effects of NAC on ROS 
levels, dihydroethidium (DHE) was employed as a probe to assess superoxide generation 
in fetal hearts at E12.5. Elevated DHE fluorescence reading in the fetal heart of diabetic 
offspring indicated excess superoxide levels, which was significantly inhibited by NAC 
treatment (P < 0.05, Figure 2.4). 
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Figure 2.4. Measurement of intracellular glutathione levels in fetal hearts at E14.5 
A) Total glutathione levels, B) Reduced glutathione (GSH) levels, C) Oxidized 
glutathione (GSSG) levels, D) GSH to total glutathione ratio, and E) GSSG to total 
glutathione ratio. Data are means ± SEM, n = 7–9 samples per group. *P < 0.05, **P < 
0.001 vs. untreated control, †P < 0.001 vs. untreated diabetes. 
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Figure 2.5. Analysis of superoxide in fetal hearts at E12.5 using dihydroethidium 
(DHE) as a probe 
A) Representative images of DHE staining in the LV myocardium of fetal hearts. B) 
Quantification of DHE fluorescence intensity. Data are means ± SEM, n = 5–6 
samples per group. *P < 0.05 vs. untreated control, †P < 0.05 vs. untreated diabetes. 
Scale bar is 20 µm. 
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2.4.4 Effects of NAC on Cell Proliferation and Apoptosis in the 
Embryonic Heart from Diabetic mice 
Proper cell proliferation and apoptosis are essential for normal embryonic heart 
development [27, 28]. Using phosphorylated histone H3 (pHH3) as a marker, we 
analyzed cell proliferation in fetal hearts at E12.5 and E14.5, that are important stages of 
myocardium growth. The offspring of mice with pregestational diabetes had a 
significantly lower number of myocardial proliferating cells at E12.5 and E14.5 (P < 
0.05, Figure 2.6 A-C). NAC treatment during gestation showed a trend but not a 
significant difference in cell proliferation at E12.5. Notably, this effect was significant at 
E14.5 (P < 0.001, Figure 2.6 C). In E12.5 endocardial cushion, cell proliferation was 
lower in the offspring of diabetic mice (Figure 2.7 A, B). NAC treatment resulted in 
significantly higher cell proliferation in endocardial cushion of control and diabetic mice 
(Figure 2.7 B). We also assessed cell apoptosis through immunohistochemical analysis of 
cleaved caspase-3 (Figure 2.7 A). Apoptosis in the endocardial cushion at E12.5 was 
significantly higher in the offspring of diabetic mice compared to controls (P < 0.05, 
Figure 2.7 A, C). NAC treatment had no significant effect on apoptosis in the offspring of 
diabetic mice, but increased apoptosis in the endocardial cushion in controls (P < 0.05, 
Figure 2.7 C). As a result of lower cell proliferation, myocardial wall thickness was lower 
in the offspring of diabetic mice at P0 (P < 0.01, Figure 2.8 A-C), which was rescued by 
NAC treatment (P < 0.05, Figure 2.8 A-C). 
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(A) Representative histological heart sections immunostained for pHH3. pHH3+ staining 
(brown) is localized in the nucleus. (B and C) Quantification of pHH3+ cells in heart 
tissue sections, which include the right, left and septal myocardium. Data are means ± 
SEM, n = 6–8 per group *P < 0.05 vs. untreated control, †P < 0.001 vs. untreated 
diabetes. Scale bar is 50 µm. 
Figure 2.6. Cell proliferation in the fetal ventricular myocardium. 
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Figure 2.7.  Cell proliferation and apoptosis in the endocardial cushion at E12.5 
 (A) Representative immunohistological staining of pHH3 (nucleus) and cleaved caspase-
3. (B and C) Quantification of pHH3+ cells (cell proliferation) and cleaved caspase-3+ cells 
(apoptosis) in relation to total endocardial cushion cells. *P < 0.05 vs. untreated control, 
†P < 0.05 vs. untreated diabetes, **P<0.001 vs. untreated control. Scale bar is 50 µm. N= 
6-7 hearts per group. 
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Figure 2.8.  Myocardial wall thickness at P0. 
(A) Representative images of myocardial wall thickness. (B and C) Quantification of 
right and left ventricular wall thickness. n = 5-6 per group, *P < 0.01 vs. untreated 
control, †P < 0.05 vs. untreated diabetes. Scale bar is 200 µm. 
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2.4.5 Effects of NAC on Transcription Factor Expression in Fetal 
Hearts from Diabetic Mice 
Pregestational diabetes alters gene expression levels in the developing heart [29]. 
To study the effect of pregestational diabetes and NAC treatment on genes essential for 
early heart development, quantitative RT-PCR analysis was performed at E11.5. Our data 
showed transcript levels of Gata4 and Gata5 were lower in the embryonic hearts of 
diabetic mice at E11.5 (P < 0.05, Figure 2.8 A-B). Since GATA4 and GATA5 regulate 
cell proliferation in the fetal heart, we evaluated expression levels of cyclin D1, an 
important cell cycle regulator. Our data showed that pregestational diabetes significantly 
decreased cyclin D1 mRNA levels in the embryonic heart (P < 0.01). On the contrary, 
Vegf-a mRNA levels were increased in the embryonic hearts from diabetic mice (P < 
0.05, Figure 2.9 C). These changes were all restored to control levels after NAC 
treatment (P < 0.05, Figure 2.9 A-D). However, other cardiac transcription factors 
including Nkx2.5, Mef2c and Tbx5 were not significantly altered by maternal diabetes or 
NAC treatment (Figure 2.9 E-G). In addition, levels of Bmp4 and Tgf-β1, which 
regulates cardiac valve formation, were not significantly altered (Figure 2.9 H-I). 
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Figure 2.9.  Gene expression levels in fetal hearts at E11.5. 
(A-D) The mRNA levels of Gata4, Gata5, Vegf-a and cyclin D1 were significantly 
altered in diabetic fetal hearts, which were restored to normal levels by NAC. (E-I) 
Neither pregestational maternal diabetes nor NAC treatment affected the mRNA levels of 
Tbx5, Nkx2.5, Tgf-β1, Mef2c and Bmp4 in the embryonic hearts by two way ANOVA. 
Data are means ± SEM, n = 6-8 hearts per group. *P < 0.05 vs. untreated control, †P < 
0.05 vs. untreated diabetes. 
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2.5 DISCUSSION 
Pregestational diabetes is a major risk factor for CHDs in humans. However, the 
molecular mechanisms that lead to the development of CHDs and possible therapeutic 
approaches to prevent those defects are still not fully understood. It is generally believed 
that oxidative stress plays a major role in the induction of birth defects in diabetic fetus 
[12, 16, 30]. Here, we employed a mouse model of pregestational diabetes induced by 
STZ and studied the effects of NAC treatment on CHDs in the offspring of diabetic mice. 
Our data showed that pregestational diabetes resulted in a high incidence of CHDs and 
decreased cell proliferation associated with altered expression levels of Gata4, Gata5 and 
Vegf-a. Importantly, GSH levels were decreased while ROS levels were increased in the 
fetal heart of pregestational diabetes. Notably, these abnormalities in the fetal heart were 
rescued by maternal treatment with NAC. Our study provides new evidence on the 
critical role of glutathione in embryonic heart development and suggests that NAC may 
have therapeutic potential in preventing CHDs in patients with pregestational diabetes. 
To simulate congenital malformations induced by maternal diabetes without 
genetic modifications, several experimental approaches have been used, which include 
STZ- or alloxan-induced diabetes, and infusion of glucose to induce hyperglycemia. 
When diabetes or hyperglycemia is induced at the time of mating or within a few days 
after gestation, congenital defects in the central nervous system and skeletal 
malformation are observed in the offspring [31, 32]. While congenital heart 
malformations have been observed in animal studies of diabetic pregnancy, a spectrum of 
defects that can arise has been less well characterized [33-35]. In the present study, 
diabetes was induced by STZ in female mice for at least one week before gestation to 
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avoid the potential teratogenic effects of STZ on developing embryo. Our results show 
that pregestational diabetes induces embryopathy with a wide range of cardiovascular 
malformations including ASD, VSD, AVSD, TGA, DORV and TOF. These 
malformations of the cardiovascular system mirror congenital defects of neonates born to 
females with pregestational diabetes [6]. Thus, our model represents an appropriate 
animal model to study CHDs induced by pregestational diabetes. 
Diabetes increases ROS production through increased activity of ROS generating 
enzymes and decreased activity of antioxidant enzymes [36, 37]. Extensive evidence 
have shown the involvement of oxidative stress in diabetic embryopathy [38] and the 
importance of glutathione in regulating ROS levels and redox signaling [26]. In the 
present study, we demonstrated that ROS levels were significantly higher in the fetal 
heart of diabetic offspring. Furthermore, total glutathione, GSH and GSSG levels were 
lower in the embryonic heart of diabetic offspring. To replenish GSH levels in the 
embryonic heart of diabetic mice, female mice with pregestational diabetes were treated 
with NAC, a precursor of cysteine essential for the production of GSH [18, 39, 40]. 
Notably, treatment with NAC normalized GSH levels and ROS levels in the fetal heart of 
diabetic mice. Importantly, NAC treatment also resulted in significantly fewer CHDs 
induced by pregestational diabetes. These data suggest an important role of GSH 
depletion and excessive ROS production in the development of CHDs. Previous studies 
have shown that treatment with NAC in vitro or GSH ethyl ester in vivo reduces gross 
embryonic malformation induced by high glucose or maternal diabetes [10, 16]. 
However, the beneficial effect of glutathione on cardiac development was limited to 
outflow tract defects induced by high glucose [20, 34]. The present study further 
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demonstrated the beneficial effects of NAC on a wide spectrum of cardiovascular 
malformations induced by pregestational diabetes in vivo. Additionally, NAC treatment 
reduced water and food intake of diabetic mice. While this phenomenon is also observed 
in NAC treated diabetic rats [41] our knowledge of the underlying mechanism is limited. 
NAC has been demonstrated to delay the onset of type 1 diabetes in biobreeding rats [42] 
and protect against hyperglycemia induced insulin resistance in rats [43]. Although, the 
beneficial effects of NAC in diabetic condition are explained by replenishing GSH levels 
and depleting oxidative stress [44], further studies are required to examine whether NAC 
has an effect on intracellular glucose metabolism or insulin sensitivity in diabetic 
condition. It should be noted that NAC treatment did not alter total glutathione levels in 
the fetal hearts of control mice. This is not surprising because intracellular GSH levels 
are regulated by a feedback inhibition to glutamate-cysteine ligase (GCL), a rate limiting 
enzyme in the production of GSH [45]. As such, the exogenous NAC participates in GSH 
synthesis only during oxidative stress conditions [39]. In addition, NAC also protects 
GSH from oxidation through its antioxidant properties independent of GSH synthesis 
[46], leading to an increased GSH/total glutathione ratio in both diabetic or control mice 
in the present study. 
It is well documented that ROS regulates gene expression, cell proliferation and 
apoptosis [47]. In the present study, transcription factors that are critical to embryonic 
heart development including Gata4, Gata5 [48, 49] were downregulated in diabetic fetal 
hearts at E11.5. However similar to previous studies, Vegf-a mRNA levels were higher in 
diabetic fetal hearts [35]. Elevated expression levels of VEGF-A are associated with 
CHDs [50, 51]. High VEGF-A levels in fetal hearts inhibit epithelial-to-mesenchymal 
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transition (EMT) in the endocardial cushion, which contributes to formation of 
atrioventricular septum [52, 53]. Although a causal relationship between altered 
expression of Gata4, Gata5, Vegf-a and the development of CHDs in our study cannot be 
established, the fact that treatment with NAC restored their expression, improved cell 
proliferation via restoring cyclin D1 expression and prevented CHDs in diabetic offspring 
suggests that these transcription factors are sensitive to redox regulation and their 
alteration may contribute at least in part to cardiac malformation in pregestational 
diabetes. 
Apoptosis is a highly regulated process and aberrant apoptosis may result in 
cardiovascular defects [54, 55]. The present study showed that apoptosis in the 
endocardial cushion was higher in diabetic embryos. Additionally, treatment with NAC 
resulted in higher apoptosis and induced 10% septal defects in control embryos. These 
data are consistent with a role of apoptosis in cardiac malformation [55, 56]. Cell 
proliferation was assessed using pHH3 staining, which marks cells undergoing mitosis. 
Notably, the number of pHH3+ cells in the endocardial cushion and myocardium was 
lower in diabetic embryos, which was rescued by NAC treatment. Cell proliferation in 
endocardial cushion was also higher with NAC treatment in the control embryos. Since 
NAC treatment did not inhibit apoptosis in diabetic embryos in our study, higher cell 
proliferation may represent a major effect of NAC in preventing CHDs in diabetes. 
In conclusion, the present study demonstrated that pregestational diabetes in mice induces 
a wide spectrum of CHDs similar to humans. Treatment with NAC increases GSH levels, 
decreases ROS levels in the fetal heart and prevents the development of CHDs in the 
offspring of pregestational diabetes. In women with pregestational diabetes, insulin is the 
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primary treatment to achieve good glycemic control [57]. However, insulin treatment is 
not sufficient to decrease the risk of CHDs in the diabetic offspring to normal levels [38, 
58]. Even with optimal care and planning of diabetic pregnancies, the risk of CHDs in the 
offspring of diabetic mothers is not as low as in the offspring of nondiabetic mothers (1-
5%). Further studies are required to investigate whether NAC, an FDA approved drug 
either alone or in combination with insulin prevents CHDs in infants of women with 
pregestational diabetes. 
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3.1 CHAPTER SUMMARY  
Hypoplastic coronary artery disease is a congenital coronary artery malformation 
associated with a high risk of sudden cardiac death. However, the etiology and 
pathogenesis of hypoplastic coronary artery disease remain undefined. Pregestational 
diabetes increases reactive oxygen species (ROS) levels and the risk of congenital heart 
defects. We hypothesized, that pregestational diabetes induces coronary artery 
malformation via ROS signaling. Our data show that pregestational diabetes in mice 
induced by streptozotocin significantly increased ROS production and decreased 
coronary artery diameter and volume in fetal hearts. Pregestational diabetes also impaired 
epicardial epithelial-to-mesenchymal transition (EMT) as shown by analyses of the 
epicardium, epicardial derived cells and fate mapping. Additionally, ROS-dependent 
hypoxia inducing factor (Hif-1α) and epicardial EMT signaling pathway was examined. 
The expression of Hif-1α, Snail1, Slug, basic fibroblast growth factor (bFgf) and 
retinaldehyde dehydrogenase (Aldh1a2) were lower while E-cadherin expression was 
higher in the fetal heart of diabetic mothers. Notably, these abnormalities were all 
rescued by treatment with an antioxidant N-Acetylcysteine (NAC) in diabetic females 
during gestation. Ex vivo analysis shows that high glucose inhibited epicardial EMT, 
which was reversed by NAC treatment. We conclude that pregestational diabetes in mice 
can cause coronary artery malformation via ROS signaling. Our study may provide a 
rationale for further clinical studies to investigate whether pregestational diabetes could 
cause hypoplastic coronary artery disease in humans. 
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3.2 INTRODUCTION 
Pregestational diabetes is a risk factor for CHDs in infants [1,2]. Clinical studies 
have shown that pregestational diabetes increases the risk of CHDs in the offspring by 3–
5 fold compared to non-diabetic pregnancies [1-3]. To date, analysis of congenital heart 
malformation in the newborn is mainly restricted to major cardiac structures, which 
include aorta, pulmonary artery, atrioventricular septum, cardiac valves and the 
myocardium, but coronary arteries are not routinely examined [4]. Importantly, 
congenital malformation can occur in coronary arteries leading to null coronary artery or 
hypoplastic coronary artery disease [5]. While null coronary artery is embryonically 
lethal, hypoplastic coronary artery disease is a rare congenital coronary abnormality 
defined by malformation of one or more major branches of the coronary arteries with a 
marked decrease in luminal diameter and length. Hypoplastic coronary artery disease can 
be asymptomatic, but is often associated with myocardial infarction and sudden cardiac 
death during intense physical activities [6]. However, the etiology and pathogenesis of 
hypoplastic coronary artery disease remain undefined. Furthermore, it is not known if 
pregestational diabetes results in coronary artery malformation in the offspring. Isolated 
cases of congenital coronary artery abnormalities have been identified in infants by 
autopsy. However, whether the mothers of these patients had pregestational diabetes was 
not disclosed in these reports [7,8]. A large multicenter case-control study showed a 
significant association between pregestational diabetes and a wide range of CHDs [1]. 
Since coronary arteries were not routinely examined, defects of coronary arteries were 
not reported in this study. Notably, a recent population-based study reported cases of 
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coronary artery anomaly born from mothers with obesity. However, patients with 
established diabetes were excluded from this study [9]. 
Coronary arteries are developed from several sources of progenitors, which include 
endothelial cells of sinus venosus, proepicardial organ and the endocardium [10-12]. The 
current understanding is that cells from the proepicardial organ migrate toward the 
myocardium and form the epicardium. Concurrent with formation of the epicardium, some 
epicardial cells undergo epithelial-to-mesenchymal transition (EMT), migrate to the 
subepicardial space and myocardium and become epicardial derived cells (EPDCs). 
Simultaneously, a sub-population of endothelial cells of the sinus venosus also migrates to 
the subepicardial space, forming subepicardial endothelial progenitors [11]. When resident 
in the myocardium, the EPDCs give rise to vascular smooth muscle cells and fibroblasts 
[13] while subepicardial endothelial progenitors give rise to coronary endothelial cells [14]. 
Together, EPDCs and subepicardial endothelial cells contribute to the development of 
coronary arteries with a minor contribution from the endocardium.  
Epicardial EMT is regulated by several epicardial transcription factors and 
myocardial induced signalling molecules [15]. An important factor in vasculogenesis and 
heart development is hypoxia inducible factor (HIF-1α) [16], which regulates many 
downstream target genes, including Wilms tumour-1 (Wt1), a critical transcription factor 
expressed in epicardial progenitors and EPDCs [17,18].  Studies have shown that Wt1 
directs epicardial progenitors to become smooth muscle cells and fibroblasts, and form 
coronary arteries [19]. Pregestational diabetes increases reactive oxygen species (ROS) 
production [20,21] and downregulates HIF-1α expression in embryos [22]. We have 
shown that treatment with an antioxidant N-Acetylcysteine (NAC) increases reduced 
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glutathione (GSH) levels and decreases ROS production in the fetal hearts of diabetic 
offspring [20]. The present study was designed to test the hypothesis that pregestational 
diabetes impairs epicardial EMT and induces coronary artery malformation in the 
offspring. We further hypothesized that these abnormalities are mediated by ROS 
signaling and can be rescued by NAC treatment in diabetic females during gestation.  
3.3 METHODS 
3.3.1 Animals 
C57BL/6 wild type, Wt1creERT2/+ and Rosa26mTmG mice were purchased from 
Jackson Laboratory (Bar Harbor, Maine).  Animals in this study were handled in 
accordance with the Guide for the Care and Use of Laboratory Animals, published by the 
U.S. National Institutes of Health (NIH publ. no. 85-23, revised 1996). All procedures 
involving mouse handling and manipulation were in accordance with the guidelines of 
the Canadian Council of Animal Care and approved by the Animal Use Subcommittee at 
the University of Western Ontario, Canada. 
3.3.2 Induction of Diabetes and NAC Treatment  
Eight week old C57BL/6 female mice were induced to diabetes by streptozotocin 
(STZ, 80 mg/kg body weight per day, IP) injections for three consecutive days as 
described previously [20,23,24]. STZ was dissolved in sodium citrate (pH 4.0) and mice 
treated with sodium citrate were served as controls. Non-fasting blood glucose levels 
were determined one week after STZ injection using a glucose meter (OneTouch Ultra2; 
LifeScan Canada, Burnaby, BC). Mice with blood glucose levels higher than 11 mmol/l 
were considered diabetic and bred to normal adult males. Vaginal plugging was 
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monitored as a sign of successful mating and the day of vaginal plugging was recorded as 
day E0.5 of gestation. A subgroup of control and diabetic mice received 4 mg/ml N-
Acetylcysteine (NAC, 1 g/kg body weight/day) in drinking water from E0.5 to the end of 
gestation or harvesting of the embryos [20].  
3.3.3 Fate Mapping Analysis  
Fate mapping of Wt1+ lineage was performed using Wt1creERT2/+ (Stock #10912, Jackson 
Laboratory) and the double fluorescent Cre reporter line Rosa26mTmG (Stock #7576). 
Wt1creERT2/+ is a heterozygous Wt1-/+ mouse, where exon 1 of the Wt1 gene is deleted and 
replaced by a CreERT2 sequence under the control of the Wt1 promoter [19]. CreERT2 is 
created by fusion of Cre recombinase to a modified human estrogen receptor ligand 
binding domain (ERT2) (Figure 3.1). The Rosa26mTmG reporter mice possess loxP sites on 
either side of a membrane-targeted tomato (mT) cassette followed by membrane-targeted 
green fluorescence protein (GFP, mG) cassette. In the absence of Cre recombinase 
activity, mT (red fluorescence) is expressed in all tissues. In the presence of Cre, the mT 
cassette is deleted and mG (green fluorescence) is expressed only in the targeted cells. 
Female Rosa26mTmG mice were induced to diabetes by STZ (80 mg/kg body weight per 
day, IP for 3 days) as described above, and were bred with Wt1creERT2/+;Rosa26mTmG 
males. Tamoxifen (50 mg/kg body weight, IP) was injected to diabetic or control 
pregnant females at E10.5. Upon tamoxifen administration, Cre is activated in Wt1 
expressing cells and induces recombination to express GFP, which is one of the two 
fluorescence proteins in the Wt1creERT2/+;Rosa26mTmG offspring. Embryos were harvested 
at E14.5. Double transgenic Wt1creERT2/+;Rosa26mTmG embryos were sectioned and 
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immunostained for GFP. The Wt1+ derivatives, which are GFP+ cells and structures, were 
quantified and compared between diabetic and control mice.  
 
 
 
Figure 3.1. Lineage tracing to evaluate derivatives of epicardial Wt1+ cells. 
A) A schematic diagram of a breeding plan to generate offspring with 
RosamTmG;Wt1CreERT2 genotype. B) Red fluorescence protein (RFP) is transcribed in cells 
with no Wt1 expression. CreERT2 is transcribed in Wt1 expressing cells. Upon 
tamoxifen administration, Cre is expressed and induce recombination at LoxP sites, thus 
Wt1 expressing cells and their lineage will express green fluorescence protein (GFP).   
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3.3.4 Analysis of Superoxide Production 
Embryonic heart tissues were harvested in all four groups at E14.5. Frozen 
samples were cut into 10-µm sections using a cryostat (CM1950, Leica). Superoxide 
levels were assessed by incubation of heart sections with 2 µM dihydroethidium (DHE) 
(Invitrogen Life Technologies) for 30 minutes in a humidified and light protected 
chamber at 37 °C [20]. DHE florescence signals were detected using a florescence 
microscope (Observer D1, Zeiss). At least 5 images were captured using fixed exposure 
time for each heart and the intensity of DHE florescence signals per myocardial area were 
quantified using AxioVision software (Zeiss, Germany).  
3.3.5 Immunohistochemistry Analysis 
Formation of coronary artery branches was studied at E16.5 and P0 when the 
coronary arteries are formed. Immunohistochemical analysis was performed to study 
formation of coronary vasculature and their precursors. In brief, the thoraxs of mice were 
harvested and processed in 4% paraformaldehyde overnight, dehydrated in ethanol, 
embedded in paraffin medium and sectioned transversely to 5 µm sections. Prior to 
immunostaining, antigen retrieval was performed in citric acid buffer (0.01 M, pH 6.0) 
for 12 minutes at 94 °C using a microwave oven (BP-111, Microwave Research & 
Applications, Carol Stream, Illinois). Samples were incubated with primary antibody 
overnight: anti-α-smooth muscle actin (1:3000, Sigma-Aldrich, Toronto, ON, Canada), 
biotinylated griffonia simplicifolia lectin-1 (1:250, Vector Laboratories, Burlington, ON, 
Canada), anti-Wilm’s tumor-1 (1:300, Calbiochem, Etobicoke, ON, Canada), anti-E-
cadherin (1:200, Santa Cruz biotechnology, Santa Cruz, CA, USA), anti-GFP (1:1000, 
Abcam, Toronto, ON, Canada), anti-phospho-histone H3 (pHH3, 1:500, Abcam, Toronto, 
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ON, Canada) and anti-cleaved caspase-3 (1:800, Cell Signaling, Danvers, MA, USA) 
followed by one of the following secondary antibodies (Vector Laboratories, Burlington, 
ON, Canada) for an hour: biotinylated goat anti-rabbit IgG (1:500), biotinylated goat anti-
mouse IgG (1:500)  or biotinylated donkey anti-goat IgG (1:500). Signals were amplified 
by incubation with the ABC reagent (Vector Laboratories, Burlington, ON, Canada) and 
visualized using 3-3’di-aminobenzidine tetrahydrochloride (Sigma-Aldrich, Toronto, ON, 
Canada). Heart sections were counterstained with hematoxylin (Thermo Scientific, 
Waltham, MA USA) and images were captured using a light microscope (Observer D1, 
Zeiss, Germany). To visualize and analyze coronary artery volume, images of every 25 
µm heart sections immunostained with α-smooth muscle actin were captured and 
imported to AMIRA® program for three-dimensional reconstructions [20]. Coronary 
arteries and the myocardium wall thickness were labeled individually. Using analytical 
tools of AMIRA, pixels were converted to volume (µl) and a ratio of coronary artery 
volume to myocardial volume was obtained. 
3.3.6 Ex vivo Heart Explant Culture 
Epicardial cells of E12.5 hearts undergo epithelial to mesenchymal transition 
(EMT) when they are cultured on collagen gel. To determine whether hyperglycemia 
impairs  EMT, the ventricles of E12.5 embryos from control dams were harvested and 
cultured on collagen gel. Collagen (1 mg/ml, type I collagen of rat’s tail, BD Bioscience) 
was prepared in M199 media (M5017, Sigma), which contained 5 mM D-glucose or in 
M199 with addition of 25 mM D-glucose, which made the final D-glucose concentration 
to be 30 mM. Casted collagen was hydrated by OPTI-MEM media plus 1% fetal bovine 
serum (FBS) and insulin-transferrin-selenium (ITS) for 30 minutes at 37 °C. E12.5 
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ventricles were explanted and incubated at 37 °C overnight. The following day, 5 or 30 
mM D-glucose in M199 media with 10% FBS were added to the heart explants. The 
glucose concentration was about 5 mM higher than the average blood glucose of diabetic 
dams at E10.5. To inhibit ROS production, heart explant cultures were treated with 0.5 
mM NAC. The number of spindle shaped cell outgrowths from the explanted ventricles 
was quantified 4 days post culturing. Images were captured using phase contrast 
microscope (Zeiss, Germany).  
3.3.7 Real-time RT-PCR Analysis 
The epicardium is formed at E10.5 and EMT is initiated followed by formation of 
the epicardial cell layer. To examine transcript levels that are important for EMT we 
harvested hearts from E11.5 embryos. Total RNA was extracted from individual E11.5 
embryonic hearts using RNeasy Mini kit (Qiagen, Burlington, ON, Canada) as per 
manufacturer’s instructions. cDNA was synthesized from 0.1 µg of total RNA using M-
MLV reverse transcriptase in 10 µl reactions, which were diluted by 3 times for genes of 
interest and 500 times for a housekeeping gene 28S, respectively. Two microliters of 
diluted cDNA were used for real-time PCR amplification using EvaGreen qPCR 
MasterMix (Applied Biological Materials, Vancouver, BC, Canada). Specific primers 
were designed for Hif-1α, Snail1, Slug, bFgf, β-catenin and Aldh1a2 (Table 3.1). 
Samples were amplified for 35 cycles using Eppendorf Realplex (Eppendorf, Hamburg, 
Germany). The mRNA levels in relation to 28S ribosomal RNA were determined using a 
comparative CT method [25].  
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3.3.8 Statistical Analysis 
Data are presented as means ± SEM. Statistical analysis was performed using 
two-way analysis of variance (ANOVA) followed by Bonferroni post test (GraphPad 
Prism program, version 5.0). The incidence of malformation was assessed by Chi-square 
test. A P value of less than 0.05 was considered statistically signiﬁcant.  
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Gene Accession No. Product Size Primer Sequence (5ʹ′→ 3ʹ′) 
Aldh1a2 NM_009022.4 219 F: GGCAGCAATCGCTTCTCACA 
R: CAGCACTGGCCTTGGTTGAA 
bFgf NM_008006.2 174 F:   CAAGGGAGTGTGTGCCAACC 
R:   TGCCCAGTTCGTTTCAGTGC 
Ctnnb1 NM_001165902.1 
 
178 F: AGCTTCCTTTTTGGAAAGCTG 
R: CTTGGCTGAACCATCACAGAT 
Snail1 NM_011427.2 
 
114 F: CACACGCTGCCTTGTGTCT 
R: GGTCAGCAAAAGCACGGTT 
Slug NM_011415.2 161 F: CAACGCCTCCAAGAAGCCCA 
R: GAGCTGCCGACGATGTCCAT 
Hif-1α NM_010137.3 
 
159 F: CTTGGACGCTCTGCCTATGA 
R: AGGTTGCGGGGGTTGTAGAT 
 
  
Table 3.1. Primer sequences for real-time PCR analysis 
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3.4 RESULTS  
3.4.1 Pregestational Diabetes Increases ROS Levels in Fetal Hearts  
To assess ROS production, dihydroethidium (DHE) was employed as a probe to 
detect superoxide generation in the fetal heart. A significant increase in DHE 
fluorescence reading in the E14.5 hearts of the offspring of diabetic mice indicated excess 
superoxide levels (Figure 3.2 A-B). Notably, treatment with an antioxidant NAC in 
drinking water in the diabetic dams during gestation significantly inhibited superoxide 
generation in the fetal hearts of diabetic mice (Figure 3.2 A-B). These data suggest that 
pregestational diabetes increases ROS levels in the fetal heart, which are effectively 
inhibited by NAC treatment. 
3.4.2 Coronary Artery Malformation in Fetal Hearts from 
Pregestational Diabetes  
A critical period for coronary artery development is from E9.5 to E14.5 in mice. 
To examine the effect of pregestational diabetes on coronary artery formation, adult 
female mice were induced to diabetes by STZ and their non-fasting blood glucose levels 
were determined during gestation. Our data show that blood glucose levels in diabetic 
females were significantly higher than normal controls (P<0.001, Table 3.2). NAC 
treatment did not significantly alter blood glucose levels in the diabetic and normal dams 
(Table 3.2). 
Formation of coronary artery and capillaries was evaluated following 
immunostaining of α-smooth muscle actin and lectin-1, respectively. Offspring ofdiabetic 
mothers show lower left and right coronary artery diameter and abundance at P0 
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Figure 3.2. Reactive oxygen species (ROS) production assessed by dihydroethidium 
(DHE) fluorescence in fetal hearts at E14.5 
A) Representative images of DHE red fluorescence in the LV myocardium. B) 
Quantification of DHE fluorescence per myocardial area. N=5 fetal hearts from 2 to 3 
litters per group. *P<0.05 vs. untreated control, †P<0.01 vs. untreated diabetes. Scale bar 
20 µm.	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 Control Diabetes Control+NAC Diabetes+NAC 
Pregnant mice (n) 8 10 8 10 
At E0.5 6.9 ± 0.3 17.2 ± 1.6 * 7.5 ± 0.3 14.9 ± 1.0 * 
At E10.5 8.6 ± 0.5 24.2 ± 2.2 * 8.9 ± 0.5 22.0 ± 1.4 * 
 
Data are mean ± SEM. *P<0.05 vs. respective controls. Fetuses and neonates from these 
dams were used for histological, immunostaining, ROS and real-time PCR analysis, and 
ex vivo heart cultures. 
 
(Figure 3.3 A-B) and at E16.5 (Figure 3.4 A-B). Additionally, coronary arteries in 
offspring of diabetic mice had lower numbers of smooth muscle cells surrounding the 
vessels (Figure 3.3 C) and lower capillary abundance at P0 (Figure 3.3 D). Impaired 
coronary artery development is illustrated in three-dimensional reconstructions of 
coronary arteries, which demonstrate smaller arteries with less arborization in offspring 
of diabetic mice at E16.5 and P0 (Figure 3.5 A). The impaired coronary artery 
development was not simply due to changes in myocardial volume as the ratio of total 
coronary artery volume to myocardial volume was lower in the offspring of diabetic mice 
at P0 and E16.5 (Fig. 3.5 B-C). The incidence of coronary artery malformation was 46% 
(see Table 3.3). To study the role of ROS in coronary artery malformation, diabetic and 
control dams were treated with an antioxidant NAC in their drinking water during  
Table 3.2. Non-fasting blood glucose levels (mM) during gestation in mice 
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Smooth muscle and endothelial cells were marked by α-smooth muscle actin (A-C) and 
lectin-1 (D) immunostaining (brown), respectively. A: Representative images of the left 
main coronary artery branch at the aortic root. B: Representative images of coronary 
artery branches in the myocardium. Arrows are pointed to coronary vessels. C: Coronary 
artery vessels in the myocardium. D: Capillaries in the myocardium. E and F: Diameters 
of the left and right coronary arteries at the aortic root (n=12-15 hearts per group). G: 
Coronary artery abundance per mm2 myocardium (n=7-10 hearts per group). H: Capillary 
density per mm2 myocardium (n=5 hearts per group). Data were collected from 3 to 5 
litters per group. *P<0.01 vs. untreated control, †P<0.01 vs. untreated diabetes. AO, 
aorta; RV, right ventricle; LV, left ventricle; NAC, N-Acetylcysteine. Scale bars are 50 
µm in A, C, D and 400 µm in B.  
  
Figure 3.3. Malformation of coronary vasculature in the offspring of diabetic mice 
restored by NAC treatment at P0.  
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A) Representative image of left coronary artery at the aortic root. B) Representative 
image of coronary artery branches in the ventricular myocardium. C) Panel C is zoom-up 
images of the boxed areas in B to demonstrate differences in vessel size. D) and E) 
Quantification of left and right coronary artery diameter. F) Quantification of coronary 
artery abundance. N=7-8 samples per group. *P<0.05 vs. untreated control, †P<0.01 vs. 
untreated diabetes. 
 
  
Figure 3.4. Malformation of coronary artery vasculature in the fetal heart of 
diabetic mice restored by NAC treatment at E16.5  
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Figure 3.5.  Analysis of three-dimensional (3D) reconstructions of coronary artery 
tree demonstrates reduced coronary artery volume in the offspring of diabetic mice 
is restored by NAC treatment at E16.5 and P0 
A) Illustrations of 3D reconstructions of coronary arteries. B and C) Quantification of the 
total coronary artery volume normalized to myocardial volume at E16.5 and P0, 
respectively. N=5 hearts from 3 litters per group. * P<0.05 vs. untreated control, †P<0.01 
vs. untreated diabetes. RV, right ventricle; LV, left ventricle; NAC, N-Acetylcysteine. 
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gestation. Notably, abnormalities in coronary artery and capillary development in the 
diabetic offspring were rescued by NAC treatment (Figure 3.3, Figure 3.4, and Figure 3. 
5). NAC treatment also significantly rescued the incidence of coronary artery 
malformation in the offspring of diabetic mice to 6% (P<0.01, Table 3.3).   
3.4.3 Pregestational Diabetes Impairs Epicardial EMT in Fetal Hearts  
To gain a better understanding of cellular and molecular events that caused 
coronary artery malformation in the offspring of diabetic mice, proepicardial organ and 
the epicardium were studied during embryogenesis using presence of Wt1 as a marker.  
Our data show that pregestational diabetes did not alter the number of Wt1+ cells in the 
proepicardial organ at E9.5 (Figure 3.6). However, the epicardium in the embryonic heart 
of diabetic mice formed a sparse and loosely attached cell layer to the myocardium with 
significant reductions in the number of Wt1+ epicardial and subepicardial cells at E12.5 
(Figure 3.7 A, D and E). Impaired Wt1 expression in fetal hearts of diabetic mothers was 
persistent at E14.5, as evidenced by a lower number of Wt1+ cells in the epicardial cell 
layer and in the compact myocardium (Figure 3.7 B, F and G). Concurrent with lower in 
the number of epicardial Wt1+ cells, the number of E-cadherin positive epicardial cells 
was higher in fetal hearts of diabetic mothers at E12.5 (Figure 3.7 C, H). Notably, NAC 
treatment during gestation reduced epicardial E-cadherin expression and restored the 
number of Wt1+ cells in the epicardium, subepicardium and myocardium in fetal hearts 
(Figure 3.7 A-H). 
 To directly evaluate the derivatives of epicardial Wt1+ cells, fate mapping analysis 
was performed using RosamTmG female mice, which were induced to have diabetes by 
STZ and then bred to tamoxifen inducible Wt1CreERT2/+;RosamTmG males. Following 
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tamoxifen treatment in the female mice at E10.5, Wt1+ derivatives including coronary 
vessels were observed in the hearts of Wt1CreERT2/+;RosamTmG embryos at E14.5 (Figure 
3.7 I). In agreement with our hypothesis, pregestational diabetes diminished Wt1+ lineage 
and coronary vessels in the hearts of Wt1CreERT2/+;RosamTmG embryos (Figure 3.7 I-K).  
  
 
  
Table 3.3. Incidence of coronary artery malformation (CAM) and congenital heart 
defects (CHDs) in fetuses from E16.5 to E18.5 
 Control Diabetes Control+NAC Diabetes+NAC 
Litters (n) 3 4 3 4 
CAM/total fetuses (n/N) 0/26 13/28* 0/25 2/34 † 
CHDs/total fetuses (n/N) 0/26 17/28* 0/25 2/34 † 
CHDs+CAM/total fetuses 
(n/N) 
0/26 11/28* 0/25 1/34 † 
CAM (%) 0 46  0 6 
CHDs (%) 0 61  0 6 
CHDs+CAM (%) 0 39 0 3 
 
CHDs include ventricular septal defects, atrioventricular septal defects, transposition of 
great arteries, and double outlet right ventricle.  *P<0.001 vs. control; †P<0.001 vs. 
diabetes by Chi-square analysis. 
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Figure 3.6. Wt1+ cells in the proepicardial organ (PEO) at E9.5.  
A) Representative images of PEO of control and diabetic offspring. B) Quantification of 
Wt1+ cells to total number of cells in the PEO. N=6 samples per group. There was no 
statistical significance in the number of Wt1+ cells in the PEO between control and 
diabetic offspring. 
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A and B) Representative heart sections of Wt1 immunostaining at E12.5 and E14.5, 
respectively. Arrows point to the epicardium in A and arrow heads point to Wt1+ cells in 
the subepicardium and myocardium in A & B, respectively. C) Representative heart 
sections of E-cadherin immunostaining at E12.5. Arrow heads indicate E-cadherin+ 
epicardial cells. D and E) Quantification of Wt1+ epicardial and subepicardial cell 
numbers, respectively. F and G) Quantification of Wt1+ cells in the epicardium and 
myocardium, respectively. H) Quantification of E-cadherin+ cells to total epicardial cell 
ratio (%). I-K: Fate mapping of Wt1+ lineage. I) Representative images of GFP staining 
in Wt1creERT2/+;RosamTmG heart sections of control and diabetic offspring at E14.5. Brown 
color marks cells and vessels derived from Wt1+ lineage. J and K) Quantification of cells 
and vessels derived from Wt1+ lineage in the myocardium, respectively. N=5-6 hearts 
from 3 litters per group. *P<0.01 vs. control or untreated control, †P<0.01 vs. diabetes or 
untreated diabetes. Scale bars: 30 µm. 
  
Figure 3.7. Analysis of the epicardium and fate mapping of Wt1+ lineage in hearts of 
diabetic offspring. 
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3.4.4 ROS-dependent Downregulation of HIF-1α  Signaling in Diabetic 
Fetal Hearts 
To further understand ROS signalling in epicardial EMT, the expression of Hif-
1α, a master regulator of vasculogenesis and epicardial EMT [26], and its downstream 
signalling molecules essential for coronary development were evaluated. The expression 
of Hif-1α was significantly lower in E11.5 fetal hearts of diabetic dams (Figure 3.8 A). 
Additionally, mRNA levels of Snail1 and Slug, which are key regulators of EMT, were 
significantly lower in fetal hearts of diabetic dams (Figure 3.8 B and C). Furthermore, 
retinoic acid signaling may be impaired in the fetal hearts of diabetic dams as evidenced 
by lower mRNA levels of Aldh1a2, which encodes the rate-limiting retinoic acid 
synthesis enzyme, retinaldehyde dehydrogenase 2 (RALDH2) [27], and its downstream 
target bFGF (Figure 3.8 D and E). Notably, these differences in the expression of Hif-1α, 
Snail1, Slug, Aldh1a2, and bFGF were restored in the hearts of offspring of diabetic 
females by NAC treatment (Figure 3.8 A-E). However, β-catenin mRNA levels that are 
essential for coronary artery formation [50] were not significantly altered by 
pregestational diabetes or by NAC treatment (Figure 3.8 F).  
3.4.5 High Glucose Impairs Epicardial EMT ex vivo 
To investigate whether hyperglycemia impairs epicardial EMT in fetal hearts of 
diabetic mothers, E12.5 hearts were cultured on collagen gel in both high glucose (30 
mM) and normal glucose (5 mM) conditions for 4 days (Figure 3.9 A). The number of 
spindle shaped cells, which are epicardial cells, which have undergone EMT was 
quantified. Our data show that the number of spindle shaped cells was significantly lower 
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in high glucose compared to normal glucose cultures. The response was restored by NAC 
(0.5 mM) treatment (Fig. 3.9 A and B).  
3.4.6 Pregestational Diabetes Diminishes Epicardial Cell Proliferation 
in Fetal Hearts  
To assess the effect of pregestational diabetes on epicardial cell proliferation, 
immunostaining for pHH3, a marker of mitotic cells, was performed in fetal hearts. Our 
results show that the number of pHH3+ epicardial cells was significantly lower in fetal 
hearts of diabetic dams at E12.5 and E14.5 (Figure 3.10 A-D). Interestingly, treatment 
with NAC in diabetic dams completely restored epicardial cell proliferation at both time 
points (Figure 3.10 C and D). Assessment of the apoptotic epicardial cells in E12.5 hearts 
using immunostaining for cleaved caspase-3 show no significant difference between the 
control (0.37±0.16%) and diabetic groups (0.33±0.12%, n=8-10 hearts per group).  
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Figure 3.8. Gene expression of HIF-1α  and its downstream targets critical to 
epicardial EMT in E11.5 hearts 
mRNA levels were analyzed by real-time PCR. A) HIF-1α. B) Snail1. C) Slug. D) 
Aldh1a2. E) bFGF. F) β-Catinin. *P<0.05, **P<0.01 vs. untreated control, †P<0.05, 
††P<0.01 vs. untreated diabetes. N=7-9 hearts from 3 to 4 litters per group. 
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A) Representative images of ex vivo E12.5 heart explant culture. Dashed line shows the 
border of migrated cells. B) Quantification of the number of spindle shaped cells, which 
are cells that have undergone EMT. Scale bar: 50 µm. *P<0.01 vs. untreated control (5 
mM D-glucose), †P<0.01 vs. untreated high glucose (30 mM). N=10-12 hearts per group 
from 4 litters. 
 
Figure 3.9. High glucose inhibits EMT ex vivo. 
  
121 
 
Figure 3.10. Reduced rate of epicardial cell proliferation in the fetal heart of 
diabetic mice restored by NAC treatment at E12.5 and E14.5. 
A and B) Representative images of immunostaining of phospho-histone H3 (pHH3, 
brown) in E12.5 and E14.5 hearts, respectively. C and D) Quantification of pHH3+ 
epicardial cells per millimeter epicardium. N=6-8 hearts from 3 litters per group. Scale 
bar: 20 µm. *P<0.05 vs. untreated control, †P<0.01 vs. untreated diabetes. 
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3.5 DISCUSSION   
To our knowledge, the present study demonstrated for the first time that 
pregestational diabetes impairs development of coronary artery vasculature in fetal hearts 
in an animal model. We further demonstrated that pregestational diabetes increases ROS 
production, diminishes HIF-1α and Wt1 expression, and decreases Snail/Slug and 
RALDH2/bFGF signalling pathways leading to disruption of epicardial EMT and 
malformation of fetal coronary arteries (for a schematic diagram of the proposed 
pathway, see Figure 3.11). Notably, inhibition of ROS production by antioxidant NAC 
restores epicardial EMT and prevents malformation of coronary arteries in the fetal heart 
of pregestational diabetes. Our study suggests a critical role of ROS signalling in 
coronary artery malformation during pregestational diabetes.    
The embryonic epicardium is a major contributor to coronary artery development 
[28,29]. In this regard, cells from the epicardium undergo EMT and become EPDCs, 
which then differentiate into vascular smooth muscle cells and cardiac fibroblasts, 
leading to formation of coronary vessels. To study if pregestational diabetes affects 
epicardial formation, immunohistochemical analysis was performed. Although there were 
no significant changes in proepicardial organ progenitor cell numbers, the number of 
epicardial cells was lower and the epicardium was detached from the myocardium with 
lower in epicardial cell proliferation at E12.5 and E14.5 in embryonic hearts of diabetic 
mothers. Epicardial attachment to the myocardium is critical to epicardial cell proliferation 
and formation of the epicardium [30]. Our study shows that pregestational diabetes inhibits 
epicardial development likely via an interruption of epicardial attachment to the 
myocardium and a reduction of epicardial cell proliferation. The number of epicardial cells  
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Pregestational diabetes increases ROS via hyperglycemia and hypoxia. ROS production 
inhibits HIF-1α and Wt1 expression in the fetal heart. Downregulation of Wt1 decreases 
epicardial EMT and results in coronary artery malformation via inhibition of Snail/Slug 
and RALDH2/bFGF pathways. These abnormalities were all prevented by treatment with 
an antioxidant NAC in the diabetic dams. 
Figure 3.11. Schematic summary of ROS signaling on coronary artery malformation 
in the offspring of pregestational diabetes 
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undergoing apoptosis was low (0.3%) and no significant difference was observed at 
E12.5 between control and diabetic offspring. However, whether pregestational diabetes 
increases epicardial cell apoptosis in the offspring at other stages of development remains 
to be determined. 
Epicardial EMT is a critical process in coronary artery development [31]. In the 
present study, we demonstrated that pregestational diabetes decreases epicardial EMT. 
This is supported by the following experimental data. First of all, the number of Wt1+ 
cells, which are EPDCs from epicardial EMT, was lower in the subepicardial space and 
in the compact myocardium of diabetic offspring. Secondly, high glucose inhibited 
epicardial cell outgrowth in cultured heart explants, and thirdly, fate mapping analysis 
revealed significantly lower Wt1+ cell lineage in the fetal heart of pregestational diabetes. 
The Wt1creERT2 line has been shown to label the epicardium and its derivatives [32]. The 
lower Wt1+ lineage in the fetal heart of diabetic offspring is consistent with our 
hypothesis that pregestational diabetes impairs epicardial EMT. To our knowledge, this is 
the first experimental evidence to show that pregestational diabetes inhibits epicardial 
EMT in the fetal heart.  
HIF-1α is a transcription factor that promotes vasculogenesis during embryonic 
development [33]. To this end, HIF-1α signalling has been shown to regulate epicardial 
EMT and EPDC migration into the myocardium, both of which are critical in patterning 
the coronary vasculature during early cardiac vasculogenesis [26]. The effects of HIF-1α 
are mediated by the expression of factors essential for coronary artery development 
including Wt1 [17,34]. Importantly, HIF-1α is also ROS sensitive. While low levels of 
ROS increase HIF-1α expression and promote cardiovascular differentiation, high levels 
  
125 
of ROS may inhibit HIF-1α activity by inhibiting the binding of co-activator p300 to 
HIF-1α [35,36]. Furthermore, diabetes via hyperglycemia, increases ROS levels and 
decreases the expression and activity of HIF-1α [37,38]. In the present study, ROS levels 
were significantly higher while HIF-1α expression and the number of Wt1+ epicardial 
cells and EPDCs were lower in the embryonic heart of pregestational diabetes. Notably, 
these changes were abrogated by NAC treatment, which reduces ROS levels in the 
embryonic heart. Our data show that pregestational diabetes impairs HIF-1α/Wt1 
signalling pathway via elevated ROS levels in the fetal heart (Figure 3.11). 
Wt1 has been shown to regulate epicardial EMT through the expression of its 
downstream targets of Snail1, Slug and RALDH2 [39-41]. In line with our observation of 
lower epicardial EMT, we further demonstrated that the expression of Snail1 and Slug 
was lower in the embryonic hearts of pregestational diabetes. Retinoic acid feeds into an 
essential signalling pathway crucial for epicardial formation, epicardial attachment to the 
myocardium, myocardial growth and proliferation, and coronary artery development 
[42,43]. bFGF is an important mediator in retinoic acid signalling that promotes 
epicardial EMT and vasculogenesis in the embryonic heart. Our results show that the 
expression levels of Aldh12a, which encodes RALDH2, and its downstream target bFGF 
were lower, suggesting an impaired retinoic acid signalling in the fetal heart of diabetic 
mothers. Thus, pregestational diabetes impairs both Wt1/Snail/Slug and 
Wt1/RALHD2/bFGF signalling pathways, which may contribute to decreased epicardial 
EMT and malformation of coronary arteries in the fetal heart (Figure 3.11). 
Physiological levels of ROS signalling regulates vasculogenesis [44]. While basal 
endogenous ROS levels are critical to normal vascular development, excessive ROS 
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production during embryogenesis may inhibit vasculogenesis. In this regard, elevated 
ROS levels induce vasculopathy in the yolk sac of embryos of diabetic rats [45]. NAC is 
a precursor of cysteine and decreases ROS levels via increases in glutathione synthesis 
and antioxidant capacity [46]. The present study showed that ROS production was higher 
in the fetal heart of pregestational diabetes. Notably, NAC treatment in diabetic females 
during gestation diminished ROS levels and restored expression of critical factors 
essential for epicardial growth and EMT. Importantly, NAC treatment rescued coronary 
artery malformation induced by pregestational diabetes. Our study suggests a critical role 
of elevated ROS and its signalling in mediating coronary artery malformation in the 
offspring of pregestational diabetic mice. Previous studies have shown that 
hyperglycemia or pregestational diabetes induces CHDs, which can be prevented by 
antioxidant treatments (Chapter 2), [47-49]. The results are consistent with our recent 
findings that elevated ROS levels contribute to the development of CHDs in the offspring 
of mice with pregestational diabetes, which are rescued by NAC treatment (Chapter 2). 
Thus, NAC may have therapeutic potential in the prevention of congenital heart defects 
including coronary artery malformation in patients with pregestational diabetes. 
 In conclusion, the present study demonstrates that pregestational diabetes impairs 
epicardial EMT and coronary artery development in mice. These abnormalities are 
associated with increased ROS production and decreased HIF-1α/Wt1 signalling (Figure 
3.11). Notably, these abnormalities were all prevented by an antioxidant NAC treatment, 
suggesting a key role of ROS signalling in the malformation of coronary arteries in 
pregestational diabetes. The coronary artery phenotype observed in the present study 
bears resemblance to human hypoplastic coronary artery disease, which has a high risk of 
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spontaneous myocardial infarction and sudden cardiac death [6]. Our study suggests that 
pregestational diabetes could cause hypoplastic coronary arteries in mice. However, 
further clinical studies are required to determine whether pregestational diabetes 
increases the incidence of hypoplastic coronary artery disease in humans.  
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4.1 CHAPTER SUMMARY 
NADPH oxidases (NOX) are a major source of reactive oxygen species (ROS) 
production in the heart. ROS signalling regulates gene expression, cell proliferation, 
apoptosis and migration. However, the role of NOX in embryonic heart development 
remains elusive. We hypothesized that deficiency of Nox2 disrupts endocardial to 
mesenchymal transition (EndMT) and results in congenital septal and valvular defects. 
Our results show that 34% of Nox2-/- neonates had various congenital heart defects 
(CHDs) including atrial septal defects (ASD), ventricular septal defects (VSD), 
atrioventricular canal defects (AVCD), and malformation of atrioventricular (AV) and 
aortic valves. Notably, Nox2-/- embryonic hearts show abnormal development of the 
endocardial cushion as evidenced by reduced rate of cell proliferation and an increased 
rate of apoptosis. Additionally, lack of Nox2 disrupted EndMT of cushion explants ex 
vivo.  Furthermore, treatment with N-Acetylcysteine (NAC) to reduce ROS levels 
significantly decreased the number of cells undergoing EndMT in wild type and Nox2-/- 
embryos. Importantly, deficiency of Nox2 reduced cardiac expression of Gata4, Tgfβ2, 
Bmp2, Bmp4 and Snail1, which are essential for EndMT and endocardial cushion 
development. We conclude that NOX2 is critical to EndMT and embryonic development 
of endocardial cushion-derived structures including heart valves and cardiac septum.  
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4.2 INTRODUCTION 
Congenital heart defects (CHDs) are the most common birth defects in infants 
affecting 1-5% of live births [1]. Malformation of septal and valvular structures are 
reported in about 40% of patients with CHDs [2]. Cardiac morphogenesis is regulated by 
an intricate network of signalling molecules and transcription factors [3]. Advances in 
genetic analysis have assisted in identifying genomic factors responsible for 
morphological abnormalities in patients with CHDs [4]. Currently, about 20% of CHDs 
are attributed to chromosomal abnormalities, single gene mutations or environmental 
teratogens. However, the etiology of 80% of CHDs remains unknown [5], indicating our 
limited knowledge on factors that regulate cardiac morphogenesis.   
Reactive oxygen species (ROS) are an important signalling molecules that 
modulate intracellular redox state and gene expression profiles to regulate cell 
proliferation, differentiation, apoptosis and migration [6,7]. An imbalance in ROS 
production may have adverse effects on fetal development [8,9]. To this end, we (Chapter 
2) and others have shown that excessive ROS generation in the embryonic heart alters 
gene expression profile and induces a wide range of CHDs [10], suggesting a pivotal role 
of ROS production in normal heart development.  
A critical process in embryonic heart development is the epithelial to 
mesenchymal transition (EMT). The endocardial EMT (EndMT) is initiated at E9.5 in 
mice when endocardial cushion swellings are formed in the outflow tract (OFT) and AV 
canal regions [11]. With contributions from neural crest cells, endocardial cushions at 
OFT form the aorticopulmonary septum and semilunar valves, while endocardial cushion 
at AV canal participate in the formation of AV valves and cardiac septum. EndMT is 
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regulated by transcription factors and signalling molecules produced in the adjacent 
myocardium and endocardium cushions [12].  
NADPH oxidases (NOX) are a family of O2- and H2O2 producing enzymes 
expressed in both phagocytic and non-phagocytic cells [13]. The enzyme complex is 
composed of NOX proteins, p22phox, p40phox, p47phox, p67phox and Rac GTPase. ROS 
production from NOX enzymes by phagocytes plays an important role in killing invading 
pathogens. The heart also expresses NOX proteins. A major source of intercellular ROS 
production in adult cardiomyocytes and embryonic cardiac stem cells is NOX2 and 
NOX4 [14,15]. Mutations of NOX genes result in chronic granulomatous disease (CGD), 
a rare disease occurring in 1:200,000-450,000 live births [16]. Notably, atrial septal 
defects are also seen in patients with CGD [17],  suggesting that mutations of NOX genes 
or a lack of NOX-derived ROS production may cause CHDs. However, mechanisms by 
which NOX enzymes regulate heart development are not clear. In this study, we 
hypothesized that deficiency of Nox2 disrupts EndMT and results in congenital septal and 
valvular defects. To test this hypothesis, a Nox2 deficient mouse was employed. Our data 
show that Nox2-/- mice have cardiac septal defects and valvular abnormalities. 
Furthermore, deficiency of Nox2 impairs EndMT and endocardial cushion development.  
Our study supports a critical role of Nox2-derived ROS signaling in promoting EndMT 
and embryonic heart development.  
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4.3 METHODS 
4.3.1  Animals 
Nox2-/- and C57Bl/6 mice were purchased from Jackson Laboratory (Bar Harbor, 
Maine). Genotype was confirmed by PCR analysis using the following primers: 5' 
AAGAGAAACTCCTCTGCTGTGAA 3' and 5' GTTCTAATTCCATCAG 
AAGCTTATCG 3', provided by Jackson Laboratory. A breeding program was 
implemented to harvest fetal and postnatal mice. Animals in this study were handled in 
accordance with the Guide for the Care and Use of Laboratory Animals, published by the 
U.S. National Institutes of Health (NIH publ. no. 85-23, revised 1996). All procedures 
involving mouse handling and manipulation were in accordance with the guidelines of 
the Canadian Council of Animal Care and approved by the Animal Use Subcommittee at 
the University of Western Ontario, Canada.  
4.3.2  Immunohistochemistry Analysis  
Heart morphology was analyzed in postnatal day 0 (P0) mice. Briefly, the mouse 
thorax was fixed in 4% paraformaldehyde overnight, dehydrated in ethanol, embedded in 
paraffin medium and sectioned transversely to 5 µm sections. Prior to immunostaining, 
antigen retrieval was performed in citric acid buffer (0.01 M, pH 6.0) for 12 minutes at 
94 °C using a microwave oven (BP-111, Microwave Research & Applications, Carol 
Stream, Illinois). Samples were incubated with primary antibodies overnight: anti-Ki67 
(1:500, Abcam, Toronto, ON, Canada), anti-caspase-3 (1:800, Cell Signaling, Danvers, 
MA, USA), anti-Snail1 (1:300, Abcam, Toronto, ON, Canada), or anti-NOX2 antibody 
(1:500, BD transduction laboratories, Mississauga, ON, Canada) followed by one of the 
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following secondary antibodies (Vector Laboratories, Burlington, ON, Canada) for an 
hour: biotinylated goat anti-rabbit IgG (1:500) or biotinylated goat anti-mouse IgG 
(1:500). Signals were amplified by incubation with the ABC reagent (Vector 
Laboratories, Burlington, ON, Canada) and visualized using 3-3’di-aminobenzidin 
tetrahydrochloride (Sigma-Aldrich, Toronto, ON, Canada). Heart sections were 
counterstained with hematoxylin (Thermo Scientific, Waltham, MA USA) and images 
were captured using a light microscope (Observer D1, Zeiss, Germany).  Endocardial 
cushion cell density was calculated at E10.5 by quantifying the number of cells in 
endocardial cushion per area.  
4.3.3  Analysis of Superoxide Levels 
Embryonic heart tissues were harvested at E10.5. Frozen samples were cut into 10-
µm sections using a cryostat (CM1950, Leica, Germany). Superoxide levels were 
assessed by incubation of heart sections with 2 µM dihydroethidium (DHE, Invitrogen 
Life Technologies, Burlington, Canada) for 30 minutes in a humidified and light 
protected chamber in room air at 37°C [18]. DHE fluorescence signals were detected 
using a fluorescence microscope (Observer D1, Zeiss, Germany). For analysis of 
superoxide levels, 5 images of each heart sample were captured using fixed exposure 
time for both groups. The intensity of fluorescence signals per myocardial area was 
quantified using AxioVision software. A limitation of this assay is that the oxygen level 
was not adjusted to that of the embryonic hearts in vivo [19]. 
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4.3.4  Real-time RT-PCR Analysis 
Total RNA was extracted from E10.5 fetal hearts using RNeasy Mini kit (Qiagen, 
Burlington, ON) as per manufacturer’s instructions. cDNA (100 ng) was synthesized 
using M-MLV reverse transcriptase. Real-time PCR was conducted using EvaGreen 
qPCR MasterMix (Applied Biological Materials, Vancouver, BC). Specific primers were 
designed for Nkx2.5, Gata4, Gata5, Tbx5, Bmp2, Bmp4, Tgf-β1, Tgf-β2, Notch1, Snail1 
and Mef2c (Table 4.1). Samples were amplified for 35 cycles using Eppendorf Realplex 
(Eppendorf, Hamburg, Germany). The mRNA levels in relation to 28S ribosomal RNA 
were determined using a comparative CT method . 
4.3.5  Ex vivo Endocardial Cushion Explant Culture 
EndMT was assessed using endocardial cushion explants ex vivo [20,21]. 
Collagen (1 mg/ml, type I collagen from rat tail, BD Bioscience, Mississauga, ON, 
Canada) was prepared in M199 culture media (M5017, Sigma-Aldrich, Toronto, ON, 
Canada). Casted collagen was hydrated by OPTI-MEM media plus 1% of fetal bovine 
serum (FBS) and insulin-transferrin-selenium (ITS) for 30 minutes at 37 °C. Hearts were 
isolated from E10.5 Nox2-/- and WT embryos. Atria and ventricular chambers were 
dissected out and the AV canal was cut open longitudinally and planted on the hydrated 
collagen gel with the endocardium facing the gel. Cushion explants were incubated at 37 
°C overnight. The following day, M199 media with 10% of FBS were added to the 
cushion explants. To inhibit ROS production, heart explant cultures were treated with 5 
mM NAC. The number of spindle shaped cells outgrowth from the explanted ventricles 
was quantified 4 days post culturing. Images were captured using phase contrast 
microscope (Observer D1, Zeiss, Germany).  
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4.3.6  Statistical Analysis 
Data are presented as means ± SEM. Statistical analysis performed using Student t-
test or two-way analysis of variance (ANOVA) followed by Bonferroni corrections 
(GraphPad Prism, version 5.0). Survival rate and incidence of congenital malformations 
was analyzed by Chi-square test. A P value of less than 0.05 was considered statistically 
signiﬁcant.   
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Gene Accession No. Product 
Size 
Primer Sequence (5ʹ′→ 3ʹ′) 
Bmp2 NM_007553.3 151 F: CAAACACAAACAGCGGAAGC 
R: CAGCAAGGGCAAAAGGACAC 
Bmp4 NM_007554.2 250 F: GTTATGAAGCCCCCAGCAGA 
R: CCCAATCTCCACTCCCTTGA 
Gata4 NM_008092.3 134 F: GCCTGCGATGTCTGAGTGAC 
R: CACTATGGGCACAGCAGCTC 
Gata5 NM_008093.2 167 F: ACCCCACAACCTACCCAGCA 
R: GCCCTCACCAGGGAACTCCT 
Mef2c NM_001170537.1 405 F: CACCGAGTACAACGAGCCGCA 
R: CTGGTGCCTGCACCGGATGTC 
Nkx2.5 NM_008700.2 162 F: GACAGCGGCAGGACCAGACT 
R: CGTTGTAGCCATAGGCATTG 
Notch1 NM_008714.3 
 
142 F: CAGCTTGCACAACCAGACAGA 
R: TAACGGAGTACGGCCCATGT 
Snail1 NM_011427.2 114 F: CACACGCTGCCTTGTGTCT 
R: GGTCAGCAAAAGCACGGTT 
Tbx5 NM_011537.3 103 F: AGGAGCACAGTGAGGCACAA 
R: GGGCCAGAGACACCATTCTC 
Tgf-β1 NM_011577.1 139 F: GCCCGAAGCGGACTACTATG 
R: CACTGCTTCCCGAATGTCTG 
Tgf-β2 NM_009367.3 230 F: CTGTGCAGGAGTGGCTTCAC 
R: GCAGGAGATGTGGGGTCTTC 
28S NR_003279.1 178 F: GGGCCACTTTTGGTAAGCAG 
R: TTGATTCGGCAGGTGAGTTG 
F: Forward, R: Reverse.Primers of Bmp4, Gata4, Gata5, Mef2c, Tbx5, Tgf-β1 and 28S 
were also used in Chapter 2.   
Table 4.1. Primer sequences for real-time PCR analysis.   
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4.4 RESULTS 
4.4.1  Reduced Viability, Litter Size and Body Weight in Nox2-/- 
Neonates 
Mortality at birth in Nox2-/- mice was about 4 fold higher than WT neonates (16% 
vs. 4.6%) with diminishing survival rate during the first three weeks of life (P<0.001, 
Figure 4.1A). Litter size in Nox2-/- mice was smaller (P<0.05, Figure 4.1B), and their 
body weight at birth was significantly lower compared to WT controls (P<0.05, Figure 
4.1C). A significantly lower in body size or growth retardation was observed in 24% of 
Nox2-/- embryos collected at E10.5-12.5 (Table 4.2, Figure 4.1D). Some of the embryos 
may undergo in utero absorption, as suggested by lower litter size in Nox2-/- mice.  
4.4.2  Septal and Valve Defects in Nox2-/- Mice 
Histological analysis of Nox2-/- hearts at P0 showed that 34% of Nox2-/- mice were 
born with various types of CHDs, which included 18% atrial septal defects (ASD) and 
18% ventricular septal defects (VSD, Table 4.3, Figure 4.2A). Additionally, severe cases 
of septal malformation in the form of atrioventricular canal defects (AVCD) were 
observed in 3.3% of Nox2-/- neonates. Furthermore, 6.6% of Nox2-/- neonates had 
bicuspid aortic valves (BAV, Table 4.3, Figure 4.2 A). It should be noted that all cases of 
BAV were associated with septal abnormalities. Most Nox2-/- mice had a single ASD or 
VSD. However, 2 out of 61 Nox2-/- mice (3.3%) had both ASD and VSD. In addition, 
Nox2-/- hearts demonstrated valvular abnormalities. Specifically, the mitral and tricuspid  
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Figure 4.1. Survival and growth in Nox2-/- mice.  
A) Mortality rate in Nox2-/- mice at birth and during the first three weeks of life compared 
to their age matched controls. N=129 in wild type (WT) group and N=112 in Nox2-/- 
group. B) Litter size at birth, N=10 or 13 litters per group. C) Body weight of neonates at 
birth, N=28 samples per group. D) Representative images of body size of WT and Nox2-/- 
mice at E10.5. Scale bar is 1 mm. *P<0.05, **P<0.001 vs. WT by Chi-square in A and 
unpaired Student t test in B and C. 
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 Number of litters Growth Retardation 
           (n/N)                            (%)  
WT 4 0/29 0 
Nox2-/- 4 6/25* 24* 
*P<0.01 vs. WT by Chi-square test. 
 
 Wild-type 
(N=35 from 5 litters) 
Nox2-/- 
(N=61 from 12 litters) 
 N % N % 
Normal 35 100 40 65.6** 
Abnormal 0 0 21 34.4** 
ASD 0 0 11 18* 
VSD 0 0 11 18* 
AVCD 0 0 2 3.3 
BAV 0 0 4 6.6 
                       
ASD, atrial septal defect; VSD, ventricular septal defect; AVCD, atrioventricular canal 
defect. *P<0.05, **P<0.01 vs. wild-type by Chi-square analysis. 
 
Table 4.2. Number and percentage of embryos with growth retardation at E10.5-
12.5.  
Table 4.3. Incidence of congenital heart defects in Nox2-/- mice at P0.  
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Figure 4.2. Congenital heart defects in Nox2-/- mice at P0.  
A) Representative histological images of normal and abnormal hearts. Nox2-/- mice 
demonstrated ASD, AVCD, membranous and muscular (arrows) types of VSD, and 
BAV. B) Representative histological images of tricuspid and mitral valves. C) 
Representative histological images of aortic and pulmonary valves. D) Quantification of 
mitral and tricuspid valve length, E) quantification of mitral and tricuspid valve 
thickness. F) Quantification of aortic valve cell density. *P<0.05 vs WT, N= 9-12 per 
group, Scale bar in A is 200 µm and in B-C is 100 µm. 
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valves were shortener in length (Figure 4.2 B & D) and the distal tip of the mitral valve 
was bigger in size in Nox2-/- mice (P<0.05, Figure 4.2 B & E), but there was no 
significant difference in the thickness of distal region of tricuspid valves (Figure 4.2 B & 
E). Additionally, aortic valves of some Nox2-/- mice had a bulging shape with lower cell 
density (P<0.05, Figure 4.2 C & F) while no apparent abnormalities were found in the 
pulmonary valves.  
4.4.3  NOX2 Expression Pattern and Endocardial Cushion Formation 
in Embryonic Heart 
To examine the expression pattern of NOX2, immunohistochemical analysis was 
performed. NOX2 immunostaining was seen in the atrial and ventricular myocardium at 
E10.5 (Figure 4.3 A). Remarkably, NOX2 expression was more robust on the left 
ventricular myocardium compared to the right (Figure 4.3 C, E). Importantly, NOX2 was 
expressed in the myocardium covering endocardial cushions at the OFT and AV canal, 
suggesting their possible role in regulation of endocardial cushion development (Figure 
4.3 D, F). However, the epicardium, endocardium and cells within the endocardial 
cushion do not express NOX2 in the WT hearts at E10.5 (Figure 4.3 C-E). As expected, 
in Nox2-/- mice, NOX2 protein was not expressed (Figure 4.3 B, G), and the ROS levels 
were lower in the myocardium (P<0.05, Figure 4.4). Furthermore, cellular density in 
endocardial cushion was significantly lower in Nox2-/- compared to WT hearts at E10.5 
(Figure 4.3 G). 
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A) Representative images of NOX2 immunostaining in embryonic heart of WT mice. B) 
Loss of NOX2 expression in Nox2-/- mice. C-E) Enlarged from A showing expression of 
NOX2 in right and left atrial and ventricular myocardium of WT mice. D &F) 
Expression of NOX2 in the myocardial cells covering the endocardial cushion at the AV 
canal and OFT of WT mice. G) Lack of NOX2 expression and lower cellular density 
were evident in OFT cushions of Nox2-/- hearts. Panels f and g are enlarged images of 
boxed area in F and G.  Scale bar is 100 µm.  
 
 
  
Figure 4.3. Expression of NOX2 in E10.5 hearts. 
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Figure 4.4.  Analysis of superoxide levels in fetal hearts at E10.5 using 
dihydroethidium (DHE) as a probe. 
 
A) Representative images of ROS levels in the left venticle myocardium. B) 
Quantification of DHE fluorescence intensity. Scale bar is 30 µm. Data are means ± 
SEM. N=3 hearts per group. *P<0.01 vs. WT by unpaired Student’s t test.  
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4.4.4 EndMT Is Impaired in Nox2-/- Hearts 
To investigate the role of NOX2 in endocardial cushion formation, we evaluated 
EndMT of endocardial cells in vivo and in vitro. To this end, expression levels of Snail1, 
an important marker of EMT [22], were analyzed. Our data show that Snail1 mRNA 
levels in the heart at E10.5 as well as the number of Snail1 positive cells in the AV 
cushion at E12.5 were lower in Nox2-/- compared to WT embryos (P<0.05, Figure 4.5 A, 
C, D). To examine EndMT, the endocardial cushion of E10.5 fetal hearts was cultured on 
collagen gel and allowed for cell outgrowth for four days (Figure 4.5 B). The number of 
spindle shaped cells, which had undergone EndMT, were quantified. Nox2-/- endocardial 
cushion had significantly lower in the number of spindle shaped cells compared to WT 
cushions (P<0.05, Figure 4.5 B, E). To lower ROS levels, wild type and Nox2-/- 
endocardial cushions were treated with a ROS quenching agent, N-Acetylcysteine 
(NAC). Notably, treatment with NAC diminished EndMT in both WT and Nox2-/- 
endocardial cushion (P<0.001, Figure 4.5 B, E).  
4.4.5  Nox2 Deficiency Reduces Expression of Genes Crucial for 
EndMT  
To further investigate the role Nox2 in regulating EndMT, we examined the 
expression of transcription factors and growth factors critical to EndMT and heart 
development in 10.5 hearts. Our data show that mRNA levels of Gata4, a transcription 
factor important in septal development, were diminished in Nox2-/- mice. As well,   
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A) Representative images of Snail1 expression in the endocardial cushion (EC) at E12.5. 
Lower panels are enlarged images of boxed areas in WT and Nox2-/-, respectively. B) EC 
ex vivo culture demonstrates EMT in the presence or absence of 5 mM NAC. Dashed line 
outlines cell migration border. C) Quantification of Snail1 positive cells in EC (N=4-5 
hearts per group). D) Analysis of Snail1 mRNA expression levels at E10.5 fetal hearts 
(N=5 hearts per group).  E) Quantification of the number of spindle shaped cells (N=4-5 
hearts per group). Data are means ± SEM. *P<0.05 vs. untreated WT, **P<0.001 vs. 
untreated WT, †P<0.05 vs. untreated Nox2-/-. Scale bars are 100 and 20 µm in A, and 200 
µm in B. 
  
Figure 4.5.  Analysis of endocardial EMT in vivo and in vitro.  
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the expression levels of members of TGF-β superfamily, including Tgf-β2, Bmp2 and 
Bmp4, which are important regulators of endocardial cushion formation [23], were 
significantly lower in Nox2-/- fetal hearts at E10.5 (P<0.05, Figure 4.6 A-D). However, 
the expression levels of other cardiac transcription factors including Nkx2.5, Tbx5, Gata5 
and Mef2c were not altered in Nox2-/- embryonic hearts (Figure 4.6 E-H). Additionally, 
the expression of Tgfβ1 and Notch1 [24-26] was not significantly different in Nox2-/- 
hearts (Figure 4.6 I-J).  
4.4.6  Nox2 Deficiency Increases Apoptosis and Reduces Proliferation 
Rate in Endocardial Cushions 
ROS regulates cell proliferation and apoptosis in a variety of cell types. Using 
immunostaining of cleaved caspase-3, we analyzed cell apoptosis in the endocardial 
cushion at E10.5. Nox2 deficiency resulted in a 2 fold higher of apoptosis in the 
endocardial cushion (P<0.05, Figure 4.7 A, C). We also assessed cell proliferation using 
Ki67 immunostaining. Our data show about 50% lower in cell proliferation rate in the 
endocardial cushion of Nox2-/- compared to WT mice (P<0.001, Figure 4.7 B, D). 
Furthermore, cellular density in the endocardial cushion of Nox2-/- mice was significantly 
lower than the WT controls (P<0.05, Figure 4.8 E). 
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Figure 4.6. Gene expression levels in fetal hearts at E10.5. 
(A-D) The mRNA levels of Bmp4, Bmp2, Tgfβ2 and Gata4 in Nox2-/- fetal hearts were 
significantly lower than WT levels. (E-J) expression levels of Nkx2.5, Gata5, Mef2c, Tbx5, 
Notch1 and Tgfβ1 were not altered in Nox2-/- fetal hearts. Data are means ± SEM. N=7-9 
hearts per group. At least two hearts were pooled for each sample. *P<0.01 vs. WT by 
unpaired Student’s t test. 
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Figure 4.7. Increased rate of apoptosis and reduced rate of proliferation in 
endocardial cushion (EC) of Nox2-/- hearts at E10.5 and E12.5 respectively. 
A) Representative images of histological sections immunostained for cleaved caspase-3 in 
E10.5 hearts. Lower panels are enlargement of the boxed areas in upper panels. Arrows 
point to positive cells (Brown). B) Representative images of histological sections 
immunostained for Ki67 in E12.5 hearts. Lower panels are enlargement of the boxed areas 
of upper panels. C) Quantification of cleaved caspase-3 positive cells. D) Quantification of 
Ki67 positive cells. E) Quantification of EC cell density at E10.5. *P<0.05 vs. WT. 
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4.5 DISCUSSION 
NOX2 is a major source of ROS production in cardiomyocytes [15]. It is well 
established that excessive ROS production is detrimental to normal embryonic 
development [27]. For example, increased ROS levels during pregestational diabetes 
result in CHDs in the offspring (Chapter 2). On the other hand, physiological levels of 
ROS function as a signalling molecule to promote cardiac differentiation and 
cardiomyocyte proliferation [14,28]. However, the role of Nox2-mediated ROS signalling 
in embryonic heart development remains unknown. The present study demonstrated that 
34% of Nox2-/- neonates had CHDs including septal defects, AVCD, AV valve 
malformation, BAV, and impaired remodeling of aortic valves.  Importantly, ROS 
deficiency resulted in lower EndMT in Nox2-/- endocardial cushions. Pharmacological 
inhibition of ROS production in vitro had even lower EndMT of endocardial cushions. 
Notably, Nox2 deficiency resulted in lower gene expression including Gata4, Tgfβ2, 
Bmp2, Bmp4 and Snail1, which are required for EndMT and endocardial cushion 
development. Our study shows for the first time a critical role of NOX2-mediated ROS 
signalling in the regulation of EndMT and embryonic heart development (Figure 4.8).  
EndMT is a critical process in the formation of endocardial cushions and 
valvoseptal development [29]. However, whether NADPH oxidase is essential in the 
regulation of EndMT during heart development remains unknown. The present study 
provides the following evidence in support of our hypothesis that NOX2-derived ROS 
signalling is required for EndMT during embryonic heart development. First of all, Nox2-
/- embryos had a lower cellular density in the endocardial cushion at E10.5. Secondly, the  
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Figure 4.8. Schematic summary of NOX2 mediated ROS signaling on directing 
EndMT and valvoseptal development.  
ROS release from NOX2 positively regulates transcript levels of factors that promote 
EndMT and formation of normal valvoseptal structures. 
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number of cells undergoing EndMT in endocardial cushion explants from Nox2-/- 
embryos was significantly lower. Importantly, treatment with the antioxidant N-
Acetylcysteine had even lower EndMT in Nox2-/- cushion explants. Thirdly, the 
expression of EndMT regulators including Gata4, Tgf-β2, Bmp2 and Bmp4 was markedly 
lower in Nox2-/- hearts. Finally, Snail1 expression, a marker of cells undergoing EMT, 
was lower in the endocardial cushion of Nox2-/- embryos. Taken together, these data 
strongly support a critical role of NOX2-derived ROS signalling in the regulation of 
EndMT during embryonic heart development.  
BMP2 and BMP4 are inductive signalling molecules that promote EndMT and are 
released from the myocardium in the AV canal and OFT regions [22]. Through activation 
of BMP receptors on endocardial cells, they increase the expression of Gata4, Tgf-β2 and 
Snail1, which are essential for EndMT [30]. In the present study, we demonstrated that 
NOX2 is expressed in the myocardium, which includes the AV canal and OFT 
myocardium, but not in the endocardium. This pattern of NOX2 expression allows 
NOX2-derived ROS to regulate BMP2/4 expression in the myocardium and subsequent 
TGF-β signalling in the endocardial cushion. Notably, ROS mediated TGFβ signalling in 
the regulation of EMT has been shown in many cell types including keratinocytes [31], 
alveolar cells [32] and mammary epithelial cells [33]. The decreased expression of 
Bmp2/4, Tgf-β2, and Snail1 in Nox2-/- hearts in the present study supports our hypothesis 
that Nox2-derived ROS promotes BMP/TGF-β signalling and EndMT in embryonic heart 
development. 
Cell proliferation and apoptosis are key cellular events that regulate heart 
development during embryogenesis. It is generally believed that excessive levels of ROS 
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favor cell apoptosis [34]. Consistent with this notion, we recently showed that increased 
ROS production during pregestational diabetes reduces cell proliferation and increases 
apoptosis in the endocardial cushion. N-Acetylcysteine restored cell proliferation ration 
but not apoptosis (Chapter 2). Surprisingly, lowering ROS levels in control mice by N-
Acetylcysteine treatment increases cell apoptosis (Chapter 2). In the present study, 
deficiency in Nox2 results in lower ROS in E10.5 hearts, higher cell apoptosis and lower 
cell proliferation in the endocardial cushion. Our findings suggest that physiological 
levels of ROS are critical to cell survival and proliferation during embryonic heart 
development. ROS signalling has been shown to induce developmental gene expression 
[34]. Thus, lower expression of Gata4, Bmp2/4 and Tgf-β2 observed in the present study 
may contribute to higher apoptosis and lower cellular density in the endocardial cushion 
of Nox2-/- hearts.   
In summary, deficiency in Nox2 results in congenital defects of the septum and 
cardiac valves. We further demonstrated that a lack of NOX2-derived ROS production 
resulted in lower gene expression in the developing heart and disrupts EndMT with lower 
cell proliferation and higher apoptosis in the endocardial cushion. Our data show that 
NOX2 is essential in valvoseptal development (Figure 4.8).  Notably, patients with 
chronic granulomatous disease (CGD) due to NOX gene mutations have ASDs [17]. Our 
study provides mechanistic insight into the development of congenital heart defects in 
CGD patients and supports a critical role of ROS signaling in embryonic heart 
development. 
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5. CHAPTER 5 
5.1 SUMMARY OF MAJOR FINDINGS 
The overall objective of this thesis was to investigate the role of ROS on cardiac 
morphogenesis in mice. Specifically, I studied the effect of excess ROS levels on heart 
development in the offspring of mice with pregestational diabetes. We aimed to unravel 
the molecular mechanisms of cardiovascular defects induced by pregestational diabetes 
and provide new insight on potential therapeutic strategies. Additionally, I studied the 
role of basal ROS levels in cardiac morphogenesis in non-diabetic pregnancies in Nox2-/- 
mice, which are deficient in ROS production. Experimental approaches included 
histological analysis of heart structure, in vitro heart explant cultures and biochemical or 
molecular analysis of embryonic hearts.  
In Chapter 2, I studied heart development in the offspring of females with 
pregestational diabetes and investigated therapeutic strategies to prevent abnormal heart 
development. To address this aim, an STZ-induced pregestational diabetes mouse model 
was employed. The offspring born to females with pregestational diabetes had lower litter 
size, lower body weight and higher mortality at birth. Importantly, a wide spectrum of 
CHDs including malformation of septal and conotruncal structures were observed in 
neonates. These malformations are comparable to CHDs in the offspring of patients with 
pregestational diabetes [1]. Increased incidence of CHDs was associated with oxidative 
stress in fetal hearts as evidenced by significantly higher ROS levels and diminished ratio 
of reduced to total glutathione levels. Molecular analysis demonstrated altered expression 
levels of factors critical to heart development including Gata4, Gata5 and Vegf-a. In 
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addition, apoptosis was increased in endocardial cushion and cell proliferation was 
markedly reduced in the embryonic hearts affected by maternal diabetes. Furthermore, I 
demonstrated for the first time that treatment of diabetic mice with an antioxidant, NAC, 
during gestation inhibits oxidative stress in fetal hearts, normalizes gene expression 
levels, improves cell proliferation, and decreases the incidence of CHDs in their 
offspring. The underlying mechanisms of NAC protection in maternal diabetes induced 
CHDs include reductions of ROS levels, elevations of glutathione levels, increases in cell 
proliferation, and restoration of altered gene expression profiles.  
Formation of coronary arteries is pivotal to myocardial development. 
Abnormalities in formation of coronary arteries such as hypoplastic coronary artery 
disease increase the risk of sudden cardiac death in youth [2]. In Chapter 3, we 
demonstrated for the first time that excess ROS induced by pregestational diabetes led to 
coronary artery malformation in the offspring. Histological analysis of fetal and neonatal 
hearts exposed to maternal diabetes demonstrated lower diameter and volume of coronary 
arteries. Furthermore, pregestational diabetes resulted in abnormal epicardial formation 
as evidenced by reduced number of Wt1+ epicardial cells and lower cell proliferation rate. 
Additionally, the number of epicardial cells undergoing EMT was lower as evidenced by 
Wt1 lineage tracing, immunostaining and in vitro analysis of epicardial EMT in high 
glucose culture media. Notably, the expression of HIF1-α, which is a critical 
transcriptional regulator of Wt1, was lower in the fetal hearts. Furthermore, the 
expression of Wt1 downstream target genes such as ALDH1a2, bFGF, Snail and Slug 
was lower in the embryonic heart of diabetic dams.  Remarkably, these abnormalities 
were all prevented by NAC treatment, leading to normal coronary artery development in 
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the offspring of diabetic dams. This study shows that maternal diabetes impairs coronary 
artery formation via elevating ROS levels, and provides a rationale for future clinical 
studies to investigate pregestational diabetes as a possible cause of hypoplastic coronary 
artery disease.  
In Chapter 4, I aimed to study the role of basal ROS production in normal heart 
development. To achieve this goal, the NADPH oxidase Nox2-/- mouse model was 
utilized. Loss of Nox2 resulted in retardation of embryonic growth and lower survival rate 
in neonates. Importantly, deficiency of Nox2 resulted in abnormalities in AV septum and 
cardiac valves. In particular, Nox2 deficiency resulted in higher cell apoptosis and lower 
cell proliferation in the endocardial cushion. In addition, lack of Nox2 impaired EndMT 
as evidenced by endocardial cushion cultures ex vivo and lower cellular density in the 
endocardial cushion in vivo. Furthermore, treatment with NAC to reduce ROS levels 
resulted in lower EndMT in both wild type and Nox2-/- endocardial cushions. Importantly, 
Nox2 deficiency resulted in lower transcript levels of Tgf-β2, Bmp2, Bmp4, Snail1 and 
Gata4, which are essential in the induction and regulation of EndMT. Overall, this study 
demonstrates an important role of NOX2-mediated ROS release in EndMT and 
embryonic development of AV septum and cardiac valves.  
In Summary, I have demonstrated a pivotal role of ROS signalling in embryonic 
heart development. My results show that normal physiological ROS production promotes 
cardiogenesis while excessive ROS levels seen in pathological conditions such as 
pregestational diabetes induce CHDs. Thus, maintaining a balance of ROS levels is of 
critical importance for embryonic heart development. Furthermore, these studies suggest 
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a therapeutic potential of NAC in the prevention of CHDs induced by pregestational 
diabetes.  A summary of these findings is presented in Figure 5.1.  
 
 
 
 
 
 
 
 
  
Figure 5.1. Schematic diagram on the role of ROS in regulating heart development 
in mice with pregestational diabetes and Nox2 deficiency.    
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5.2 STUDY LIMITATIONS 
5.2.1 Justification of Diabetes Induced Animal Model  
A variety of strategies have been employed to study mechanisms of embryopathy 
and CHDs induced by maternal diabetes in animal models. The techniques include 
glucose-induced diabetes [3,4], drug-induced diabetes [5-8] and genetic models that 
develop diabetes spontaneously [9]. Two important diabetogenic agents are alloxan and 
STZ [10,11], which are analogues of glucose and enter pancreatic beta cells via glucose 
transporter 2 (GLUT2). Intracellularly, they induce alkylation of DNA that ultimately 
leads to oxidative stress and cell death [12].  In comparison to alloxan, STZ maintains 
higher levels of drug stability, specificity and efficiency [13,14]. Diabetes induced by 
administration of diabetic agents is considered an acute form of type 1 diabetes, where 
the onset of diabetes occurs in about ten days following drug administration. To avoid the 
risk of STZ teratogenic effects on the fetus, STZ was adminestered to female mice prior 
to breeding. The biochemical characteristics of STZ induced diabetes may differ from 
clinical cases of patients that progress to diabetes over the years due to genetic changes or 
complications from immune deficiencies. An important difference between our 
pregestational diabetes mouse model and clinical cases is that diabetic mice did not 
receive insulin treatment before or during gestation. As a result, a much higher incidence 
of CHDs was observed in our model. Nevertheless, our mouse model demonstrates a 
wide spectrum of embryonic defects similar to patient cases. Thus, we believe this is an 
excellent mouse model for studying diabetic embryopathy [1].  
The offspring of diabetic rodents induced by STZ demonstrate variable 
susceptibility to congenital malformation from no congenital malformation to minimal or 
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frequent cases [8,15,16]. Part of this variability is due to dose of STZ, animal age and the 
time of drug administration in relation to gestation. As an example, if embryos are 
affected by maternal diabetes at early gestation congenital defects could occur in central 
nervous system or cardiovascular structures and the embryo may demonstrate general 
retardation of growth [5]. However, embryos that are affected by maternal diabetes at late 
gestational age may suffer from macrosomia, childhood obesity and metabolic disorders 
[6]. In addition, variability exists among the offspring of the same litter, which were 
exposed to the same level of glucose. It has been suggested that genetic background or 
strain variability plays a major role in susceptibility of animals to diabetic embryopathy 
[17-19]. Based on our observations and previous reports, C57Bl/6 diabetic mice are 
resistance to neural tube defects [17], but are susceptible to CHDs (Chapter 2). The fact 
that morphological characteristics of CHDs are comparable to human cases suggests that 
the therapeutic strategies can be applied to clinical conditions. 
5.2.2 Challenges in Understanding Causes of CHDs Induced by 
Diabetes  
Reports of increased prevalence of congenital defects in infants of diabetic 
women in early1950s [20,21] initiated several experimental studies to elucidate the cause 
of diabetic embryopathy. Animal models have been developed to characterize the birth 
defects and to investigate their molecular mechanisms [4,8,22,23]. These studies have 
shown that hyperglycemia induces biochemical disturbances including oxidative stress in 
embryos [24-27]. Advances in molecular analysis have expanded our knowledge of 
factors that are altered by maternal diabetes [28].  However, these studies did not fully 
clarify the molecular mechanisms of diabetic embryopathy.  
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A major challenge in our understanding of diabetic embryopathy is the variable 
abnormalities among individuals affected by similar maternal blood glucose levels. This 
phenomenon could arise from epigenetic effects of maternal diabetes on the developing 
embryo [29,30]. Epigenetic modifications are heritable without any changes in the 
genome coding sequence [31]. As an example, microarray analysis revealed altered 
expression of over a thousand genes that control transcription, organ morphogenesis or 
cell cycle regulation in the heart of diabetic embryos [32,33]. Many of these genes are 
target of epigenetic modifications such as histone methylation or acetylation, leading to 
inhibition or activation of gene expression [33]. Recent analysis showed increased 
intracellular glucose metabolism may elevate acetyl-CoA levels in the nucleus and lead to 
excess histone acetylation of DNA[34]. In a separate study, diabetic environment in utero 
modulates DNA methylation in the placenta of mice with pregestational diabetes [35]. 
Other than direct effects of diabetes on embryonic epigenetics, hyperglycemia may 
modify epigenetic patterns indirectly by altering the expression of chromatin modifying 
factors [36].  
Another epigenetic factor, which may interfere with gene expression in diabetic 
embryopathy, are non-coding RNAs, such as microRNA. MicroRNA may hybridize with 
complementary mRNA sequences and interfere with their translation. Cell culture 
experiments demonstrated high glucose alters levels of microRNAs in vitro, thus 
interferes with translation of mRNAs [37]. In addition, retrospective analysis of genes 
that are altered by maternal diabetes revealed that majority of them are targets of at least 
one microRNA [33,38]. According to these studies hyperglycemia or high glucose 
conditions increase the risk of epigenetic alterations [39]. These results challenged 
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identifying a distinct molecular mechanism that defines a causal relationship between 
hyperglycemia-induced alterations of gene expression and embryonic defects. 
Nevertheless, the experimental analysis provided in this thesis demonstrates that 
antioxidant treatments normalize gene expression levels and reduced the incidence of 
CHDs. These results support our hypothesis that oxidative stress is the main cause of 
CHDs induced by maternal diabetes. 
5.3 SUGGESTIONS FOR FUTURE RESEARCH 
Insulin treatment to diabetic women reduces the risk of congenital defects in 
newborns [40,41]. Therefore, women with pregestational diabetes are strongly advised to 
plan their pregnancy and control their glucose levels by insulin injections or medications 
prior to conception and during gestation [42]. It should be noted that pregnancy alters 
glucose metabolism and insulin sensitivity, thus, achieving optimal glycemic control in 
diabetic women is challenging [43]. Because of this, the risk of birth defects in insulin 
treated diabetic women is still higher than non-diabetic population [44,45], indicating that 
insulin alone is not sufficient to protect against congenital defects in the offspring of 
diabetic women. In this thesis, we overcome this challenge by demonstrating the 
protective effect of NAC in reducing the risk of birth defects in the offspring of non-
insulin treated pregestational diabetic mice. Future studies should also investigate the 
effects of insulin treatment on CHDs induced by pregestational diabetes in mice. 
5.3.1 Therapeutic Potential of NAC on Prevention of CHD 
Birth defects induced by pregestational diabetes are highly attributed to increased 
ROS levels and reduced antioxidant levels. Thus, an important therapeutic strategy of 
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diabetic embryopathy is replenishing antioxidant capacity of the embryo. Previous 
studies on diabetic embryopathy reported deficiencies of glutathione or antioxidant levels 
in embryos. Vitamins C, E and folic acid have the ability to scavenge free oxygen 
radicals [46,47] and their efficiency in diminishing embryonic malformation has been 
demonstrated in diabetic animal models [48-53]. NAC is a derivative of amino acid 
cysteine, which is an intracellular source of glutathione [54].  In pathological conditions 
where GSH levels are diminished, NAC treatment demonstrates higher efficiency and 
consistency in replenishing GSH levels in comparison to cysteine or glutathione. Oral 
treatment of glutathione does not increase plasma levels of cysteine or glutathione 
effectively due to enzymatic actions that hydrolyze glutathione in the digestive tract [55]. 
Likewise, cysteine oxidizes promptly in oxygenated extracellular environment, and only 
some cells have the ability to import the oxidized cysteine and reduce it [56]. In addition, 
systemic administration of cysteine shows disruptive effects on neurons of the central 
nervous system [57,58]. Remarkably, the acetyl group of NAC protects it against 
oxidation or hydrolysis and can efficiently elevate glutathione bioavailability [59]. NAC 
has been used in several pathological conditions to rescue GSH deficiency and inhibit 
oxidative stress [59]. Previous studies demonstrated in vitro or in ovo treatment of NAC 
reduces the rate of congenital defects in embryos induced by high glucose [60,61]. 
Additionally, treatment with GSH-ester decreases outflow tract defects induced by 
maternal diabetes [62]. We investigated whether oral treatment of NAC in diabetic 
females during gestation prevents the incidence of CHDs in their offspring. Remarkably, 
NAC treatment successfully elevated total and reduced GSH levels in fetal hearts of 
embryos of diabetic dams and prevented the development of CHDs (Chapter 2). 
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Additionally, NAC adminstration restore transcript levels in embryos affected by 
pregestaional diabetes. Previous studies demontrated that NAC can alter proteins activity 
and transcript levels of many genes [10]. Whether gene expression levels are directly 
affected by NAC or intracellular glutathione levels or as an indirect effect of reduced 
oxidative stress remains to be investigated. Further experimental analysis is also required 
to expand our knowledge on the pharmacokinetics of NAC prior to its application for 
clinical studies.  
Although NAC is generally considered a safe antioxidant, cautions should be 
taken in prescribing the right dose of NAC to pregnant women. Our experimental 
analysis demonstrated a slight increase in the rate of CHDs (10%) in the control offspring 
by NAC treatment. Although this was not statistically significant due to a small sample 
size, it suggests that reduction of ROS levels below normal physiological levels may also 
be detrimental to normal heart development. Additionally, exposure to higher 
concentrations of NAC induces reductive stress, as evidenced by mitochondrial oxidation 
and elevated cytotoxicity in cultured cells [63]. In agreement with this notion, a high dose 
of NAC in rats has been shown to reduce fertility in females [64]. However, with the dose 
used in our studies, we did not observe any difference in pregnancy success rate between 
groups. Thus, dosage of NAC treatment should be carefully examined in further animal 
studies before initiating clinical trials.  
NAC from the maternal circulation can cross the placenta and reach the 
developing embryos [65]. However, a possible impact of antioxidant activities of NAC 
on other maternal organs including kidneys, liver and pancreas should not be neglected. 
Our studies demonstrated that NAC has beneficial effects on metabolism as shown by 
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reduced food and water intake in the diabetic mice (Chapter 2). A small but non- 
significant reduction of blood glucose levels in diabetic females was also observed with 
NAC treatment. It is possible that NAC may have beneficial effects on insulin release or 
insulin sensitivity. Further studies are required to study these effects and associated 
molecular mechanisms of NAC.  
As discussed before, maternal diabetes impairs embryonic development through 
multiple signalling pathways. Previous experimental studies demonstrated 
supplementation of folic acid, vitamin C or E reduces the risk of birth defects in diabetic 
pregnancies [48-53]. Here, we demonstrated that NAC is a potent molecule that protects 
embryos against oxidative stress induced by maternal diabetes. It is possible that a 
combination of folic acid, vitamins and NAC may have a synergistic benefit on the 
prevention of birth defects in the offspring of women with pregestational diabetes. To test 
this hypothesis, further pre-clinical and clinical studies are required to investigate the 
appropriate dose and their efficiency in preventing birth defects induced by maternal 
diabetes.  
5.3.2 Role of NOX2 in Heart Development 
NOX2 and NOX4 are expressed in both adult cardiomyocytes and cardiac stem 
cells, but are distinctly localized on the plasma membrane and mitochondrial cell 
membrane, respectively [66,67]. In Chapter 4, we demonstrated that NOX2 mediated 
ROS release regulates Tgf-β/Bmp signalling and promotes EndMT required for cardiac 
septum and valve development. Furthermore, we demonstrated during early heart 
development (E10.5) NOX2 expression pattern is more robust in the left ventricular 
myocardium compared to the right (Figure 4-3). While cellular and molecular 
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characteristics of cardiomyocytes of the right and left ventricle are distinct [68], 
understanding the regulators of this distinct gene expression profile become an essence in 
topics such as induction of embryonic stem cells differentiation to cardiomyocyte. 
Previous studies have demonstrated an important role of NOX4 in the regulation of 
cardiac stem cell differentiation [67]. Whether ROS release from NOX2 regulates cardiac 
differentiation in the same or a different mechanism is not known. Thus, an interesting 
extension to studies performed in Chapter 4 is to evaluate the role of ROS released from 
NOX2 or 4 in the regulation of factors essential for cardiomyocyte differentiation. This 
can be performed primarily by evaluation of temporal and spatial expression of NOX2 
and NOX4 during cardiogenesis in the embryos. Followed by this, the effect of NOX2 
expression or inhibition in embryonic stem cells in relation to gene expression levels has 
to be investigated. Distinct expression pattern of NOX proteins might imply different role 
of ROS released from each source.  Further studies are required to examine the temporal 
and spatial expression of NOX family and their contributions to cardiomyocyte 
differentiation and proliferation.  
5.4 CONCLUSION 
This thesis provides evidence of a pivotal role of ROS signalling in the regulation 
of embryonic heart development. Here, I demonstrated that excess ROS levels induced by 
pregestational diabetes alter gene expression profiles required for cardiovascular 
development and thus lead to CHDs in the offspring. Additionally, I have shown that 
treatment with an antioxidant, NAC, restores altered gene expression and reduces the 
incidence of CHDs in the diabetic offspring. Furthermore, this thesis provided valuable 
insight into a critical role of basal ROS levels in promoting EndMT and heart 
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development. Overall, my doctoral research thesis has broadened our understanding of 
ROS levels on heart morphogenesis and our findings may have implications in the 
clinical prevention and treatment of CHDs during pregestational diabetes.   
 
5.5 REFERENCE  
1. Lisowski LA, Verheijen PM, Copel JA, Kleinman CS, Wassink S, Visser GHA, 
Meijboom E-J: Congenital heart disease in pregnancies complicated by maternal 
diabetes mellitus. An international clinical collaboration, literature review, and 
meta-analysis. Herz 2010, 35(1):19-26. 
2. De Giorgio F, Abbate A, Stigliano E, Capelli A, Arena V: Hypoplastic coronary 
artery disease causing sudden death. Report of two cases and review of the 
literature. Cardiovasc Pathol 2010, 19(4):e107-111. 
3. Fine EL, Horal M, Chang TI, Fortin G, Loeken MR: Evidence that elevated 
glucose causes altered gene expression, apoptosis, and neural tube defects in a 
mouse model of diabetic pregnancy. Diabetes 1999, 48(12):2454-2462. 
4. Cockroft DL: Abnormalities Induced in Cultured Rat Embryos by 
Hyperglycemia. British Journal of Experimental Pathology 1984, 65(5):625-636. 
5. Wentzel P, Gareskog M, Eriksson UJ: Decreased Cardiac Glutathione Peroxidase 
Levels and Enhanced Mandibular Apoptosis in Malformed Embryos of Diabetic 
Rats. Diabetes 2008, 57(12):3344-3352. 
6. Roest PA, Molin DG, Schalkwijk CG, van Iperen L, Wentzel P, Eriksson UJ, 
Groot ACG-d: Specific Local Cardiovascular Changes of N -
(Carboxymethyl)lysine, Vascular Endothelial Growth Factor, and Smad2 in the 
Developing Embryos Coincide With Maternal Diabetes-Induced Congenital Heart 
Defects. Diabetes 2009, 58(5):1222-1228. 
7. Sakamaki H, Akazawa S, Ishibashi M, Izumino K, Takino H, Yamasaki H, 
Yamaguchi Y, Goto S, Urata Y, Kondo T et al: Significance of glutathione-
dependent antioxidant system in diabetes-induced embryonic malformations. 
Diabetes 1999, 48(5):1138-1144. 
8. Deuchar EM: Embryonic malformations in rats, resulting from maternal diabetes: 
preliminary observations. J Embryol Exp Morphol 1977, 41:93-99. 
9. Morishima M, Yasui H, Ando M, Nakazawa M, Takao A: Influence of genetic 
and maternal diabetes in the pathogenesis of visceroatrial heterotaxy in mice. 
Teratology 1996, 54(4):183-190. 
10. Mansford KR, Opie L: Comparison of metabolic abnormalities in diabetes 
mellitus induced by streptozotocin or by alloxan. Lancet 1968, 1(7544):670-671. 
11. Rerup CC: Drugs producing diabetes through damage of the insulin secreting 
cells. Pharmacol Rev 1970, 22(4):485-518. 
12. Eleazu CO, Eleazu KC, Chukwuma S, Essien UN: Review of the mechanism of 
cell death resulting from streptozotocin challenge in experimental animals, its 
  
175 
practical use and potential risk to humans. J Diabetes Metab Disord 2013, 
12(1):60. 
13. Lee JH, Yang SH, Oh JM, Lee MG: Pharmacokinetics of drugs in rats with 
diabetes mellitus induced by alloxan or streptozocin: comparison with those in 
patients with type I diabetes mellitus. J Pharm Pharmacol 2010, 62(1):1-23. 
14. Junod A, Lambert AE, Orci L, Pictet R, Gonet AE, Renold AE: Studies of the 
diabetogenic action of streptozotocin. Proc Soc Exp Biol Med 1967, 126(1):201-
205. 
15. Padmanabhan R, al-Zuhair AG: Congenital malformations and intrauterine 
growth retardation in streptozotocin induced diabetes during gestation in the rat. 
Reprod Toxicol 1987, 1(2):117-125. 
16. Giavini E, Broccia ML, Prati M, Roversi GD, Vismara C: Effects of 
streptozotocin-induced diabetes on fetal development of the rat. Teratology 1986, 
34(1):81-88. 
17. Pani L, Horal M, Loeken MR: Polymorphic susceptibility to the molecular causes 
of neural tube defects during diabetic embryopathy. Diabetes 2002, 51(9):2871-
2874. 
18. Machado AF, Zimmerman EF, Hovland DN, Jr., Weiss R, Collins MD: Diabetic 
embryopathy in C57BL/6J mice. Altered fetal sex ratio and impact of the splotch 
allele. Diabetes 2001, 50(5):1193-1199. 
19. Bohuslavova R, Skvorova L, Sedmera D, Semenza GL, Pavlinkova G: Increased 
susceptibility of HIF-1alpha heterozygous-null mice to cardiovascular 
malformations associated with maternal diabetes. J Mol Cell Cardiol 2013, 
60:129-141. 
20. Malins JM: Congenital malformations and fetal mortality in diabetic pregnancy. J 
R Soc Med 1978, 71(3):205-207. 
21. Steel JM, Johnstone F, Duncan LJ: Abnormal infants of diabetic mothers. Lancet 
1980, 1(8171):771. 
22. Eriksson UJ: Diabetes in pregnancy: effects on post-implantation embryos. Isr J 
Med Sci 1991, 27(8-9):478-486. 
23. Sadler TW: Effects of maternal diabetes on early embryogenesis: II. 
Hyperglycemia-induced exencephaly. Teratology 1980, 21(3):349-356. 
24. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. 
Nature 2001, 414(6865):813-820. 
25. Hagay ZJ, Weiss Y, Zusman I, Peled-Kamar M, Reece EA, Eriksson UJ, Groner 
Y: Prevention of diabetes-associated embryopathy by overexpression of the free 
radical scavenger copper zinc superoxide dismutase in transgenic mouse embryos. 
Am J Obstet Gynecol 1995, 173(4):1036-1041. 
26. Eriksson UJ, Borg LA: Protection by free oxygen radical scavenging enzymes 
against glucose-induced embryonic malformations in vitro. Diabetologia 1991, 
34(5):325-331. 
27. Forsberg H, Borg LA, Cagliero E, Eriksson UJ: Altered levels of scavenging 
enzymes in embryos subjected to a diabetic environment. Free Radic Res 1996, 
24(6):451-459. 
  
176 
28. Reece EA, Ji I, Wu YK, Zhao Z: Characterization of differential gene expression 
profiles in diabetic embryopathy using DNA microarray analysis. Am J Obstet 
Gynecol 2006, 195(4):1075-1080. 
29. Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Romano-Adesman A, 
Bjornson RD, Breitbart RE, Brown KK et al: De novo mutations in histone-
modifying genes in congenital heart disease. Nature 2013, 498(7453):220-223. 
30. Lehnen H, Zechner U, Haaf T: Epigenetics of gestational diabetes mellitus and 
offspring health: the time for action is in early stages of life. Mol Hum Reprod 
2013, 19(7):415-422. 
31. Van Speybroeck L: From epigenesis to epigenetics: the case of C. H. 
Waddington. Ann N Y Acad Sci 2002, 981:61-81. 
32. Vijaya M, Manikandan J, Parakalan R, Dheen ST, Kumar SD, Tay SS: 
Differential gene expression profiles during embryonic heart development in 
diabetic mice pregnancy. Gene 2013, 516(2):218-227. 
33. Pavlinkova G, Salbaum JM, Kappen C: Maternal diabetes alters transcriptional 
programs in the developing embryo. BMC Genomics 2009, 10:274. 
34. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB: 
ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009, 
324(5930):1076-1080. 
35. Ge ZJ, Liang QX, Luo SM, Wei YC, Han ZM, Schatten H, Sun QY, Zhang CL: 
Diabetic uterus environment may play a key role in alterations of DNA 
methylation of several imprinted genes at mid-gestation in mice. Reprod Biol 
Endocrinol 2013, 11:119. 
36. Keating ST, El-Osta A: Chromatin modifications associated with diabetes. J 
Cardiovasc Transl Res 2012, 5(4):399-412. 
37. Tang X, Muniappan L, Tang G, Ozcan S: Identification of glucose-regulated 
miRNAs from pancreatic {beta} cells reveals a role for miR-30d in insulin 
transcription. RNA 2009, 15(2):287-293. 
38. Salbaum JM, Kappen C: Diabetic embryopathy: a role for the epigenome? Birth 
Defects Res A Clin Mol Teratol 2011, 91(8):770-780. 
39. Salbaum JM, Kappen C: Neural tube defect genes and maternal diabetes during 
pregnancy. Birth Defects Res A Clin Mol Teratol 2010, 88(8):601-611. 
40. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD: 
Preconception care of diabetes. Glycemic control prevents congenital anomalies. 
JAMA 1991, 265(6):731-736. 
41. Ray JG, O'Brien TE, Chan WS: Preconception care and the risk of congenital 
anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM 
2001, 94(8):435-444. 
42. International Diabetes Federation: IDF Diabetes Atlas, 5th edn. Brussels, 
Belgium: IDF. 2011. 
43. Langer O, Anyaegbunam A, Brustman L, Guidetti D, Levy J, Mazze R: 
Pregestational diabetes: insulin requirements throughout pregnancy. Am J Obstet 
Gynecol 1988, 159(3):616-621. 
44. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, 
Warnes CA, Webb CL: Noninherited risk factors and congenital cardiovascular 
defects: current knowledge: a scientific statement from the American Heart 
  
177 
Association Council on Cardiovascular Disease in the Young: endorsed by the 
American Academy of Pediatrics. Circulation 2007, 115(23):2995-3014. 
45. Correa A, Gilboa SM, Besser LM, Botto LD, Moore CA, Hobbs CA, Cleves MA, 
Riehle-Colarusso TJ, Waller DK, Reece EA: Diabetes mellitus and birth defects. 
Am J Obstet Gynecol 2008, 199(3):237.e231-239. 
46. Bagchi D, Garg A, Krohn RL, Bagchi M, Tran MX, Stohs SJ: Oxygen free radical 
scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin 
extract in vitro. Res Commun Mol Pathol Pharmacol 1997, 95(2):179-189. 
47. Joshi R, Adhikari S, Patro BS, Chattopadhyay S, Mukherjee T: Free radical 
scavenging behavior of folic acid: evidence for possible antioxidant activity. Free 
Radic Biol Med 2001, 30(12):1390-1399. 
48. Viana M, Herrera E, Bonet B: Teratogenic effects of diabetes mellitus in the rat. 
Prevention by vitamin E. Diabetologia 1996, 39(9):1041-1046. 
49. Cederberg J, Siman CM, Eriksson UJ: Combined treatment with vitamin E and 
vitamin C decreases oxidative stress and improves fetal outcome in experimental 
diabetic pregnancy. Pediatr Res 2001, 49(6):755-762. 
50. Sivan E, Reece EA, Wu YK, Homko CJ, Polansky M, Borenstein M: Dietary 
vitamin E prophylaxis and diabetic embryopathy: morphologic and biochemical 
analysis. Am J Obstet Gynecol 1996, 175(4 Pt 1):793-799. 
51. Simán CM, Eriksson UJ: Vitamin C supplementation of the maternal diet reduces 
the rate of malformation in the offspring of diabetic rats. Diabetologia 1997, 
40(12):1416-1424. 
52. Simán CM, Eriksson UJ: Vitamin E decreases the occurrence of malformations in 
the offspring of diabetic rats. Diabetes 1997, 46(6):1054-1061. 
53. Oyama K, Sugimura Y, Murase T, Uchida A, Hayasaka S, Oiso Y, Murata Y: 
Folic acid prevents congenital malformations in the offspring of diabetic mice. 
Endocr J 2009, 56(1):29-37. 
54. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND: Glutathione metabolism and its 
implications for health. J Nutr 2004, 134(3):489-492. 
55. Witschi A, Reddy S, Stofer B, Lauterburg BH: The systemic availability of oral 
glutathione. Eur J Clin Pharmacol 1992, 43(6):667-669. 
56. Lu SC: Regulation of glutathione synthesis. Mol Aspects Med 2009, 30(1-2):42-
59. 
57. Olney JW, Zorumski C, Price MT, Labruyere J: L-cysteine, a bicarbonate-
sensitive endogenous excitotoxin. Science 1990, 248(4955):596-599. 
58. Puka-Sundvall M, Eriksson P, Nilsson M, Sandberg M, Lehmann A: 
Neurotoxicity of cysteine: interaction with glutamate. Brain Res 1995, 705(1-
2):65-70. 
59. Ruffmann R, Wendel A: GSH rescue by N-Acetylcysteine. Klin Wochenschr 
1991, 69(18):857-862. 
60. Roest PAM, van Iperen L, Vis S, Wisse LJ, Poelmann RE, Steegers-Theunissen 
RPM, Molin DGM, Eriksson UJ, Gittenberger-De Groot AC: Exposure of neural 
crest cells to elevated glucose leads to congenital heart defects, an effect that can 
be prevented by N-Acetylcysteine. Birth Defect Res A Clin Mol Teratol 2007, 
79(3):231-235. 
  
178 
61. Wentzel P, Thunberg L, Eriksson UJ: Teratogenic effect of diabetic serum is 
prevented by supplementation of superoxide dismutase and N-Acetylcysteine in 
rat embryo culture. Diabetologia 1997, 40(1):7-14. 
62. Morgan SC, Relaix F, Sandell LL, Loeken MR: Oxidative stress during diabetic 
pregnancy disrupts cardiac neural crest migration and causes outflow tract 
defects. Birth Defects Res A Clin Mol Teratol 2008, 82(6):453-463. 
63. Zhang H, Limphong P, Pieper J, Liu Q, Rodesch CK, Christians E, Benjamin IJ: 
Glutathione-dependent reductive stress triggers mitochondrial oxidation and 
cytotoxicity. FASEB J 2012, 26(4):1442-1451. 
64. Harada M, Kishimoto K, Furuhashi T, Naito K, Nakashima Y, Kawaguchi Y, 
Hiraoka I: Infertility observed in reproductive toxicity study of N-acetyl-L-
cysteine in rats. Biol Reprod 2003, 69(1):242-247. 
65. Horowitz RS, Dart RC, Jarvie DR, Bearer CF, Gupta U: Placental transfer of N-
Acetylcysteine following human maternal acetaminophen toxicity. J Toxicol Clin 
Toxicol 1997, 35(5):447-451. 
66. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J: Regulation of 
myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 2011, 
50(3):408-416. 
67. Li J, Stouffs M, Serrander L, Banfi B, Bettiol E, Charnay Y, Steger K, Krause 
KH, Jaconi ME: The NADPH oxidase NOX4 drives cardiac differentiation: Role 
in regulating cardiac transcription factors and MAP kinase activation. Mol Biol 
Cell 2006, 17(9):3978-3988. 
68. Srivastava D, Olson EN: A genetic blueprint for cardiac development. Nature 
2000, 407(6801):221-226. 
 
  
179 
APPENDIX A 
 
 
  
 
Qingping Feng - eSirius Notification - Annual Protocol Renewal APPROVED by the AUS 2007-
011-03::6 
2007-011-03::6:
AUP Number: 2007-011-03
AUP Title: Modulation of Myocardial Function in Myocardial Infarction, Sepsis, anemia and 
Diabetes
Yearly Renewal Date: 12/01/2013
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2007-011-03 has been approved, 
and will be approved for one year following the above review date.
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through the ACVS office.
Health certificates will be required. 
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this 
protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with institutional safety 
standards and have received all necessary approvals. Please consult directly with your institutional 
safety officers.
Submitted by: Kinchlea, Will D 
on behalf of the Animal Use Subcommittee 
From: eSiriusWebServer <esiriusadmin@uwo.ca>
To: <qingping.feng@schulich.uwo.ca>
Date: 21/01/2014 9:11 AM
Subject: eSirius Notification - Annual Protocol Renewal APPROVED by the AUS 2007-011-03::6
CC: <auspc@uwo.ca>, <auspc@uwo.ca>
Page 1 of 2
21/01/2014file:///C:/Users/qfeng/AppData/Local/Temp/XPgrpwise/52DE39BBMedPo21001336D37...
  
180 
 
CURRICULUM VITAE 
Hoda Moazzen 
Education 
Ph.D. in Physiology                  2009-2014 
& Developmental Biology     
Western University 
Supervisor: Dr. Qingping Feng 
 
M.Sc. in Biology        2007- 2009 
Western University 
Supervisor: Dr. Antony Percival-Smith        
 
B.Sc. in Biology       2002-2006 
Razi University, Iran 
Honors and Awards 
Western Graduate Research Scholarship (WGRS) for Ph.D. studies 2009-2013 
Western Graduate Research Scholarship (WGRS) for M.Sc. studies 2007-2009 
Recipient of 2nd best oral presentation in the 3rd Annual Diabetes Research Day, St. 
Joseph’s Health Care, London, Canada, 2012 
Recipient of 3rd best poster presentation in Natural Bioactives International Conference, 
London, Canada, 2012  
Recipient of research thesis award, Western University, 2008, 2011 and 2013 
Recognized as honored student by the Dean of Science for the years 2004-06 
Publications 
H. Moazzen, X. Lu, T. Velenosi, et al. “N-Acetylcysteine Prevents Congenital Heart 
Defects induced by Pregestational Diabetes” Cardiovasc Diabetol, 2014, 13:46 
 
H. Moazzen, R. Rosenfeld, and A. Percival-Smith, “Non-requirement of a regulatory 
subunit of Protein Phosphatase 2A, PP2A-B', for activation of Sex comb reduced activity 
in Drosophila melanogaster,” Mech Dev 2008, 126:605-61 
